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Although stenting as a medical procedure is well established, it is clear from clinical data that there is 
much left to learn about the long-term impact of in-stent restenosis (ISR) and how it can be prevented. 
Inadequacies in traditional 2D cell culture and poor in vitro and in vivo correlation contribute to this 
knowledge gap. In vitro cell studies of hydrophobic drugs, frequently used in drug eluting stents to combat 
ISR, face difficulties associated with their low aqueous solubility. Solubilization strategies that dissolve the 
drugs during in vitro assays result in drug concentrations that are not representative of those that will 
occur in vivo. This may result in non-representative changes in cell behavior, leading to further poor in 
vitro and in vivo correlation. Furthermore, a large share of the in vitro studies do not consider the dynamic 
flow of blood through a layer of cells, as occurs in the body.  
ISR, or re-narrowing of blood vessels, develops through a complex cascade of cellular events and is a 
pathological response to stent-induced vascular injury. Stent-induced vascular injury is manifested by 
removal of the endothelium and phenotypic changes in the underlying medial smooth muscle cells layer. 
This results in pathological vascular remodelling called neointimal hyperplasia (NIH). While drug-eluting 
stents contain anti-proliferative agents to inhibit the proliferation of smooth muscle cells (SMC), they also 
delay the regrowth of the intimal endothelial cells (EC) resulting in the subsequent development of late 
stent thrombosis. It is proposed that promoting rapid endothelial repair can minimize formation of NIH 
by preventing phenotypic switch in SMCs. 
The work presented in this thesis focuses on: i) a novel method development to investigate existing stent 
coatings and their impact on vascular repair, ii) evaluation of a novel bioactive stent coating candidate 
and its role in promoting vascular healing and iii) the establishment of a 3D cellularized tubular vascular 
model to bridge the gap between in vitro and in vivo studies.  
In the first phase of the project, a method for the preparation of stent conditioned media for in vitro 
evaluation of drug eluting stents was proposed and validated. In the next phase, citric acid as a novel 
bioactive candidate for stent coatings was investigated by studying its impact on endothelial growth and 
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CHAPTER 1  
Introduction, Literature Review & Project Aim 
_____________________________________ 
1.1 Introduction 
Cardiovascular disease (CVD), a disease of coronary arteries and blood vessels, as a general term applies 
to a range of vascular disorders among which atherosclerosis is the most predominant cause [1]. 
Atherosclerotic disease, or a plaque build-up in arteries, leads to a condition known as stenosis. Stenosis, 
corresponding to a late stage atherosclerosis, is narrowing of blood vessels causing obstruction and 
disturbances to blood flow [2]. Heart ischaemia, decreased blood supply of coronary arteries to heart 
muscle, may result in acute myocardial infarction while stenosis of arteries supplying brain can cause 
ischemic stroke [3, 4]. Disease of blood vessels carrying blood to legs, arms, kidneys or stomach is referred 
as peripheral artery disease (PAD) with the most commonly affected iliac, femoral, popliteal and tibial 
arteries [5]. PAD has seen increase of 24 % to the total number of 202 million cases globally in the decade 
between 2000 and 2010 with further an increase of almost 15 % to the total number of 236.62 million 
patients in 2015 [6, 7]. Undetected or untreated PAD can lead to critical limb ischemia often resulting in 
lower limb amputations [5].  
According to European Cardiovascular Disease Statistics, 5.4 million men and 5.8 million women were 
diagnosed with CVD in 2015 alone, with 17,268 new cases in Ireland [8].  Percutaneous transluminal 
angioplasty (PTA) is a standard procedure to open blocked blood vessels, yet 3.9 million people die each 
year in Europe as a result of CVD. The total estimated cost to the EU economy is €210 billion a year [8]. 
These numbers make CVD the leading cause of mortality under 65 years in Europe, leaving cancer behind 
on the second place [9]. These are worrying statistics  for an economically productive population and call 
for the need of prevention and proper treatment of the disease to improve patient quality of life.  
Medical stents are one of the major healthcare advancements in the last three decades in treating 
diseases including coronary and peripheral artery disease. Among others, bare metal stents (BMS) and 
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drug-eluting stents (DES) are most commonly used. Although the stenting procedure is well established, 
it is clear from clinical data that there is a large void of comprehension in its long-term impact in 
preventing in-stent restenosis (ISR), re-occurrence of stenosis. This arises due to the inadequacies of 
traditional 2D cell culture and the disconnect between in vitro and in vivo data [10]. Cells grown in culture 
plates significantly differ from those in the physiological environment, influencing basic cellular functions 
such as migration and proliferation [11, 12]  and it is proposed that 3D culture would be a better approach 
in mimicking stent-cell interactions due to improved representation of the physiological environment [13]. 
Although, the use of DES can minimize BMS-associated restenosis, there are several areas of concern; the 
drugs chosen were not intended nor designed specifically to address thrombosis, and DES can interrupt 
the natural post-injury cellular response, i.e. re-endothelialization [14-16]. 
The work presented here involves the development of a method for studying existing and novel stents 
and stent coatings via 2D cell culture to contribute to a deeper understanding of vascular healing following 
stent implantation. The project will focus on assessment of a novel stent bioactive coating candidate with 
the ability to target key events in the pathogenesis of restenosis. As a more representative manner of 
studying stent-cell interaction requires a third dimension, the project aims to establish a 3D tubular 
cellularized vascular model to study stents in their macro-scale. In this introductory chapter, several areas 
of research are discussed including: biological cascades associated with the development of 
atherosclerosis and restenosis, treatment strategies and current state-of-the-art stent products and 





Atherosclerosis, hardening of the arteries, has been extensively studied since the 1970’s, namely through 
systematic studies conducted by the research group of Ross and Glomset  which greatly contributed to 
the early understanding of atherosclerosis [17-20]. A number of risk factors associated with the 
progression of atherosclerotic lesions leading to obstructed blood flow due to vessel blockage exist; 
obesity, hypertension, diabetes mellitus, tobacco smoking, elevation of atherogenic lipopropteins and 
reduction of high density lipoprotein (HDL) [21-26]. A blockage of an iliac artery, illustrated in Figure 1.1, 
shows the occlusion of the left external iliac artery as detected by computed tomography angiography 
(CTA) [27].  The following sections provide a brief description of vessel wall anatomy, atherosclerosis 
pathogenesis and cells involved in its development as well as a discussion of atherogenic risk factors.  
 
Figure 1.1: Schematic representation of iliac artery stenosis and oclusion (panel A), and the same artery 
as seen using computed tomography angiography (panel B). Blue arrowhead indicates origin of the 
common iliac artery and the black arrowhead indicates site of calcification [27] 
1.2.1 Arterial Vessel Wall Anatomy 
Since atherosclerosis develops within the structure of blood vessel walls, knowledge of vessel wall 
anatomy is necessary to better understand the disease pathogenesis. Blood vessels consist of three main 
sections: intima (tunica intima), media (tunica media) and adventitia (tunica adventitia) [28]. Intima is the 
innermost layer directly in contact with flowing blood consisting of an endothelial cell (EC) monolayer 
anchored on a basement membrane. Due to their direct blood contact, all other tissues are reliant on 
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proper functioning of ECs for nutrient transport. Their remarkable migration ability allows them to 
regenerate damaged and create new vessels [29]. They play a role in a wide range of critical functions, 
including homeostasis and vascular wall remodeling but also thrombosis and inflammation [30]. The 
internal elastic lamina is the barrier between the intima and the underlying media or tunica media.  
The media consists of multiple layers of smooth muscle cells (SMCs) controlling the diameter of the blood 
vessel by contracting or relaxing in response to neural and chemical signals. SMCs bound to each other 
are embedded in collagen, elastic fibers and proteoglycans. External elastic lamina is the barrier between 
layers of SMCs and connective tissue (collagen and elastic fibers) of the outermost layer adventitia. 
Adventitia consists of fibroblasts connective tissue and also contains interdisperesed SMCs, nerves and 
small blood vessels supplying the artery itself. Layers of connective tissue are found between the 
individual barriers, such as between EC and internal elastic membrane [18]. 
 
Figure 1.2: Schematic cross-sectional representation of a simplified  blood vessel anatomy [28]. Figure 
created with BioRender (https://biorender.com) 
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1.2.2 Development of Atherosclerosis 
The fundamental features of atherosclerotic pathogenesis, the type of cells involved and the 
morphological changes have been described by the innovative research of Ross et al. [17, 18, 20]. In recent 
years, the extensive studies of Libby et al. immensely improved the current knowledge of molecular 
machinery orchestrating atherosclerosis and the role of inflammation in the disease [2, 31-33]. The 
individual events accompanying development of atherosclerosis have been described by Stary et al. in a 
few excellent review papers [34, 35]. Atherosclerotic lesion in the vessel wall progresses over decades 
(Figure 1.3). The lesion classification distinguishes between early I-III and advanced lesions IV-VI. The early 
type I-III lesions correspond to initial lesion, fatty streak and intermediate lesion while the advanced IV-VI 
correspond to atheroma, fibroatheroma (fibrous plaque) and complicated lesion in Figure 1.3 [34].  
 
Figure 1.3:  Progression of atherosclerotic lesion over decades, adapted from reference [35]. Figure 
created with BioRender (https://biorender.com) 
Earliest onset of atherosclerotic disease is seen from the first decade of life in infants and children. During 
this time, initial type I lesion is characterized by isolated lipid-laden macrophage foam cells in the intimal 
layer attributed to high plasma lipid levels. This early lesion then progresses to fatty streak formation 
defined mainly by accumulation of macrophage foam cells in layer arrangements. The foam cell content 
is largely formed by cholesterol esters, but can also contain cell debris and calcium deposits. In addition 
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to macrophages, SMC can also contain lipids [36]. T-lymphocytes and mast cells are present in type II 
lesions. Early and fatty streak lesions commonly seen in the first and second decade of life are clinically 
silent and fully reversible. From the third decade onwards, intermediate lesions appear as a result of 
changes in fatty streak. Intermediate lesions have characteristic small extracellular lipid pools due to foam 
cells death and release of contained lipids. The lipid pools can replace intercellular matrix proteoglycans 
and fibers, and disrupt the coherence of SMC. These silent precursors of advanced lesions do not cause 
significant changes in intimal structure or endothelial function and may be fully reversed if risk factors are 
not sustained [34].  
The third decade intermediate lesions develop into atheroma, characterized by large extracellular lipid 
cores formed by dying foam cells, causing distortion in intimal morphology [35]. SMCs stimulated by 
cytokines proliferate and migrate from media to intima [37, 38].  Evidence of calcification is present not 
only in macrophages but also some organelles of SMCs [39]. Macrophages and SMCs with and without 
lipid droplet inclusions are found in the space between lipid core and endothelial monolayer while other 
cell types such as macrophages, macrophage foam cells and lymphocytes are concentrated at the lesion 
periphery. In this type of lesion the intimal layer exhibits nearly normal morphology but with cell 
infiltration [35, 40].  
From the fourth decade, SMCs, now present in the intimal layer, start synthesizing fibrous components, 
mainly collagen. Collagen synthesis is an attempt of SMCs to isolate lipid core from circulation. This type 
of lesion termed fibroatheroma is identified by fibrin deposition refered as a “fibrin cap” [41].  Fibrin caps 
covering the plaque, depending on the amount of collagen fibers, can be either be thin or thick, thus are 
an important factor in determing the plaque stability [42, 43]. The dead cells and extracellular lipid can be 
replaced by calcium deposits. Type V lesions are mainly composed of either layers of thick fibrous tissue 
and lipids (multilayered fibroatheroma) or calcified components (calcific lesion) or fibrous tissue with 
minimal lipid (fibrotic lesion) [44]. Fibrotic lesions are often seen in lower extremities. Surface disruption 
of type IV and V lesions, such as thin fibrin cap rupture triggers acute thrombosis, pathological formation 
of blood clot obstructing blood flow, resulting in catastrophic death causing events [45]. As depicted in 
Figure 1.3, the progression of the atherosclerotic lesion through the decades causes the endothelium to 
become more dysfunctional, loosing its native anti-thrombogenic, anti-inflammatory and vasodilatory 
properties [35].  
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The traditional view that an atherosclerotic plaque in the blood vessel keeps growing inwardly obstructing 
blood flow was proved wrong by Glagov et al. who showed that vessels without detectable luminal 
narrowing present significant plaques in the sub-intimal space. [46-48]. It is now known that plaque builds 
up outwardly first causing no obstruction;  termed as positive remodeling. Positive expansion of vessel 
walls is mediated by external elastic lamina. For this reason early lesions are often not detected by 
angiography. Once no more positive remodelling can be accommodated by the vessel the lesion starts 
growing inwardly in the process of negative remodelling [49, 50]. 
Calcium deposition in the intima and media, once thought to be a passive process resulting in the 
hardening of arteries, is now recognized to strongly correlate with atherosclerosis extent. The calcification 
is a result of osteoblast-like cells derived from SMCs, differentiation of which  is induced by inflammatory 
cells, and their increased uptake of calcium and phosphate. SMC also have the capability to overcome the 
mechanism by which osteoclast-like cells resorb minerals [51]. Osteoblast-like cells exhibit increased 
expression of proteins regulating mineralization. These proteins are normally restricted to connective 
tissue of bones and cartilage [39]. At high calcium levels, hydroxyapatite laden vesicles-derived from SMC 
apoptotic cells found in ECM serve as calcification platforms. Evidence suggests that under physiological 
conditions calcification and differentiation of SMC is inhibited by release of nitric oxide. However, the 
control of calcium levels in the body is not fully understood [52].  
1.2.3 The Role of Endothelial Cells and Endothelial Dysfunction 
The vascular endothelium, comprised of a tightly packed endothelial cell monolayer, in its healthy state 
provides a highly selective non-thrombogenic barrier that regulates vascular homeostasis by allowing 
entry of small molecules and solutes for nutrient transport and limits entry of larger molecules and blood 
cells [53, 54]. Vascular homeostasis is achieved through vaso-active properties, dilation or constriction of 
vessels, as a response to increased nutrient requirement controlled by the release of nitric oxide (NO) [55]. 
NO, synthesized by endothelial nitric oxide synthase (eNOS) acts as a crucial regulator of vascular health 
by maintaining the vascular wall in a quiescent state characterized by inhibition of inflammation, cell 
proliferation and thrombosis [53, 56].  Therefore, EC monolayer and subtle changes in its barrier property 
are central to the development of atherosclerosis. Pathological stimuli  such as hypertension and smoking 
may cause endothelial activation, a switch from a quiescent state, which if not reversed results in 
endothelial dysfunction and progression of atherosclerosis [57, 58]. A dysfunctional endothelium allows 
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capture and infiltration of inflammatory cells, exhibits increased oxidative stress, coagulation and 
proliferation. Such an endothelium is said to be ‘leaky’ and have a pro-inflammatory, pro-oxidant, pro-
coagulation, proliferative and adhesive phenotype. The increased leakiness or permeability of the 
endothelium is related to the expression of vascular endothelial cadherin (VE-cadherin), forming adherens 
cell-cell junctions and thus playing an important role of restrictive endothelial barrier and function in cell-
cell adhesion and intracellular communication [59]. In mature quiescent endothelial cells, the adherens 
junctions, controlling the barrier property, are established through VE-cadherin association with VEGFR-
2, suppressing cell growth and promoting survival. In sparse sub-confluent cells, vascular endothelial 
growth factor 2 (VEGFR-2) dissociates from VE-cadherin by dephosphorylation  and initiates proliferation 
through ERK/MAPK pathway. Once cells grow to confluence and junctions are fully established VEGFR-2 
associates with VE-cadherin again and proliferation ceases. Therefore, alteration in adherens junctions 
such as dephosporylation of VE-cadherin, as seen in atherosclerosis, results in increased vascular 
permeability and leakiness [60-62]. One of the main hallmarks of endothelial dysfunction is loss of 
vasodilatory properties. The loss of vasodilation is attributed to the inability of endothelial nitric oxide 
synthase (eNOS) to synthesize nitric oxide (NO), resulting in low bioavailibility of this potent vasodilator 
and increased expression of the superoxide, O2-. Superoxide is a cytotoxic oxidant that is damaging to 
vasculature and its increased levels trigger inflammatory signalling. In healthy inactive endothelium, 
expression of adhesion molecules is kept low by crucial release of NO which maintains healthy 
endothelium by inhibiting platelet aggregation and inflammatory cells infiltration [63, 64]. Aggregation of 
platelets initiates coagulation while monocyte and T-lymphocytes infiltration increases local inflammation 
contributing to endothelial dysfunction [64-66]. The inflamed environment characterized by release of 
chemokines and cytokines stimulates cell proliferation further exacerbating the pathological state [67-69]. 
An angiography of normal coronary arteries showed that the endothelial dysfunction preceeds the 
thickening of tunica intima and that it is necessary for initiation of atherosclerotic events [70]. Impaired 
vasodilation as a result of dysfunctional endothelium has been reported in peripheral circulatory disease 
[71]. In the early atherosclerotic lesion, changes in EC morphology such as  loss of orientation with the 
blood flow direction, rounded appearance, increased stomata and cilia, decreased microfilamnet bundles, 
increased stress fibres and formation of multinucleated cells are observed [34]. This pathology occurs 
predominantly at points of distorted blood flow such as branching points and bifurcations resulting in 
increased endothelial permeability [72, 73]. 
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Atherosclerosis  is a chronic disease that develops over decades in the presence of risk factors. Sustained 
exposure to risk factors leads to endothelial activation and later dysfunction characterized by 
vasoconstrictive phenotype of the vessel wall. Dysfunctional endothelium, unable to mediate vasodilation, 
fails to exert its protective mechanisms such as inhibition of platelet aggregation and inflammatory cell 
infiltration [63]. Inflammatory cell invasion is a result of increased endothelial permeability, either by 
upregulation of protein mediating transcytosis or disruption of cell-cell junctions 
Loss of endothelium-mediated vasodilation due to low NO bioavailability as seen in atherosclerosis brings 
into attention endothelial nitric oxide synthase (eNOS) and its impaired activity in atherosclerosis. eNOS 
is synthesizes NO from L-arginine and molecular oxygen [74] in response to high shear stress and cyclic 
circumferential stretch. eNOS is a calcium dependent enzyme, continuously producing low levels of NO..  
Structurally, eNOS is composed of an N-terminal catalytic oxygenase domain and a C-terminal reductase 
domain interconnected. The oxygenase domain carries a heme group and binds a cofactor 
tetrahydrobiopterin (BH4), molecular oxygen and  substrate L-Arginine [55]. The C-terminal reductase 
domain supplies electrons through bound NADP, FAD and FMN. A central linker binds calmodulin (CaM) 
and modulates the electron transfer from the reductase domain of one monomer to the heme in the 
oxygenase domain of a second monomer. In a first step of NO synthesis, eNOS hydroxylates L-Arginine to 
N- hydroxy-L-Arginine which remains bound to the enzyme. In a second step, sNOS oxidizes N-hydroxy-L-
Arginine to L-citrulline and nitric oxide [55].  
Endothelial dysfunction and low NO bioavailability is not due to downregulation of eNOS but rather its 
impaired activity. eNOS can become uncoupled due to deficiency of one of the cofactors, in most cases 
BH4 or low L-arginine concentrations. The uncoupling of the enzyme leads to production of superoxide 
O2- over nitric oxide. Superoxide, a highly reactive species, can now react with free NO and produce 
peroxynitrite NO3- which further uncouples eNOS [65]. This mechanism is highlighted by the fact that eNOS 
is paradoxically up-regulated in hypertensive and hyperglycaemic conditions [75].  
Actions of TNF-alpha in vasculature result in gene expression enhancing inflammation, coagulation and 
proliferation. It has been shown in experimental studies that eNOS expression is decreased by TNF-alpha, 
which inhibits eNOS promoter and destabilizes mRNA. CAM expression is induced via NF-kB on the surface 
of EC by TNF-alpha binding to TNFR1 receptor. eNOS activity is also suppressed by TNF-alpha which 
prevents degradation of ADMA, an eNOS endogenous inhibitor    [75]. 
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Increased oxidative stress and decreased levels of antioxidant enzymes are seen in atherosclerosis. The 
presence of reactive oxygen species (ROS) contribute to the endothelial dysfunction and progression of 
atherosclerosis by decreasing NO bioavailability. For examples, NADPH oxidase responsible for ROS 
production such as superoxide in blood vessels is upregulated in hyperglycaemic and hyperlipidemic 
patients, both risk factors for atherosclerosis. On the other hand, antioxidant enzyme superoxide 
dismutase and its protective mechanism is overwhelmed in presence of high level of ROS resulting in 
decreased levels of cardio protective enzymes [65, 76].  
1.2.4 Smooth Muscle Cells in Healthy Vessels and Role in Atherosclerosis (SMC) 
Layers of contractile SMCs residing in the tunica media maintain the vascular tone of blood vessels by 
means of  vasodilation and vasoconstriction [55]. Vasodilation is primarily mediated through NO release 
by endothelial cells of the intimal layer and its rapid diffusion into the medial layer where NO acts on 
smooth muscle cells [55]. Low molecular weight and lipophilic properties of this gaseous free radical allow 
it to easily cross cell membranes making NO a potent vasodilator of the vascular vessels [77]. NO binds 
and activates guanyl cyclases that in turn catalyse dephosporylation of guanosine-5-triphosphate (GTP) to 
cyclic guanosine-3′,5′-monophosphat (cGMP) inducing relaxation of SMC contractile filaments [78]. 
NO regulates cardiovascular motor tone where SMC relaxation and vasodilation inhibits platelet 
aggregation and inflammatory cell adhesion to the endothelium and inhibition of SMC proliferation and 
migration [77]. These important functions are mediated by SMC relaxation causing vessel dilation as a 
response to NO diffusion. Therefore, healthy medial layer exhibits quiescent contractile phenotype and is 
characterized by anti-thrombotic and anti-inflammatory properties [67, 79].  
Vasodilation is also partially controlled by gap junctions which are involved in transmission of 
hyperpolarization from EC to SMC to hyperpolarize SMC causing their relaxation [80]. Gap junctions are 
known among others to regulate death/survival pathways, cell quiescence, endothelial repair and 
angiogenesis. Structural units of gap junctions are connexins (Cx), transmembrane proteins with four 
transmembrane domains, two cytoplasmic loops and two extracellular loops. Six connexins make a 
connexon hemichannel which when bound to another hemichannel forms a gap junction. Under 
physiological conditions, Cx37 and Cx40 are co-expressed in EC and Cx43 and Cx45 are expressed in SMCs, 
assembled into homomeric and heteromeric connexons, which then form homocellular and heterocellular 
gap junctions. These gap junctions enable communication between EC and SMC in both directions [80]. 
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Gap junctions are crucial for vessel wall development and function. For example connexin gene knockout 
causes death of foetuses in animals [81]. SMC experience increased expression of Cx43 during early 
atherosclerotic lesions, whereas in advanced lesion Cx43 is decreased. EC co-express Cx37 and Cx40, 
however as the disease progresses EC lose the expression of Cx completely [80]. 
In atherogenesis, SMCs when stimulated by the influence of reactive oxygen species and cytokines 
produced in the activated endothelium can switch from contractile to synthetic phenotype and initiate 
vessel remodelling [67, 82].  Remodelling takes place by SMCs proliferation, synthesis of extracellular 
matrix (ECM) and SMC migration to the intima resulting in thickening of intimal layer of the blood vessel 
[38]. Accumulation of synthetic SMCs in the intimal layer of atherosclerotic lesions have been reported to 
contain lipid droplets due to scavenger receptor expression and exhibit synthetic rather than contractile 
myofilament-rich phenotype [35, 83]. ECM produced by synthetic SMCs assists in wound healing by 
providing a scaffold for attachment of new cells [84], thereby contributing to plaque growth and formation 
of a fibrous cap [82, 85]. The main components of ECM in atherosclerosis; proteoglycans and fibronectin 
can retain low-density lipoprotein (LDL), which when oxidized will stimulate further proteoglycan 
production. SMCs produce platelet derived growth factor (PDGF), transforming growth factor beta (TGF-
β), macrophage inhibitory factor (MIF), interferon gamma (IFN-ϒ) and monocyte chemoattractant protein 
1 (MCP-1). These cytokines not only attract monocytes and leukocytes but also further stimulate SMC 
proliferation and ECM deposition [36]. For example, platelet derived growth factor (PDGF) produced by 
platelets aggregated in the intima acts as a chemoattractant for SMC and induces SMC migration from 
media and their accumulation in intima  [86]. In terms of the plaque, SMCs are predominantly found in 
the area between the lipid core and vessel lumen. Changes in SMC associated with atherosclerosis have 
been described as; increased SMC cell proliferation and cytokine production, increase in rough 
endoplasmatic reticulum (RER), production of extracellular matrix by expression of collagen type I and III, 
accumulation of lipoproteins and expression of scavenger receptor and lipoprotein lipase. Cytokines 
produced by activated SMC include macrophage colony stimulating factor (MCSF), tumor necrosis factor 
(TNF) and MCP-1[35]. These changes are observed in advanced lesions, but not early lesions. In summary, 
intimal SMC of atherosclerotic lesion exhibit synthetic phenotype, greatly contributing to early lesion 
formation, mainly by ECM deposition capable of lipid retention.  
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1.2.5 Risk Factors 
Many risk factors for the development of atherosclerosis exist; aging, smoking, hypertension, 
hyperglycaemia and hyperlipidemia. Even though obesity represents major risk in cardiovascular disease, 
it is now considered that obesity is rather a factor contributing to cardiovasuclar disease factors since it is 
observed in association with hypertention and diabetes [65]. Chronic exposure to risk factors and harmful 
stimuli associated with these conditions at the early stages induce changes in endothelial function 
compromising its integrity that then leads to the onset of atherosclerosis. 
Smoking has been found to impair endothelial function by decreasing NO bioavailability and increasing 
levels of oxidized LDL and decreasing HDL due to the presence of exogenous free radicals. Interestingly, 
passive smoking has been shown to induce similar endothelium impairing changes in the vasculature [87]. 
In smokers, vascular vessels exhibit vasoconstrictive phenotype due to loss of flow mediated vasodilation 
and inflammatory phenotype, both of which accelerate progression of atherosclerosis. However, smoking 
poses a dose-dependent reversible risk on the vasculature if smoking is ceased [88].   
Hypertension, is associated with loss of endothelium-dependent vasodilation by altering shear stress in 
the blood vessels due to changes in gene expression of proteins and molecules regulating vascular tone 
such as NO, angiotensin II and endothelin [89]. Endothelial response to shear stress is reduced or absent 
in hypertensive patients. The conditions displays itself with vasoconstrictive phenotype due to a loss of 
endothelial function [68].  
Hyperglycaemia as occurs in diabetes mellitus is an independent risk factor for atherosclerosis 
development [90], associated with increased oxidative stress (production of superoxide) primarily due to 
upregulation of NADPH Oxidase and increased production of advanced glycation end-products (AGE) [91]. 
Superoxide scavenges NO, decreasing its bioavailibility and thus impairing endothelium-dependent 
vasodilation. Dysfunctional endothelium is then a stepping stone in atherosclerosis initiation. AGE, 
produced by irreversibly adding glucose (glycation) to extracellular and intracellular lipids and proteins 
are capable of further decreasing NO bioavailability as well as bind to monocytes, macrophages and SMC 
resulting in amplification of an inflammatory response, increased vascular permeability and oxidative 
stress [92, 93].   
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Hyperlipideamia is a condition in which high circulating levels of LDL, cholesterol and triglycerides pose a 
a risk of endothelial dysfunction and development of atherosclerosis, a disease related to lipid 
accumulation. Hyperlipidaemia can occur due to a genetic predisposition or be acquired through 
metabolic abnormalities as a result of diet [94]. The mechanism of hyperlipidaemia-associated endothelial 
dysfunction has been reported to lie in increased plasma levels of asymetric dimethylarginine (ADMA) and 
oxidation of LDL. ADMA inhibits eNOS, thereby decreases NO levels and impares EC function whereas 
oxidized LDL, promotes expression of adhesion molecules and contributes to foam cell formation thus 
plaque development [93, 95]. 
Lastly, as we age, the ability of endothelium to produce NO is reduced due to lower L-arginine levels. L-
arginine is a substrate of eNOS, the enzyme synthesizing NO. Arginase I on the other hand exhibits 
increased activity and competes for the same substrate with eNOS by uncoupling eNOS [96]. Aging is also 
often associated with other conditions, already atherosclerotic risk-factors, such as hyperlipedeamia, 
hyperglycaemia and hypertension, thereby exacerbating the risk of endothelial dysfunction and 
atherosclerosis [65].  
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1.2.6 Treatment Strategies 
The strategies for treatment of vascular stenosis rely on mechanically opening affected blood vessels by 
endovascular stents or balloons or a combination of both [97-99]. Deflated balloons and stents delivered 
to the lesion via catheter are expanded to open up vessels in the procedure called percutaneous 
transluminal angioplasty (PTA) as illustrated in Figure 1.4 [100, 101]. In 1974, a German physician, Andreas 
Gruentzig, carried out balloon angioplasty on peripheral arteries to treat vascular stenosis and performed 
the very first balloon angioplasty on a human coronary artery in 1976. Ten years later, the first coronary 
stent was deployed by Puel and Sigwart in 1986, to prevent vessel renarrowing associated with the use of 
balloons. The utilization of stents, however did not resolve the problem of blood vessel re-narrowing and 
their use required reinterventions as soon as 3-6 month post-angioplasty due to excessive SMC 
proliferation. Proliferation of SMCs in the intimal layer resulted in neointimal thickening also known as 
neointimal hyperplasia leading to occlusion of the stented vessel segment and therefore in-stent 
restenosis (ISR) [102]. Stents composed of various metal materials are now known as bare metal stents 
(BMS). The beginning of the new millenium saw the introduction of drug-eluting stent (DES) in an effort 
to combat neointimal thickening associated with the use of BMS [103, 104]. Even though the advantage 
of DES over BMS was clear in suppressing neointimal thickening by elution of anti-proliferative drugs, a 
new issue of late stent thrombosis was identified (Navarese et al. 2014). Late stent thrombosis can occur 
up to 1 year post-implantation and very late stent thrombosis after 1 year post-intervention [105, 106]. 
The complications of in-stent restenosis and late stent thrombosis arise due to pathological healing 
responses of denuded endothelium in the vascular vessel wall, as a result of trauma experienced during 
angioplasty [107, 108]. The imbalance of growth promoting and inhibiting factors during chronic healing 
response leads to intimal thickening, resulting in ISR [107].  First generation drug-eluting stents employed 
the use of mainly paclitaxel and sirolimus to combat restenosis, both of which inhibit smooth muscle cell 
proliferation [109]. The occurence of macrophage-derived foam cell in the neointima of DES, greatly 
resembling early atherosclerotic events, has been recognized as a factor contributing to late stent 
thrombosis associated with delayed re-endothelialization [110]. It is important to notice that these 
catastrophic events occur long after the drug is eluted from the stent. For this reason persistent 
inflammation has been pinpointed as one of the main aspects of late stent failure [111]. The extended 
drug retention in the lipophilic atheroma of the vascular wall has been suggested to contribute to delayed 
vascular repair and associated post-implantation invasion of inflammatory cells [108]. For example the 
COOK Medical Zilver PTX stent has  been reported to elute the polymer free anti-proliferative agent 
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paclitaxel within 72 hours but remains retained in the arterial wall tissues for 56 days. [112].  The self-
expanding Zilver PTX stent made of nitinol is the only stent approved by FDA for intervention in popliteal 
and superficial femoral arteries [113]. Despite nearly half a century passing since the first angioplasty, the 
issue of cardiovascular re-interventions due to stent failure remain a problem, highlighting the need for 
smart stents capable of inhibiting neointimal growth as well as accelerating endothelial repair [114]. 
 
Figure 1.4: Summary of percutaneous coronary intervention where stent delivered through a catheter is 
used to open up blocked blood vessels and restore blood flow. Figure created with BioRender 
(https://biorender.com) 
1.3 Restenosis 
1.3.1 Post-implantation Cascade 
Restenosis, as the name suggests is the re-occurrence of stenosis. In stent restenosis (ISR) is a result of 
exaggerated neointimal tissue growth as a healing response to vascular injury caused by stent deployment. 
Restenosis is  defined as a >75 % cross-sectional area luminal narrowing of the stented artery [115]. Three 
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basic mechanisms leading to luminal narrowing after angioplasty exist; elastic recoil, negative remodelling 
and neointimal hyperplasia (NIH). After balloon angioplasty, the affected blood vessel experiences dilation.  
Elastic recoil is a result of the passive process of opposite forces of vessel laminae to the vessel dilation. 
Negative remodelling caused by shrinkage of the external elastic lamina is a response to changes in the 
vessel wall structure such as intimal hyperplasia (intimal thickening). Oxidative stress is known to be 
increased post-angioplasty and may be involved in negative remodelling by increasing  nitric oxide 
breakdown, hence increased vessel constriction. Exaggerated healing response, neointimal growth itself, 
represents a third mechanism leading to restenosis [116].  
As discussed in section 1.2, endothelial denudation, thrombus formation, inflammation, proliferation, 
matrix formation and re-endothellialization are the main events after vascular injury caused by stent 
implantation. The early phase of thrombus formation and inflammation happens immediately after injury, 
followed by granulation tissue formation resulting from proliferation of mainly SMCs and lastly ECM 
deposition responsible for tissue remodelling, possibly leading to intimal hyperplasia and ISR. Intricate 
molecular mechanisms orchestrating the process of vascular healing become dysregulated in presence of 
persistent inflammation due to imbalance of growth-promoting and growth-inhibiting signals (Inoue et al. 
2011). Re-endothelialization, regenerationn of denuded endothelial layer, is a complex process not yet 
fully understood [115, 117].  
Vascular endothelial growth factor (VEGF) is known to promote angiogenesis and growth of endothelial 
cells in injured arteries [118]. The degree of NIH correlates inversely with the extent of cells contributing 
to the regeneration of the endothelium, in fact re-endothelialization is associated with termination of 
SMC proliferation [119]. However, the regenerated endothelium often fails to perform its biological 
functions and is said to be dysfunctional. The impaired endothelium is primarily formed by inflammatory 
SMC which provide basis for inflammatory cells invasion and neo-atherosclerosis development.  
Vascular stent implantation initiates a chronic healing response of the affected blood vessel and is 
accompanied by incomplete endothelial coverage that increases permeability and allows entry of high 
levels of  lipoprotein and inflammatory cells and by presence of ROS [120]. Even after formation of an 
intact endothelial layer, the endothelium does not exhibit its most important function which is 
vasodilation [121-123].  
17 
 
1.3.2 Stent-induced Endothelial Injury and EC Dysfunction 
The endothelium as the innermost layer is heavily impacted by angioplastic intervention. The EC 
experiences denudation, re-endothelialization and neoendothelium formation [115]. Denudation of cells 
of various degree takes place. The cells lose cell-cell junctions and the endothelium becomes leaky. The 
affected arteries experience stretch, mechanical disruption of atherosclerotic plaque and possible 
dissection into tunica media.  
These initial events cause endothelial activation; membrane bound molecules are cleaved and secreted,  
generation of reactive oxygen species, cytokines and expression of adhesion molecules takes place. The 
injured endothelium loses its anti-thrombogenic, anti-inflmmatory barrier properties which lead to 
increased leakiness [115, 120]. Circulating endothelial cells (CEC) considered to be markers of endothelial 
injury are cells shed from endothelium after the injury. As part of normal cell turnover these cells are 
present in low levels under physiological conditions, however their levels are greatly increased after 
angioplasty [120]. At the time of vascular injury, denuded endothelium exposes subendothelial matrix and 
tissue factor initiating platelet adherence and aggregation with subsequent fibrin deposition – thrombus 
formation via a fibrin clot. Collagen in the subendothelial matrix attracts the protein, von Willebrand 
factor (vWF), which when bound via the specific GP1 receptor causes platelet activation, initiating a 
coagulation cascade [120]. VWF, considered a plasma marker of endothelial injury is released from 




Figure 1.5: Adhesion molecules expressed by platelets and luekocytes during recruitment of leukocytes to 
the injury site [108] Figure created with BioRender (https://biorender.com). 
 
Immediately, after platelet adhesion to the denuded areas, leukocyte capture takes place by interaction 
between adhesion molecules of platelets and leukocytes. This physiological response to injury recruits 
leukocytes through process of rolling, activation, adhesion and transmigration. Leukocytes express the 
leukocyte integrin Mac-1 on their surface to mediate firm adhesion necessary for transmigration 
subendothelial space. It has been shown that targeting Mac-1 which is significantly upregulated after 
vascular injury reduces neointimal thickening by combating inflammation [108]. Leukocyte interactions 
with platelets and the endothelium is illustrated in Figure 1.5. 
Persistent inflammatory responses associated with vascular implants lead to thrombus formation and may 
result in occlusion. For this reason patients are prescribed dual anti-platelet therapy (DAPT) after 
intervention [125]. DAPT involves a combination of aspirin and other adenosine diphosphate (ADP) 
receptor antagonists involved in platelet aggregation, such as clopidogrel [126]. Patients with BMS are 
usually on DAPT for approximately 30 days. After this time regeneration of injured endothelium is said to 
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be complete [127]. DES patient are on DAPT much longer, up to 12 months, due to the action of the anti-
proliferative drug which delays endothelial regeneration and leads to endothelial dysfunction via 
sustained endothelial activation  [125, 128]. Endothelial activation and associated adhesion molecules, 
especially P-selectin and ICAM-1, mediate adhesion of neutrophils – a type of white blood cell, followed 
by monocytes and their migration to subendothelial space, further increasing inflammation. Expression 
of adhesion molecules enhances infiltration of monocytes and lymphocytes [36]. Adhesion molecules, 
intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule (VCAM-1) and chemokine 
CX3CL1 expressed on human SMC, enable retention of inflammatory cells and their protection from 
apoptosis [67, 129]. Migration of inflammatory cells is directed by cytokines such as interleukins, mainly 
IL-6 and IL-8 [120]. Regenerated endothelium, although appearing intact, have been reported to be 
dysfunctional, presumably due to sustained endothelial activation which alters endothelial functionality 
[120]. The main characteristics of endothelial dysfunction is loss of endothelium-dependent vasodilation, 
increased permeability, presence of oxidative stress and inflammation. The inability of endothelium to 
mediate vasodilation is due to a decrease in nitric oxide (NO) bioavailability, which is synthesized by the 
homodimeric eNOS enzyme. Reactive oxygen species in injured vasculature inactivate eNOS by uncoupling, 
the enzyme which then preferentially synthesizes superoxides instead of NO. Superoxides scavenge NO, 
further decreasing its bioavailability [120]. In peripheral artery disease specifically, expression of 
asymmetric dimethylarginine (ADMA) was found to be increased in animal studies which as a competitive 
inhibitor of eNOS and competes for the same substrate; L-arginine [130]. Increased oxidative stress and 
decreased levels of antioxidant enzymes is seen after coronary interventions such as stent implantation 
as well as atherosclerosis. The presence of reactive oxygen species (ROS) contribute to the extent of injury 
and endothelial dysfunction. The main sources of ROS in vasculature after coronary intervention is 
uncoupled eNOS, xanthine oxidase and cyclooxygenase. Contribution of eNOS to oxidative stress has been 
described in an earlier section. DES such as paclitaxel eluting stents have been reported to produce 
increased levels of superoxide compare to use of BMS, by inducing NADPH Oxidase activity [131, 132]. 
 Evidence from a study of neovascularization in animals suggests eNOS involvement in endothelial 
progenitor cell (EPC) mobilization, therefore low expression of eNOS after stent implantation may impair 
the healing process [133]. When eNOS gene transduction was used in stented rabbit iliac arteries to induce 




Initial apoptosis, migration and proliferation of SMC have also been attributed to the presence of ROS 
[135]. It has been suggested that the increase of ROS could be due to inflammatory cells recruitment, 
which themselves can generate superoxide.  Endothelial dysfunction has been more pronounced after 
DES than BMS implantation. However, BMS–associated endothelial dysfunction is greater than the one 
after balloon angioplasty. Paclitaxel and sirolimus, used in drug-eluting stents, are known to decrease 
eNOS activity, resulting in low NO bioavailability [131].  
1.3.3 Role of Progenitor Cells in Vascular Healing 
The term progenitor cells refers to a cell population able to differentiate into cells with specific 
functionality. Endothelial progenitor cells (EPC) can differentiate into a functional mature EC. This 
knowledge has been at the centre of angiogenesis and vasculogenesis as well as re-endothelialization 
research, since their discovery in 1997, due to direct involvement of EPC in these processes and therefore 
their therapeutic potential [124, 136]. Bone marrow-derived endothelial progenitor cells are involved in 
the vascular repair process by migration and proliferation to the injured endothelium [115], where they 
serve as patches to cover denuded areas, contributing to re-endothelialization. EPC can be mobilized to 
the injured artery in response to tissue ischemia, thrombosis of atherosclerotic plaque and vessel wall 
injury such as the one after stent implantation [137-140]. It has been suggested that early EPC with low 
proliferative activity and late EPC with high proliferative activity exist in the vasculature during vascular 
repair [141, 142]. The late EPC exhibit greater resemblance to mature EC by expression of vWF, E-selectin, 
VE-cadherin and eNOS. Both, the early and late EPC express surface specific antigen CD133+ [119].  
The process of homing and proliferation of EPC has been suggested to be impaired by the action of anti-
proliferative agents typically used as DES coatings such as taxanes and rapamycins, which mode of action 
not only supresses SMC proliferation but also EC thus affecting the re-endothelialization process [109, 
143]. Delayed re-endothelialization has been reported in iliac arteries in animal models implanted with 
taxol eluting stent [111]. Human studies suggest the time for complete endothelialization after BMS stents 
is between 3 – 4 months [144], while re-endothelialization after DES implantion has been shown to be 
significantly delayed compare to BMS, with late stent thrombosis occurring beyond 1 year post-
implantation [105, 106, 143]. 
Despite their great repair potential, EPCs, depending on local environment can differentiate into several 
cell types [120]. Bone marrow-derived progenitor cells from peripheral blood with CD34 surface antigen 
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have been identified to be involved in re-endothelialization [145]. This antigen, although non-specific, 
commits cells to travel to the site of vascular injury. Under tissue ischemia conditions, such as in 
myocardial infarction, CD34 progenitor cells preferentially differentiate into endothelial progenitor cell to 
mediate angiogenesis. Conversely, during vascular injury such as after cardiovascular intervention, CD34-
positive progenitor cells preferentially differentiate into SMC-like progenitor cells as a response to 
inflammatory mediators at the site of stent implantation, increasing the risk of ISR [108, 146]. The 
illustration in Figure 1.6 shows the differentiation paths of bone marrow-derived CD34 positive stem cell. 
Hematopoetic CD34 cell and CD133-positive cells have been identified to date as stem cell markers for 
endothelial progenitor cells [136].  Co-expression of the these markers (CD34 & CD133), EC markers 
(CD62E, CD144, VEGFR-2), kinase insert domain receptor, Tie-1 angiopoietin receptor and ability to form 
colony-forming units are all markers of endothelial progenitor cells [120].  
 





1.3.4 Smooth Muscle Cells Migration and Proliferation 
Granulation tissue is formed by the action of SMCs which replace thrombi or fibrin clots. Proliferation of 
SMCs and EC is stimulated by fibroblast growth factor (FGF), insulin-like growth factor (IGF), transforming 
growth factor- β (TGF-β) and platelet-derived growth factor (PDGF) released by macrophages, EC and 
platelets [115]. These growth factors have been shown to be strongly associated with neointimal growth 
in animal studies and in tumors in vivo. FGF is capable of stimulating angiogenesis; new vessel wall 
formation [117]. PDGF is known to induce synthetic phenotype in SMC and cause cell migration from 
media to intima while TGF-β expression correlates with synthesis of ECM proteoglycans [147].  
Mechanical factors, such as the stretch experienced during angioplasty are also known causes of SMCs 
leaving the quiescent state and entering the cell cycle [148]. SMC migration from the media to the intima 
is mediated by degradation of extracellular matrix by matrix metalloproteases (MMP), in particular MMP-
2 and MMP-9 in the process of remodelling [149]. Early after stenting, intimal SMCs synthesize ECM 
components; proteoglycans, hyaluronan and collagen type I and III fragments, differing from the medial 
layer that consists mainly of fibrillar collagen type I and III, proteoglycans and elastin fibers [150]. 
Accumulation of medial SMCs in intima and ECM deposition leading to NIH are critical factors in the 
development of ISR. SMC in this process acquire a highly proliferative and migratory synthetic phenotype. 
For this reason DES have been designed to release antiproliferative agents to suppress SMC proliferation 
[115]. 
Two signalling pathways are activated during injury induced SMC proliferation by stimuli such as PDGF, 
endothelial growth factor (EGF), basic fibroblast growth factor (bFGF): PI3K/Akt/mTOR and 
Ras/RAF/MEK/ERK1/2. Intense vascular injury may lead to apoptosis of  the SMCs and this may limit the 
capacity of a proper wound-healling response of medial SMC. Apoptosis of SMC activates pro-
inflammatory gene expression and thus release of CCL2, IL-8 and IL-1 which attract leukocytes and triggers 
pro-inflammatory SMC phenotype following vascular injury. IL-1 can induce SMC proliferation and 
expression of NF-kB dependent genes in SMC. Neointimal SMC exhibit NF-kB signalling, which links the 
inflammatory and proliferative response of SMC. [151] Overall, the SMCs switch from quiescent to 
synthetic phenotype is a multifactorial and complex process resulting in neointimal thickening and ISR. 
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Connexins, structural units of gap junctions, transmit hyperpolarization of ECs to SMCs causing their 
relaxation and therefore are important elements of the vasodilation mechanism. SMC Cx43  and Cx40 in 
restenotic lesions are highly upregulated in both; migrated intimal and residing medial SMCs  [80], while 
C-reactive protein, biomarker of inflammation, has been shown to upregulate Cx43 mRNA expression. 
These findings suggests that during chronic inflammation in restenosis expression of connexins is modified 
and therefore Cx expression could serve as a marker for NI prognosis [152]. 
1.4 Drug-eluting Stent Platforms and Bioactive Agents 
1.4.1 Drug-eluting Stents 
The beginning of the new millenium was the start of drug-eluting stents (DES) deployment, but also 
introduced the problem of late stent thrombosis associated with the DES use [103, 104]. First generation 
drug-eluting stents employed the use of mainly paclitaxel and sirolimus drugs loaded onto a stainless steel 
stent with struts of thickness up to 140 µm [153]. The design of second generation DES  involved use of 
new alloy materials such as cobalt-chromium along with thinner stent struts and lower drug concentration 
of the sirolimus analogues [153]. Thinner stent struts not only provide improved flexibility but also have 
been shown to improve endothelialization process [154]. The term drug-eluting stent is described as 
“device that presents or releases one or more bioactive agents to tissue at and near implant” [155].  The 
bioactive agents are released from the stent surface via a carrier-free platform or are embedded in a 
carrier molecule, typically polymer-based, and their release is subsequently controlled by the polymer 
[156]. Many stent manufacturers use polymers for controlled drug release, however inflammation 
associated with use of polymers led to the development of polymer-free approaches or biodegradable 
polymeric carriers. The polymer free approach involves coating the antiproliferative agent directly on the 
stent surface [157, 158]. Surface modifications  including porous and microtextured surfaces or drug 
reservoirs machined directly into the stent surface are necessary for the success of this approach to retain 
and release the pure drug in a controlled way [157]. Although, many new stent stent coatings have 
emerged in the last decade, the most widely used and FDA approved coatings belong to the two classes 
of drugs; taxanes and rapamycins.  Both taxane and rapamycin drugs fight NI growth by their ability to 
target the key event of restenosis development, i.e. suppressing SMC proliferation, hence matrix 
production by exhibiting anti-proliferative effects [109]. Although, the taxanes and rapamycins achieve 
the same end result, they differ in the mechanism of action to induce these (see section 1.5.2 and 1.5.3). 
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The reason why these drugs were selected as stent coatings apart from exhibiting cell growth suppressive 
properties lies in their physicochemical properties; that is their lipophilicity and low solubility. The low 
solubility and high tissue retention properties, that make them very difficult for systemic delivery, make 
them ideal for local stent delivery, allowing a slow and sustained drug release into the vascular wall. 
Taxanes and rapamycins are associated with poor in vitro to in vivo data correlation due to their poor 
solubility [159]. This is due to the solubilization strategies used to reconstitute hydrophobic drugs resulting 
in solution behavior that is not representative of in vivo pharmacokinetics [159, 160].  
Due to the limited ability of traditional stent coatings using taxanes and rapamycins to improve vascular 
response, alternative strategies for improving endothelialization have been explored. Noteworthy are 
phosphorylcholine (PC)-based coatings, shown to generate highly biocompatible stent surface by 
mimicking the hydrophilic head group of cell membrane phospholipids. These coatings have later 
transitioned into drug coatings as in the example of the Endeavor ® stent by Medtronics that uses PC  
system to elute a rapamycin analogue [157, 161]. In recent years, cell capture strategies to promote 
endothelial repair by direct immobilization of biomolecules to the stent surface have been employed, for 
example, CD34-antibody coated stents to capture endothelial progenitor cells, or VE-cadherin and VEGF 
coated stents to preferentially capture EC [120, 162]. Immobilization of heparin to the stent surface, an 
anti-thrombotic and anti-coagulant drug, has been shown to suppress platelet aggregation and to improve 
EC proliferation [163]. Similarly, ECM components such as laminins, fibronectin and hyaluronic acid were 
used to improve cell attachment and spreading of ECs [164-166].  
The following sections review key properties and mechanism of action of paclitaxel and sirolimus, the two 
typically used DES coatings due to their anti-proliferative action. The anti-proliferative action of these 
drugs allows fighting the progression of NIH by targeting proliferative phase of the post-implantation 
cascade. The review of post-implantation cascade has highlighted the issue of DES-associated stent 
thrombosis and a need for novel bioactive agents that can selectively target cell proliferation and improve 
endothelialization. Citric acid (CA) emerges as a novel bioactive compound exhibiting properties such as 
anti-coagulation and anti-thrombogeneity that are relevant to the post-implantation cascade. CA is 




Table 1.1: Principal characteristics of selected DES eluting drugs from family of taxanes and rapamycins. 
Paclitaxel belongs to taxanes while zotarolimus, everolimus and Biolimus A9 are rapamycins semisynthetic 
derivatives.  
TRADE NAME MANUFACTURER DRUG DRUG CARRIER PLATFORM 
Zilver® PTX® [171] Cook Medical Paclitaxel Carrier free Nitinol 
TAXUS™ Liberté™ 
[172] 
Boston Scientific Paclitaxel SIBS (Translute) 316 SS 
Endeavor® [173] Medtronic Zotarolimus Phosphorylcholine CoCr 
XIENCE Sierra [174] Abbott Everolimus Fluoropolymer CoCr 
Zomaxx (IDE) [175] Abbott Zotarolimus Phosphorylcholine CoCr 
BioFreedom [176] Biosensors Biolimus A9 Carrier free 316 SS 
 
1.4.2 Paclitaxel 
Paclitaxel, a taxane drug, is a naturally occurring diterpenoid, extracted from the bark of yew tree, Taxus 
brevifolia and initially identified in a search for new anti-cancer drug candidates in 1967 [177]. The newly 
isolated compound taxol was given a generic name paclitaxel after it was commercialized by Bristol-
Myers-Squibb for treatment of ovarian and lung cancer among others [178]. Its high lipophilicity and low 
solubility allows direct coating of the drug onto a stent [153]. Paclitaxel stabilizes microtubules by binding 
to the N-terminal 31 amino acids of the β-tubulin component of microtubules during the mitotic spindle 
disassembly in telophase of cell division. The binding prevents microtubule depolymerization leading a 
sustained activation of the spindle assembly checkpoint with the cells are arrested in the G2/M phase of 
the cell cycle [179-181]. This way paclitaxel induces cytostatic effects on cell. However, three different 
mechanisms of cell response to paclitaxel-induced mitotic arrest have been described. First, the sustained 
mitotic arrest can promote apoptosis or programmed cell death which is characterized by membrane 
blebbing and DNA fragmentation [182]. The second type of cell fate results in mitotic slippage, where cells 
return back to interphase without chromosome segregation resulting in the formation of micronuclei 
[183]. The third scenario, uncommon at high PTX doses, sees cells completing the mitosis following a long 




Figure 1.7: Chemical structure of Paclitaxel.  
1.4.3 Sirolimus 
Sirolimus (SIR) a macrolide discovered during a search for new antimicrobial agents in soil samples in 1975  
[185]. It is a potent immunosuppressant with anti-fungal and anti-tumor properties and has been an FDA 
approved immune-suppressant for renal transplants since 1999 [186]. Originally known as rapamycin, it 
is produced and isolated from a fermentation of fungal species Streptomyces hygroscopicus [185, 187]. 
Similarly to paclitaxel, its physicochemical properties, low aqueous solubility and high lipophilicity, ensure 
local delivery to the arterial wall where it can target cellular proliferation. SIR mechanism of action inhibits 
mTOR mediated signal transduction pathways. SIR arrests the cell cycle in the late G1 phase by interacting 
with a cytosolic receptor FKBP12, creating immunosuppressive complexes. These complexes then target 
mTOR (mammalian target of rapamycin), a central regulator of cell growth and proliferation, and by doing 
so they inhibit pro-survival cell signaling and progression from G1 to S phase [188, 189]. Semi-synthetic 
derivatives of sirolimus now exist including zotarolimus, an analogue made by substitution of a tetrazole 
ring in place of the native hydroxyl group in rapamycin, everolimus, a hydroxyethyl derivated of sirolimus 
and reported to have improved pharmacokinetic profile compare to its original counterpart and biolimus 
A9, another analogue of sirolimus, Figure 1.8. However, zotarolimus and everolimus dominate the stent 
market [190, 191]. Examples of the major stent manufacturers shown in Table 1.1.   
Although taxanes and rapamycins combat neointimal proliferation by their anti-proliferative mechanisms 
they impede proliferation of all cells types in the vascular system and thus in the long term prevent 
endothelial healing. This is a very significant issue as the injured endothelium regenerates by proliferation 
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of mature EC, recruitment of vascular progenitor cells and circulating endothelial cells (CEC), as discussed 
(1.3. Due to their lack of cell target specificity, both, taxanes and rapamycins inhibit these processes [192-
194].    
 
Figure 1.8: Sirolimus analogues derived by hydroxyl group substitution [191]. 
 
1.4.4 Citric Acid 
Citric acid or 2-hydroxy-,12,3-propanetricarboxylic acid, C6H8O7, (Figure 1.9), is formed as part of the 
tricarboxylic acid cycle (Krebs cycle) or citric acid cycle in all aerobically metabolizing organisms. Citrate  is 
formed as an intermediate metabolite in the matrix of the mitochondrion after condensation of acetate 
with oxaloacetate before it is degraded to a series of 4-carbon acids and finally to carbon dioxide and 
water  [195, 196].  Citric acid appears colourless and odourless with a high aqueous solubility (62.07 g/ml 
at 25°C) with a molecular weight of 210.14 g/mol (monohydrate) and 192.12 g/mol (anhydrous) [197]. In 
solution it exhibits weak acidity with pKa values 5.21, 4.28 and 2.92 at 25 °C corresponding to the three 
carboxylate functional groups [198]. As the name suggests, citric acid is predominantly found in citrus 
fruits such as lemons and limes and in fact was initially crystallized from lemon juice in 1784 [199, 200]. 
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As a central molecule of the tricarboxylic acid cycle, discovered in the 1930s, it has since been utilized in 
a wide range of applications [201]. For industrial purposes citric acid was traditionally extracted from 
lemon juice, nowadays it is almost solely produced from a fungus Aspergillus niger, also known as black 
mold, capable of converting sugars into citric acid [202]. In the food and beverage industry, citric acid is 
used as an acidulant and preservative while pharmaceutical formulations take advantage of its antioxidant 
properties where it is used as excipient. It is also often seen as one of the basic components in cosmetic 
preparations [195]. Citric acid is used in medicinal preparation to treat various conditions such as to 
dissolve bladder stones, gastrointestinal disturbances or renal acidosis [203].  
Citric acid exhibits metal chelating properties which find application in the removal of contaminants from 
soils as part of environmental remediation [204]. Other uses such as crosslinking agent and disinfectant 
prove that citric acid is a versatile yet environmentally friendly compound causing no harm to humans, 
supported by its GRAS (Generally recognized as Safe) status [205]. The metal chelating properties play a 
critical role in the vasculature where citric acid acts as an anticoagulant by chelating and thus reducing 
the extracellular Ca2+ ions,  a required enzyme co-factor in the coagulation cascade [206]. The lack of 
calcium prevents the coagulation cascade from progression and therefore blocking platelet adhesion. The 
citrate-calcium complexes lead to a negligible plasma acidification as they are rapidly cleared from the 
blood [207].  
The anticoagulation property of citric acid has been of interest in blood contacting applications to improve 
material-tissue interactions such as in the case of vascular implants where thrombosis poses a risk. A 
number of studies describe the beneficial properties of citric acid pre-treated surfaces on lowering 
inflammation by inhibiting platelet adhesion and improving re-endothelialization [170, 208, 209]. CA has 
been shown to reduce endothelial dysfunction and inflammation, promote EC sprouting and expression 
of angiogenic factors [210, 211] and has been used as a coating or in combination with other materials on 
a number of blood contacting devices [124]. CA may improve material-tissue interactions in terms of 
endothelial cells adhesion followed by the formation of functional endothelium at lesion sites - a main 
indicator of stent implantation patency. Encouraging cell adhesion properties of CA crosslinked 
elastomers as a coating for vascular grafts were shown in a number of studies [170, 208, 209]. Kibbe et al. 
have demonstrated enhanced formation of an endothelial monolayer and decreased leukocyte adhesion 
[170], while CA treated heart valves were reported to improve endothelial attachment [212]. Since CA 
plays a major role in energy making TCA/Krebs cycle of the mitochondria, Yuan et al.  hypothesized that 
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citrate may be beneficial in healing energy-demanding tissues such as the heart after myocardial infarction. 
Their experiments showed evidence of the angiogenic potential of citrate through tubule formation by 
upregulating CD31 and VEGF in HUVEC [211].  
Citric acid is a weak acid that may cause local acidity in the extracellular environment. Local acidosis is 
observed in a number of physiological and pathological contexts such as wound healing and cancer 
microenvironments [150, 151]. The normal physiological pH is 7.4, while it is 6.2-6.9 in tumor 
microenvironments [213] and 5.7-6.1 in wound healing [214] where the acidosis may have beneficial or 
negative effects. For example, acidosis in wounds promotes healing and suppresses bacterial infection, 
while in cancers, acidosis, due to lactic acid accumulation, drives tumor vascularization and progression. 
It has been shown that extracellular acidification affects cellular adhesion and migration by integrin 
activation. For example, EC preferentially migrate towards an acidified environment and exhibit stronger 
adhesion under the acidic conditions as reported by stronger αvβ3 integrin-extracellular matrix ligand 
bond under these conditions [215, 216]. A separate study has reported increased osteoclast adhesive and 
migratory properties in acidified environments [217]. In a study with a vascular scaffold local acidic 
environment  showed a downregulated release of pro-inflammatory cytokines such as IL-1α, IL-6 and TNF-
α [218].  
It has been shown in cancer research studies that accumulation of citrate in tumors, could promote 
endothelial cell growth by expression of growth factors such as VEGF thus angiogenesis and 
vascularization of tumors [219]. A similar study showed angiogenic effects of citrate on EC where the 
authors hypothesized a potential beneficial effect for cardiac repair [211].   
  
In summary, its anticoagulant properties would make CA an ideal candidate for vascular applications 
where persistent inflammation poses a risk of thrombosis as in the case of DES. The potential extracellular 
acidosis may lead to improved endothelial healing by expression of angiogenic growth factors and by 






Figure 1.9: Chemical structure of citric acid  
 
1.5 Current Strategies for Studying Stent-cell Interactions 
Research into cardio vascular disease is traditionally carried out using 2D in vitro cell culture models.  2D 
cell culture is relatively cheap and simple, providing vital insights into elucidation of complex biological 
interactions, such as cardiovascular disease and in-stent restenosis. However, by default it studies cells in 
isolation of their natural environment where cells form a part of intricate 3D tissue architecture, receiving 
and transducing a plethora of signals by communicating with their cellular neighbors and extracellular 
matrix. The 3D architecture of tissues have been shown to influence basic cellular properties such as 
migration, morphology and proliferation [11, 12].  Thus, the translation of 2D in vitro data into clinical 
application remains challenging.  3D in vitro models allow better representation of tissue 
microenvironment and with the scientific advancement and the development in the area of polymers and 
scaffolds, are quickly becoming standard in the research of regenerative medicine and vascular disease. 
Therefore, 3D models with improved representation of physiological environments could close a gap 
between the in vitro cell culture and in vivo data. Pre-clinical in vivo studies in animal models represent a 
safety requirement in the route of pharmacological and medicinal product approval but they pose a 
considerable financial burden, ethical concern and a challenge in reproducing the human pathological 
state [220-222]. The physiological responses in animals, repeatedly shown to be significantly different to 
those of humans, has led to the withdrawal of many Phase I trials, further highlighting the inadequacies 
of traditional 2D cell culture [223, 224]. Moreover, the increased level of ethical concern with the use of 
animals in research have led to the establishment of the 3R principles of animal testing; replacement, 
reduction and refinement. In line with these principles falls a critical need in the area of vascular research 
for a representative and reproducible in vitro model that would allow quantitative assessment [225, 226]. 
In fact, there has been a great expansion in the research of in vitro cardiovascular models that would 
mimic in vivo conditions [227]. This development is driven by the on-going issue of in-stent restenosis in 
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BMS and late stent thrombosis associated with the use of DES and a need for standardized platform for 
testing novel stent platform candidates. The field of 3D models has seen development of organoids and 
spheroids, hydrogels, natural and synthetic derived polymer scaffolds as well as development of full 
tissues and organs [228]. While, organ-on-a-chip have been a buzzword in recent years, they do not solve 
the issue of studying endovascular devices in physiological dimensions of vasculature [229-231]. To tackle 
these concerns, more complex, multi-layered 3D cellularized tubular constructs have emerged, that have 
been show to assemble and grow under in vitro conditions and exhibit tunable biomechanical properties 
[232-234]. Such tubular constructs are engineered to mimic the distinct layers of vasculature by creating 
a layered scaffold composed of typically ECM-derived polymers such as collagen and elastin with 
embedded vascular cell types. Fibroblasts are seeded in the outer most adventitial layer, while SMCs are 
embedded in the medial layer and EC grown into a monolayer comprising the inner most layer are in direct 
contact with the blood [229, 232, 235]. In the context of tubular tissue engineering, implantable tissue-
engineered blood vessels (TEBV) have gained the most attention. TEBVs seeded with autologous and 
allogenic cells and studied under pulsatile blood flow systems signify a tremendous opportunity for clinical 
applications in arterial grafts [236].This approach has been adopted by leading commercial companies in 
regenerative medicine, Humacyte Inc. and Cytograft Tissue Engineering Inc [236, 237].  Two as well as 
three-layered collagen based  cellularized tubular  tissue fabricated in bioreactor systems have been 
shown to display similar biomechanics to native tissues [238, 239]. 
The field of vascular engineering has certainly made a considerable advances from mimicking vascular 
microenvironments by lining artificial vessels such as PTFE tube with ECs to fully assembled tubular 
cellularized vessels.  3D in vivo models represent a great opportunity in the field of vascular research.  
Their in-vivo relevance allows the study of vascular pathophysiology, testing new endovascular candidates 
and their therapeutic potential can be utilized in the regenerative medicine [240, 241].  3D models have 
been shown to provide advantageous modeling of cellular migration, proliferation, differentiation, 
apoptosis, gene expression and cell signaling due to increased mimicking of physiological environment 
[13, 242]. To illustrate the tremendous impact of 3D environment on the translation to physiological 
response a study of drug treatment efficacy in breast cancer is used as an example. It has been shown 
that in 3D model of breast cancer the necrotic or quiescent cells buried within the tumor unlike the ones 
on its periphery were not susceptible to apoptosis through the drug treatment. This is not seen in 2D 
cultures were necrotic cells detach into the medium and all viable cells are exposed to the drug treatment 
[243]. In a another study, 3D lung cancer model have been found to correlate with the in vivo biology of 
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human lung cancer by exhibiting increased cell apoptosis and proliferation and production a MMP subtype, 
not seen in the 2D model [244].  
1.5.1 Scaffold Materials and Fabrication Strategies 
Materials used in the tissue engineering of tubular scaffolds can be of synthetic or biological origin or 
combination of both; so call hybrid scaffolds [245]. Synthetic scaffolds, typically fabricated by 
electrospinning, are a material of choice where mechanical strength is preferable but result in reduced 
tissue response and therefore are suitable for arterial graft applications. Synthetic materials mostly 
comprise bio-degradable polymers where tunable degradation takes place over time via hydrolysis of 
ester bonds [246, 247]. The degradation rate of biodegradable scaffolds can be tuned by tailoring the 
physical properties of the polymeric material such as molecular weight and surface-area-to-volume ratio 
[245]. The use of co-polymeric scaffolds allows fine-tuning of the mechanical properties and degradation 
rates by varying the polymer ratio [245]. The most widely used polymers in the tissue engineering are 
polyglycolic acid (PGA), polylactic acid (PLA) and poly-Ɛ-caprolactone (PCL). PGA and PLA are structurally 
related with PLA having an additional single methyl group resulting in increased hydrophobicity a 
determining factor in degradation rate. Small structural differences have a big impact on the degradation 
rate while PGA degrades rapidly within 1 month, PLA prolonged degradation can take place from months 
to years [247, 248]. PCL exhibits highest degree of hydrophobicity out of the three polymers and its 
degradation rate is therefore the longest; more than a year. All of the three polymers are well understood, 
FDA-approved as generally recognized as safe (GRAS) with use in tissue engineering and many clinical 
applications such as grafts and other surgical implant materials [246, 247, 249].   
Strategies in tissue fabrication using biological scaffolds include self-assembly, hydrogels and 
decellularized tissue scaffolds [245]. The self-assembly approach takes advantage of cells’ innate ability 
to produce ECM resulting in a highly biocompatible scaffold with physiological strength. Cells stimulated 
with ascorbate yielded a tissue sheet composed of cells embedded in an intricate network of ECM that 
can be manipulated to produce desired tubular shapes [250]. Hydrogel scaffold fabrication consists of 
molding cell-seeded solubilized protein matrix into a desired shape, typically tubular in vascular 
applications, that is then solidified [239]. The 3D construct is then remodeled into vascular tissue via cell 
signaling and proliferation. The most frequently used materials are collagen type I but also II and III and 
fibronectin, providing a fully biocompatible matrix, however lacking in mechanical strength [238, 239, 
251]. To obtain intact native scaffold, native tissue can be decellularized and subsequently seeded with 
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cells of choice. Through the process removal of native cells, immunogenic components are eliminated 
while a scaffold matrix of physiological strength is obtained allowing seeding the scaffold with allogenic 
cells [252]. Although, the concept of tissue fabrication appears straightforward, multifactorial challenges 
exist in terms of delivering functional tissue: location-specific mechanical strength, low immunogenicity, 
anatomical representation of native tissue and long-term patency.  
1.6 Conclusions and Resulting Research Objectives 
From the literature review, it is evident that the concerns associated with stent implantation are 
significant on two levels: endothelial denudation of the intimal layer and phenotypic changes in the medial 
layer. The removal of endothelium during angioplasty causes underlying SMCs of the medial layer to 
change phenotype as a result of which NI forms. Drug-eluting stents were developed to combat this issue. 
However, endothelial regeneration following drug-eluting stent implantation is impaired due to the 
presence of non-selective anti-proliferative drugs. Even if the endothelium regenerates, it fails to perform 
its physiological functions and is considered dysfunctional. It is thought that promoting endothelialization 
during the early phases of endothelial healing will stimulate the exposed medial cells to return to a 
quiescent state, thus preventing formation of NIH.  
Currently, a disconnect between in vitro and in vivo data exists in the traditional cell culture methods in 
the area of stent-cell research. This is mainly due to the issue of neglecting dynamic blood flow, outer 
radial force of the expanded stent and using vessels that do not match mechanical properties of the native 
tissues. Therefore, the medical devices industry relies on costly animal testing before proceeding to 
clinical trials in humans. However, it is known that healing response in animals is significantly different to 
humans. Conclusions are often drawn based on a different stent platforms and length of studies. In 
summary, the literature review suggests a need for novel DES capable of inhibiting NIH while promoting 
re-endothelialization and a need for 3D model to study stent-cell interactions. 
During this project, significant research will be conducted into method development to study existing and 
novel stents and stents coatings and to elucidate a deeper understanding of vascular healing following 
stent implantation. In vitro testing of typically poorly water soluble DES coatings does not represent in 
vivo pharmacokinetics due to the use of solubilizers. Endothelialization studies will be used to understand 
how the cells interact with the stent surface and how endothelialization could be enhanced. Further, this 
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thesis will investigate the hypothesis that two-dimensional cell culture provides only limited data on 
biocompatibility of cardiovascular stents and that a three-dimensional model will allow for better 
prediction of tissue-stent response. Overall, this work aims to help to close the gap between 2D and 3D 
cell culture by developing a model of stent implantation that potentially could be used for standardized 
stent testing.    
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2 CHAPTER 2  
Stent conditioned media for in vitro 
evaluation of hydrophobic stent coating 
___________________________________ 
2.1 Introduction 
The ever-increasing number of new drugs in development are hydrophobic in nature [253]. The poor 
water solubility of these new therapeutic agents represents challenges not only for formulation strategies 
to increase bioavailability but also for studying the solution behavior in bio-relevant media and in in vitro 
assays during cell culture studies [159, 160]. Solubilizers and surfactants are frequently used to increase 
the solubility of a hydrophobic drugs [160, 253]. In cell culture assays, poorly soluble drugs are often 
utilized when completely pre-dissolved in organic solvents as concentrated stock solutions, most 
commonly in DMSO or other organic solvents, before dilution to working concentrations in a biologically 
relevant buffer [159]. We are particularly interested in the challenges associated with such preparations 
for in vitro testing. The in vitro evaluation of candidate drugs is typically conducted in aqueous biologic 
buffers and media.  The type of evaluation depends on the tested hypothesis but may include enzyme 
inhibition studies, metabolic activity, maximum inhibitory concentration or cellular uptake studies, all 
relying on known concentrations of the tested drug to draw conclusions. 
The main, and the most apparent concern with fully dissolved hydrophobic drugs in vitro arises from 
artificially high quantities of drug acting on cells that is not representative of the true situation in vivo. 
Clofazamine, an antimicrobial agent typically dissolved in DMSO, exhibits excellent anti-mycobacterial 
activity in vitro, yet the clinical use is limited due to its hydrophobic nature [254, 255]. Paclitaxel, as 
discussed in section 1.4.2, is similar. This is because, drugs with poor aqueous solubility such as clofazimine 
and paclitaxel will bury themselves in the lipophilic tissues within the body thus decreasing their 
bioavailability while increasing bioaccumulation [256, 257]. The less obvious concern is with drug carriers 
that are harmful themselves, as is the case where another hydrophobic antimicrobial drug triclosan loses 
its activity when solubilized in most organic solvents due to a strong interaction with the solubilizing 
agents [258, 259]. Various carrier systems are utilized to improve the solubility of poorly soluble drugs, 
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such as oils, surfactants, emulsifiers or solvents and co-solvents [260]. The properties of the carrier 
systems have also been shown to greatly influence the behavior of the drug in vivo [261, 262]. For example, 
cremophor, an oil used in parenteral preparations for poorly soluble paclitaxel and doxorubicin, was found 
to alter the pharmacokinetics of the drugs in mice [159]. During in vitro tests, the use of appropriate 
experimental controls may account for the potential cytotoxic impact of the drug vehicles but may still 
hinder the study of the impact on the cell’s fundamental properties, e.g. where the use of drug carriers 
may leads to the disruption of tight junctions in cells monolayers during permeability studies [263]. Similar 
cytotoxic effects on membrane diffusion, cell lysis and even hemodynamic disturbances in vivo have been 
reported with the use of DMSO that is not recommended for parenteral formulations yet is the most 
commonly used solvent in cell culture [264].  Taken together, the solution behavior of poorly soluble drugs 
reconstituted in organic solvents, is not representative of the true pharmacokinetics or bioactivity in vivo. 
Although solubilization of hydrophobic drugs provides a means of overcoming the challenges associated 
with its poor aqueous solubility and accurate quantification of concentration, direct solubilisation in a 
physiologically relevant medium offers the opportunity to more accurately represent its response 
following in vivo administration. This may be especially relevant in applications such as drug-eluting stents 
and balloons, where a solid form of drug is coated on the stent surface.   
One of the widely used stent coatings is paclitaxel. As discussed in section 1.4.2, paclitaxel (PTX), a potent 
mitotic inhibitor, was originally isolated from the bark of Pacific yew tree  Taxus Brevifolia during the 
National Cancer Institute search for the next antineoplastic agents in the 1960s [178, 179]. Paclitaxel has 
extremely low solubility in aqueous media (1µg/ml or 1.17 µM in water at 37 °C with shaking) making it 
very difficult to quantify in solution [265].  
In the presence of endogenous compounds, cells and tissues in vivo, this solubility changes but animal and 
ex vivo models are cost consuming and may not always be available [266]. Due to its highly hydrophobic 
nature, and subsequent challenges in delivery, paclitaxel for intravenous administration is formulated in 
the presence of adjuvant Cremophor EL ®, a mixture of polyoxyethylated castor oil and dehydrated alcohol 
to increase its solubility [267]. While PTX hydrophobicity is a challenge in systemic delivery, it is suitable 
for local delivery due to strong tissue retention [266]. As described in chapter 1, the lipophilic nature of 
PTX has been utilized in the design of drug-eluting stents and drug-eluting balloons; where a solid drug 
form is used as a coating to fight neointimal thickening by supressing SMCs proliferation [15]. One such 
example is a self-expanding Zilver PTX vascular stent (Cook Medical) on a nitinol platform containing a 
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polymer free 3 µg/mm2 paclitaxel coating. Currently, PTX-cell interactions are studied in vitro by 
dissolution in DMSO or other organic solvents [184, 268, 269], where concentrations of < 200 nM, usually 
10 – 100 nM, and 0.1- 10 µM have been established as low and high doses respectively, but concentrations 
as high as 30 µM have been tested [270].   
In this study, we propose a method of stent conditioned media preparation for the in vitro assessment of 
hydrophobic drugs, with paclitaxel used as a model drug. Paclitaxel was released from the surface of Zilver 
PTX drug-eluting stent into culture media and the stent conditioned media was then evaluated for content 
uniformity and biological assays via a comparative study against a conventional reconstitution method in 
DMSO. Conditioned media containing free drug without any solvent carriers such as presented here could 
be used to evaluate stent coating of existing or new hydrophobic agents and to determine the effect of 
different coating densities and production methods on cell biocompatibility. Although, paclitaxel is 
selected here as a model drug, the relevance of this method can be extended to other poorly soluble drugs 
with similar physicochemical properties such as sirolimus, another poorly soluble anti-proliferative agent 
used in drug-eluting stent coatings [193]. 
2.2 Materials and Methods 
2.2.1 Materials 
Mouse Cardiac Endothelial Cell Lines (MCEC)  (CLU510) VH Bio, Rhodamine Phalloidine (R415) Invitrogen, 
Dulbecco’s Modified Eagle’s Medium (D5796), Fetal Bovine Serum (F7524), L-Glutamine (G7513), 
Penicilin/Streptomycin (P0781), 1X Trypsin-EDTA (T3924), Phosphate Buffer Saline (P3813), Thiazolyl Blue 
Tetrazolium Bromide (M5655) and DAPI (D9543) all from Sigma Aldrich. Vascular stents, Zilver® PTX® drug-
eluting peripheral stents and paclitaxel powder, used throughout the study were kindly supplied by Cook 
Medical, Limerick, Ireland. All stents were of 40 mm length and 5 mm diameter with 3 µg/mm2 paclitaxel 
coating, ethylene oxide sterilized and supplied in sealed sterile Tyvek pouches. 
2.2.2 Preparation of PTX stent conditioned media 
Paclitaxel coating was released from the stent surface following an approach similar to the ISO 10993-12 
“Extractables/leachables Testing of Medical Devices”, specifically section 12 of the standard. Here, Zilver® 
PTX® stent sample with 3 µg/mm2 paclitaxel coating equating to a total target dose of 429 µg was 
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immersed in 5 ml of complete cell growth media in 15 ml centrifuge tubes followed by sonication for 10 
min to release the paclitaxel coating. Samples were then incubated at 37 oC, 5 % CO2 for 48 hours. 
Following the incubation time, stents were discarded and the required volume of PTX stent conditioned 
media was used in cell assays. All PTX stent conditioned media was prepared 48 h in advance of the 
scheduled experiments.  
2.2.3 Cell Culture 
Immortalized Mouse Cardiac Endothelial cells (MCEC) were used in this study. This cell line although it 
grows indefinitely, continues to display normal endothelial characteristics such as exhibiting contact 
inhibition, cellular markers, and tight intercellular junctions that are usually not seen in other endothelial 
cell lines. Therefore, it is a suitable model for studying endothelial cells’ physiology. Cells were cultured in 
DMEM supplemented with 5 % FBS and 1 % Penicillin/Streptomycin in a 5 % CO2 incubator at 37 oC. Cells 
were passaged at 70-80 % confluency in a dilution of 1:5 or 1:10, reaching 80 % confluency after 2 days or 
3 days, respectively.  
2.2.4 Cell viability assays 
The effect of PTX stent conditioned media and DMSO reconstituted paclitaxel on cell viability was assessed 
using an MTT assay. Cells seeded in a 96-well plate at a concentration of 1x104/well were allowed to 
adhere overnight. The next day cells were treated with PTX stent conditioned media or DMSO 
reconstituted paclitaxel. After 48 h, the MTT reagent was added to samples for 2 h at 37 °C. The MTT 
formazan crystals were dissolved by solubilisation buffer (10 % SDS in 0.01 M HCl) followed by further 
incubation for 4 h at 37 °C. Absorbance was read at 570 nm using a microplate spectrophotometric reader. 
Cell viability was determined by comparing absorbance values of treated cells to absorbance values of 
untreated control cells. A ratio of percentage reduction of cell viability relative to that of control cells was 
used to express the obtained data. 
2.2.5 Cell visualization and quantification 
Confocal fluorescent images were captured with ImageXpress Micro Spinning Disc Confocal Microscope, 
Molecular Devices. DAPI and TRITC filters were used to detect nuclei and f-actin (Phalloidin-Rhodamine), 
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respectively. Emission spectra was used under default settings. Images were stored in TIFF file format and 
cellular analysis was performed using in Image J. (https://imagej.nih.gov/ij/) 
2.2.6 HPLC Separation Conditions for Paclitaxel Samples (work carried out by Michele Dully, Bernal 
Institute, University of Limerick) 
The HPLC system used was an Agilent 1200 Infinity Series (Agilent Technologies, Palo Alto, USA) 
comprising: G1311B 1260 quaternary pump, G1329B 1260 ALS autosampler, G1316A 1260 TCC 
(thermostated column compartment) and a G1365D 1260 MWD VL diode-array detector. The acquired 
data was processed with the Agilent OpenLAB CDS software. Chromatographic separations of Paclitaxel 
samples were achieved using an Agilent Poroshell 120 PFP (3 x 100 mm, 2.7 µm) column fitted with a 
UHPLC Poroshell 120 guard module (3 x 5 mm, 2.7 µm). The system was maintained at 25 °C with a run 
time of 18 minutes. The mobile phase which comprised A: HPLC Analytical grade Acetonitrile (Fisher 
Scientific) and B. deionized water (A:B 13:87, v/v) was delivered to the column at a flow rate of 1 ml/min 
which yielded a column back pressure of ~260 bar. Samples were filtered through a 0.2 µm Nylon filter 
(Fisherbrand®). The volume of analyte injected was within the range of 0.5 to 10 µl. Column effluent was 
detected at a UV detector wavelength of 228 nm. 
2.2.7 PTX coating release consistency in culture media 
Zilver PTX stents were weighed out using a 5-decimal place balance to determine the total weight of stent 
with the paclitaxel coating. The stent conditioned media was then prepared as outlined in section 2.2.2 
Following 48 h incubation, the stent was removed and washed in PBS and water to remove traces of media, 
dried in the oven at 45 ◦C for 30 min and weighed out to determine the weight of the stent without the 
paclitaxel coating. The PTX stent conditioned media was centrifuged at 15 000 x g, then placed in the oven 
to evaporate the growth media at 60 ◦C over 48 h. The solids collected at the bottom of the 15 ml conical 
tube were reconstituted in 1 ml of ethanol and HPLC analysis was run to quantify the quantity of released 
paclitaxel. Images of stent samples before and after stent conditioned media preparation were taken with 
optical reflection microscope with a dark field filter. 
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2.2.8 PTX stent conditioned media content uniformity 
The content uniformity, thus potency reproducibility of the PTX stent conditioned media preparation was 
validated using two parameters; cell viability and variation in the nuclear perimeter. MCEC viability after 
treatment with 200 µl of the PTX stent conditioned media per sample was assessed across 25 samples 
with the use of an MTT assay at 48 h as described in section 2.3. The 25 samples, each 200 µl represent 
the entire volume of the stent conditioned media preparation. In the second method, standard deviation 
of cells nuclear perimeter exposed to PTX stent conditioned media at 48 h was assessed. Here, MCEC 
samples alongside controls were seeded at a 20,000 cells/well seeding density of a 96-well plate and 
allowed to proliferate in a complete growth media overnight before incubation with 200 µl of PTX stent 
conditioned media for each cell sample and media changes for the controls. After 48 h incubation both 
samples and the controls were fixed in 4 % PFA for 15 min at RT, f-actin filaments were stained with 
Phalloidin-Rhodamine (1:500) and nuclei counterstained with DAPI (1:1000) followed by confocal 
fluorescent imaging using spinning disc confocal ImageXpress High-throughput Imaging System. Image J 
analysis was carried out on the blue channel (nuclei) for each of the samples. The perimeters of particles 
ranging from 10 to infinity pixel size were counted. Standard deviation across the mean for each of the 
samples was then plotted. Pooled standard deviation was calculated using the following formula; 
  
𝑠𝑝𝑜𝑜𝑙𝑒𝑑 =  √
(𝑛1 − 1)𝑠1
2  +  (𝑛2 − 1)𝑠2 
2 + ⋯ + (𝑛𝑘 − 1)𝑠𝑘
2




                 
 
n1, n2 = sample size of population 1, 2 
 nk = sample size of population k 
 s1, s2 = sample standard deviation of population n1, n2 
sk = sample standard deviation of population k 
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2.2.9 Zeta potential measurements (zeta potential measurements carried out by Michele Dully, 
Bernal Institute University of Limerick) 
Adherent EC were incubated in the presence of PTX stent conditioned media for 30 min, 2 h and 12 h in 
separate cell culture plates. At the given time points the cells were harvested by trypsinization. Cells 
pelleted by centrifugation were resuspended in 1 ml of growth media at a cell density 0.5x106 cells/ ml. 
Approximately 1 ml of each cell suspension was then transferred into the capillary zeta cell and zeta 
potential measurements were taken using Zetasizer Nano ZS (Malvern Instruments). The samples were 
kept at 37 ◦C using a heating block. All measurements were carried out using zeta (electrophoretic light 
scattering) mode. The mean zeta potential was determined from 2 runs of 10 measurements for each 
sample. The zeta (ξ) potential was calculated from the electrophoretic mobility based on the 
Smoluchowski equation, u=Eξ/η, where u is the measured electrophoretic mobility, ξ is zeta potential 
value; E is the dielectric constant and η is the viscosity of the electrolytic solution.  
2.2.10 Quantification of cellular concentrations 
To evaluate cellular uptake of free paclitaxel, MCEC grown in a T75 flask were treated with paclitaxel 
“supplemented” growth media at approx. 70 % confluency. To prepare this media, a 1 mM stock was first 
prepared by transferring 10 mg of PTX into 11.5 ml of growth media. To achieve a homogenous mixture, 
paclitaxel supplemented media was sonicated for 10 min and shaken at each 1-minute interval using a 
vortex mixer. To achieve a final concentration of 0.1 mM corresponding to the theoretical concentration 
of PTX conditioned media, a 1 in 10 dilution was carried out with growth media followed by further 
sonication. When MCEC grown in a T75 flask were at approx. 70 % confluence the growth media was 
replaced with 10 ml of 0.1 mM paclitaxel media.  After 24 h of paclitaxel exposure, cells were washed 
three times with PBS, gently tapping the flask to dislodge PTX particles stuck to the flask surface during 
the washings. Cells were harvested and resuspended in 1 ml of PBS with 30 µl used for cell counting with 
trypan blue. The cell suspension was pelleted at 1000 x g for 5 min. The supernatant was discarded and 1 
ml of ethanol was added to the cell pellet followed by incubation on ice for 15 min. Probe sonication was 
used to break open the cells and to release the intracellularly bound paclitaxel. To collect the supernatant, 
the cell debris were pelleted at 5000 x g for 5 min followed by solvent evaporation at RT and addition of 
200 µl ethanol to concentrate the sample. Presence of PTX was then detected using HPLC.  The cellular 
uptake was determined in µg/cell.     
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2.2.11 Statistical Analysis 
All experiments were carried out in independent triplicates or duplicates and are expressed as the mean 
± standard deviation (SD). The number of independent replicates and sample size is indicated for each 
respective figure. Statistical analysis was computed in SPSS Statistics for Windows, Version 26.0 (IBM SPSS 
Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp). Repeated-measures analysis of variance 
(ANOVA) was done to test for statistical significance of the nuclear perimeter variance. Comparison of 
differences between the groups was analyzed by One-way ANOVA followed by Tukey’s post hoc test, p-






2.2.12 PTX Coating Release  
Table 2.1: Quantity of the PTX coating released from the Zilver PTX drug-eluting stent after the preparation 
of the stent conditioned media as determined from stent mass change. ‘Before’ represents initial stent 
weight including PTX coating and ‘after’ represents bare stent weight. Experiment carried out in 




Figure 2.1: Optical reflection images taken of Zilver PTX drug-eluting stent strut surface before (PTX 
coated) and after (uncoated) preparation of the PTX stent conditioned media. Scale bars = 500 µm. 
As discussed in section 1.4, difficulties are associated with studying poorly soluble drugs used in coatings 
on medical devices such as stents and in many cases result in a poor correlation with in vivo response. 
Here a simple method for poorly soluble drug preparation in bio-relevant media is proposed. The surface 
coating of Zilver PTX stent containing 429 µg total dose was released by sonication into cell culture growth 
media followed by 48 h incubation at 37 oC, 5 % CO2. To quantify the amount of PTX coating released from 
the stent surface, the mass change was measured. Here, the stent samples were weighed out before and 
after the conditioned media preparation with the average value for the released coating for three stent 
samples calculated to be 0.43 ±0.01 mg, Table 2.1. The mean released quantity falls within the expected 
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range of lower specification limit (LSL): 0.386 mg and upper specification limit (USL): 0.461 mg PTX coating 
for 5 mm diameter, 40 mm length Zilver PTX stents.  It was not possible to quantify the PTX released into 
the media by chromatography due its solubility in the media being less than the HPLC PTX detection limit 
of 0.5 µg/ml. 






Figure 2.2: (A) Representative confocal images of MCEC treated or untreated with the PTX stent 
conditioned media. Cytoskeletal f-actin filaments are stained with Phalloidin-Rhodamine (red) and nuclei 
are counterstained with DAPI (blue). Monochromatic images show individual blue and red channels in 
grayscale. Scale bars = 100 µm. Experiment carried out in independent triplicates with sample size n=3. (B) 
Variation in the perimeter of MCEC nuclei; samples 1 -25 represent cells treated with PTX stent conditioned 
media; samples C1-C3 represent control cells without any treatment. Cells with and without treatment 
were cultured for 48 h. After 48 h cell samples were stained and nuclear perimeter was quantified from 
blue channel (DAPI) using Image J software. Variances of the treatment group p value > 0.05. Error bars 
represent standard deviation. Experiment carried out in independent duplicates with sample size n=50. 
Representative data set of the duplicates shown. (C) Content uniformity of the PTX stent conditioned media 
volume tested across 25 samples using cell viability as a measured response. The line graph shows 
percentage viability of MCEC with respect to control treated with 200 µl PTX stent conditioned media per 
sample as determined by MTT assay after 48 h of exposure.  Reference line is plotted at the overall mean 
51.20 %. Overall SD: 4.03 %. Experiment carried out in independent duplicates with sample size n=3. 
Representative data set of the duplicates shown.  
 
The low solubility of PTX in the aqueous media means that it is often present as a suspension, making it 
difficult to have confidence in the concentrations that the cells are exposed to. Thus, the content 
uniformity of the PTX stent conditioned media was validated by exposing MCEC (n=25) to 200 µl aliquots 
of the prepared stent conditioned media, representing the total volume of media (5 ml) that had been 
incubated with the stent. After 48 h of cell incubation in the PTX stent conditioned media, formation of 
micronuclei in the treated samples is evident from confocal imaging as shown in Figure 2.2 (A). The 
variation in the nuclear perimeter caused by the presence of variously sized micronuclei was used to 
measure the content uniformity of the PTX stent conditioned media. Figure 2.2 (B) shows no significant 
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difference between sample and control group in the mean perimeter. However, an increased nuclear 
perimeter variation was noted across the treated group compared to the control samples that exhibit a 
much tighter variance. This observation was depicted by following values for sample mean perimeter 
52.15 ±29.50 µm and controls 56.62 ±10.46 µm, where variance is denoted by pooled standard deviation. 
Statistical analysis showed that the variances are equal, and no significant difference exists within the 
treatment group with the p > 0.05. To further determine whether the PTX stent conditioned media 
maintains its potency across all aliquots, cell viability was examined using an MTT assay, Figure 2.2 (C). 
The percentage cell viability was in a narrow range of 44.56 % to 58.86 % with 51.20 ±4.03 % mean viability. 
No significant differences were found within the samples (p > 0.05).    
2.2.14 Cellular uptake of PTX  
 
Figure 2.3: Zeta potential measurements as determined by exposure of MCEC to PTX stent conditioned 
media for 30 min, 2 h and 12 h. Trypsinized cells were re-suspended in the PTX stent conditioned media at 
a density of 0.5x106 cells/ ml. Measurements taken using Zetasizer Nano ZS (Malvern Instruments). Error 




Table 2.2:  Intracellular uptake of the PTX by MCEC at 24 hours as quantified by HPLC. Experiment carried 
out in independent triplicates with sample size n=1.  
 











1x106 cells (µg) 
2400000 972.30 61.87 5.00 309.33 128.89 
1900000 895.25 56.11 5.00 280.54 147.65 
1700000 866.76 53.98 5.00 269.90 158.77 
                                                                                                x̅   286.59 ±16.65 µg/ml       145.10±12.33 µg 
 
Fully solubilized PTX easily penetrates the cell membranes and exerts its mechanism of action by binding 
to microtubuli [178]. When an aqueous solvent is used (which has a low solubility for PTX), such as cell 
culture media without the use of a solubilizing agent, much of the added PTX is present in suspension. In 
order to investigate the interactions of the PTX stent conditioned media with the MCEC, zeta potential 
measurements (Figure 2.3) and high-performance liquid chromatography (Table 2.2) were used to 
evaluate and quantify cellular uptake of PTX in the conditioned media. Zeta potential measurements were 
carried out at 30 min, 2 h and 12 h after the PTX stent conditioned media exposure. Figure 2.3 shows that 
exposing the MCEC to the PTX stent conditioned media for 30 min did not inflict a change in the zeta 
potential value when compared to the control, -8.515 ±0.135 mV and -8.525 ±0.185 mV, respectively. 
Increasing the exposure time to 2 h resulted in a more negative zeta potential, indicating paclitaxel binding 
to the cell surface. The internalization, thus cellular uptake of the PTX is observed at the 12 h time point 
by a shift of zeta potential to a more positive value of -8.430 ±0.460 mV.  
To quantify the cellular uptake of PTX, adherent cells were treated with 0.1 mM PTX prepared directly in 
cell growth media. This concentration relates back to the Zilver PTX stent that contains 429 µg of PTX total 
target coating, which is then released into 5 ml of aqueous media, 0.1 mM. Cellular uptake expressed per 
1x106 cells was found to be 145.10 ±12.33 µg. The actual concentration was determined to be 286.59 
±16.65 µg/ml corresponding to 66.80 % cellular uptake of total target PTX quantity (429 µg) that would 
be present in 5 ml of stent conditioned media. 
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Figure 2.4: (A) Percentage proliferation of MCEC with respect to control treated with a PTX stent 
conditioned media and a range of concentrations of DMSO dissolved PTX. (B), (C) Representative images 
of MCEC treated with 0.1 mM paclitaxel in DMSO (B) and in PTX stent conditioned media (C) as captured 
by phase contrast optical microscopy at 48 h. Scale bars: 500 µm. (D) MCEC treated with PTX stent 
conditioned media, 1 µM and 0.1 µM PTX dissolved in DMSO. Cytoskeletal f-actin filaments are stained 
with Phalloidin-Rhodamine (red) and nuclei are counterstained with DAPI (blue). Grayscale images 
representing blue channel (DAPI) show formation of micronuclei. Scale bars = 100 µm. All experiments 
carried out in independent triplicates with sample size n=3. * indicates a significant difference with p value 
≤  0.05. 
Figure 2.4 (A) shows the percentage viability of MCEC cells exposed to free paclitaxel present in the stent 
conditioned media and DMSO dissolved PTX at 48 h. Unlike the PTX stent conditioned media with 0.1 mM 
theoretical concentration, which suppresses cells growth (48 % viability), the 0.1 mM DMSO dissolved PTX 
induced severe cytotoxic effects with practically no viability (3 %) at 48 h. The 48 % viability of cells treated 
with the PTX conditioned media falls between the concentration range of 0.1 – 1 µM PTX in DMSO, 
indicating at least 100 fold lower concentration than the theoretical 0.1 mM concentration. Figure 2.4 (B) 
shows representative images of MCEC treated with 0.1 mM PTX in DMSO with apparent presence of 
circular cells, indicating loss of viability, surrounded by needle-like paclitaxel structures. In Figure  (C), PTX 
crystal-like particles present in the conditioned media lie on top of a cell layer (cells not seen in the image). 
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Formation of micronuclei in Figure 2.4 (D) shows that the PTX stent conditioned media induces the same 
response on a subcellular level as the 0.1 and 1 µM concentrations that were identified as the theoretical 
concentration range of PTX in aqueous media.  
To account for the possible impact of nickel component of the nitinol stent surface on the cells viability 
presented in this section, atomic absorption spectrometry was carried out on the PTX stent conditioned 
media. The results showed no detectable nickel in the conditioned media (results shown in Appendix  A: 
Supplementary Information, Figure A1). 
2.3 Discussion 
A literature survey revealed that hydrophobic drugs, such as paclitaxel are typically pre-dissolved in DMSO 
in biological assays [159]. However, this approach leads to artificially high doses of drug not representative 
of in vivo concentrations, resulting in non-representative compromised cellular functions. To study 
hydrophobic drugs in bio-relevant media, especially those used for stent coatings, a simple and 
reproducible method was developed and validated in this study. In order to release the PTX coating from 
the stent surface, the stent samples were sonicated directly in cell growth media followed by incubation 
at 37 °C, 5% CO2. The approach described herein was inspired by the ISO 10993-5 standard “Biological 
Evaluation of Medical Devices” used during the in vitro biocompatibility testing of medical devices prior 
to animal studies. The standard recommends that the extraction occurs at 37 °C for 24 to 72 h using 
mammalian cell culture media supplemented with 5-10 % serum, to extract both hydrophilic and 
hydrophobic substances [271].  
Paclitaxel, coated on the Zilver PTX vascular stent, is a highly hydrophobic drug, with very low solubility in 
aqueous media, ~ 1 µg/ml [265]. Due to its poor solubility, during the preparation of stent conditioned 
media as proposed in this study, the majority of the PTX from the stent is most likely to be suspended in 
the media. With the small volume aliquots of the stent conditioned media used in cell assays, the 
homogeneity of the PTX-media suspension needed to be validated. Variation in the nuclear perimeter was 
selected as one of the validation parameters as paclitaxel is known to induce micronucleation in cells at 
nM concentrations [272], thus providing a picture on the paclitaxel solubility and potency in a water based 
solution. The fluorescent images in Figure 2.2 show formation of micronuclei in the treated group 
especially evident from the blue channel and demonstrated by an almost 3-fold increase in pooled 
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variation of the mean nuclear perimeter 52.15 ± 29.50 µm in the samples treated with stent conditioned 
media compare to 56.62 ± 10.46 µm in cells treated just with media. Thus there is consistency in the PTX 
content of the stent conditioned media sample aliquots (n= 25) to induce variances in the perimeters of 
nuclei as a result of micronuclei formation that is induced by genotoxic response to the paclitaxel exposure. 
The cell viability results across 25 samples, each treated with 200 µl of the PTX stent conditioned media 
showed a low-level variation in viability with the mean value of 51.02 ± 4.03 %, demonstrating consistency 
in the aliquot potency of the PTX stent conditioned media to inflict reduced cell proliferation due to the 
presence of PTX.  Unfortunately, the PTX concentration in the conditioned media is below the limit of 
HPLC detection. Nevertheless, both validation methods revealed no significant difference within the 
treatment groups (p>0.05) confirming the use of PTX stent conditioned media as a valid tool for evaluating 
the biocompatibility of the paclitaxel stent coating in cellular assays.   
Solubilized paclitaxel, such as the DMSO dissolved PTX used in this study, is known to enter and 
accumulate in tissues [273], targeting intracellular microtubules. To investigate how the PTX stent 
conditioned media will interact with cells, zeta potential measurements, which describe cell surface 
electrostatics and can be used for adhesion and interaction studies, were conducted [274-276]. Based on 
the increase in electronegativity, the PTX in the stent conditioned media appears to interact with the 
negative cell surface upon 2 h exposure in the culture and is taken up by the cells at 12 h as demonstrated 
by the subsequent decrease in electronegativity  in Figure [277].   
The theoretical concentration 0.1 mM of the PTX stent conditioned media was calculated from the total 
mass of PTX in 5 ml of conditioned media. However, it was expected that due to its poor solubility in 
aqueous media, a large fraction of PTX would be in suspension rather than in solution, resulting in a lower 
effective concentration. This expectation was demonstrated by 48 % cell growth for the PTX stent 
conditioned media at 0.1 mM theoretical concentration, while the same concentration of PTX in DMSO 
exhibited severe cytotoxic effects with 3 % cell growth at 48 h. In fact, the 0.1 mM PTX in DMSO 
concentration was so high that the PTX crystalized into needle-like particles, phenomenon previously 
described in the literature [278], as seen in Figure (B). As mentioned above, the molar concentration of 
soluble fraction of PTX could not be analytically quantified due to being below the detection limit of the 
HPLC, 0.5 µg/ml. Thus, the molar concentration was estimated from a comparison of PTX stent 
conditioned media cell growth results (48 %) to those of PTX in DMSO (Figure 2.4 (A)) and found to fall 
between 1 – 0.1 µM (45 %, 59 %). Correlating the estimated PTX concentration from viability assay to the 
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PTX HPLC detection limit of 0.5 µg/ml or 0.59 µM, the actual concentration of the soluble fraction in the 
PTX stent conditioned media, appears to lie between 0.59 to 0.1 µM.  
PTX, an anti-mitotic drug, supresses cells proliferation by binding to microtubuli during cell mitosis [279, 
280]. As a result paclitaxel treated cells experience prolonged mitotic arrest [281-283]. Cells exposed to 
prolonged mitotic arrest can often undergo a return to the interphase without proper chromosome 
segregation, leading to the formation of micronuclei. This phenomenon was well described for paclitaxel 
[183]. The formation of micronuclei, that occurs at nanomolar concentration of PTX and is unlikely to 
occur at higher concentrations, was confirmed for PTX conditioned media and the 0.1 and 1 µM PTX in 
DMSO from fluorescent imaging [183, 284], supporting the claim that the PTX stent conditioned media is 
suitable for cell-based assays and may provide a better model of the in vivo response.   
 
2.4 Conclusions 
In summary, the use of organic solvents to dissolve extremely hydrophobic drugs coatings from stents 
during in vitro cell culture studies has been compared with a novel stent conditioned media approach. 
PTX coated on a drug-eluting stents, intended for vascular applications, were used in this study. A simple 
method for preparation of a hydrophobic drug suspension of PTX desorbed from the stent in bio-relevant 
media, without the use of organic solvents to pre-dissolve the drug was developed. This ‘PTX stent 
conditioned media’ preparation was validated in terms of content uniformity and potency for in vitro 
assay use.  It was shown that using DMSO to solubilise the PTX lead to distinctively different cellular 
responses than the PTX stent conditioned media.  PTX stent conditioned media, 0.1 mM theoretical 
concentration, is taken up by EC and results in similar growth cell suppression as 0.1 µM DMSO dissolved 
PTX. PTX released from the stent surface was used as a model drug but this method can be extended to 
other hydrophobic drugs. In vivo studies need to be conducted to test if the stent conditioned media gives 




3 CHAPTER 3  
The effects of citric acid, ascorbic acid and 
paclitaxel for cardiovascular medical device 
applications: a comparative study with 
endothelial and smooth muscle cells 
___________________________________ 
3.1 Introduction 
Every year, millions of patients are treated with medical stents, making them  one of the major approaches 
to treat occluded segments of the cardiovascular system [9]. DES were developed as the next step up from 
BMS to prevent re-narrowing of vessel lumen caused by SMCs proliferation as a response to the trauma 
of denuded ECs experienced during deployment of the stent, as discussed in chapter 1 [103, 104]. 
Although, anti-proliferative drugs containing DES have been shown to greatly reduce the occurrence of 
restenosis, there is a major area of concern associated with their use; namely increased risk of late stent 
thrombosis due to delayed healing [285].  
Late stent thrombosis can occur up to 1 year post-implantation and very late stent thrombosis after 1 year 
post-intervention [105, 106]. It is important to notice that these catastrophic events occur long after the 
drug is eluted from the stent and for this reason persistent inflammation has been pinpointed as one of 
the main aspects of late stent failure [108]. Extended drug retention in lipophilic atheroma of the vascular 
wall has been suggested to contribute to delayed vascular repair and associated post-implantation 
invasion of inflammatory cells [108]. For example the COOK Medical Zilver PTX stent, the only stent 
approved by FDA for intervention in popliteal and superficial femoral artery [113], has  been reported to 
elute its polymer free anti-proliferative agent paclitaxel within 72 hours but the drug remains retained in 
the arterial wall tissues at the site of the stent placement for 56 days. It is also important to notice that 
this study involved use of porcine arteries, while it is known that the healing response is significantly 
different in animals compare to humans [112].  
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As described in section 1.4, the main anti-proliferative agents used in DES are sirolimus, paclitaxel, 
zotarolimus and everolimus all of which not only impede SMC proliferation, but also delay vascular repair 
of EC due to their non-selectivity [108, 286]. Furthermore, evidence shows that impaired healing 
mechanism and delayed re-endothelialization lead to persistent inflammation due to the lack of a natural 
‘non-adhesive’ barrier that a healthy endothelium provides [108]. Therefore, a search for novel stent 
platforms that would have the capability to selectively suppress SMC growth and promote EC proliferation 
while preventing thrombosis by lowering inflammation is on the rise.  Vitamin C (L-ascorbic acid, L-AA) 
has been shown in a number of studies to favor growth of EC [287, 288] over SMC [288, 289]. L-AA is 
naturally occurring drug, a known anti-oxidant acting as a co-factor in enzymatic reactions [289].  
In this study we aim to investigate another naturally occurring molecule; citric acid (CA), described in 
section 1.4, which plays a role in the tricarboxylic acid (TCA) cycle of the mitochondria. Although CA is well 
studied in the context of the TCA cycle, more recent studies indicate it may have many functions and 
additional therapeutic potential [290]. CA is mainly recognized for its anti-coagulant properties due to its 
ability to chelate Ca2+ ions [291-293]. Its anti-coagulant properties would make it an ideal candidate for 
vascular applications where persistent inflammation poses a risk of thrombosis as in the case of DES. CA 
has been shown to reduce endothelial dysfunction and inflammation, promote EC sprouting and 
angiogenic factors [167, 219, 294-296]. CA, to the best of our knowledge has not been studied in the 
context of stent coatings and neither have its selective growth properties on EC over SMC.  In the first part 
of this study the effects of a range of CA and L-AA doses on EC and SMC growth are investigated, followed 
by a comparative study of CA against L-AA and the typically used dose of paclitaxel (PTX). Subsequently, 
the potential of CA to lower inflammation in a lipopolysaccharide (LPS)-induced in vitro inflammation 





Figure 3.1: Chemical structure of citric acid (A), L-ascorbic acid (B) and paclitaxel (C). 
3.2 Materials and Methods 
3.2.1 Materials  
The endothelial cells used in this study were mouse cardiac endothelial cell lines (MCEC CLU510) 
purchased from VH Bio.  Mouse vascular smooth muscle cells (MOVAS ATCC® CRL-2797) were purchased 
from American Type Culture Collection. Calcein-AM 1 MG/ML (C3099) for fluorescent labelling was 
obtained from BioSciences and mouse cytokine assay (LXSAMSM) from R&D Systems. The following 
reagents were obtained from Sigma Aldrich: Dulbecco’s Modified Eagle’s Medium - without sodium 
pyruvate (D5796), DAPI, Fetal Bovine Serum (F7524), L-Glutamine (G7513), Penicillin/Streptomycin 
(P0781), 1X Trypsin-EDTA (T3924), Phosphate Buffer Saline (P3813), dimethyl sulfoxide (C6164), L-ascorbic 
acid (AG92902), citric acid (251275), G 418 disulfate salt solution (G8168), Thiazolyl Blue Tetrazolium 
Bromide (M5655) and lipopolysaccharides from Escherichia coli O111:B4 (L4391) . 
3.2.2 Cell culture 
All cell culture work was performed in a biological safety cabinet under laminar flow maintaining sterile 
conditions. Immortalized Mouse Cardiac Endothelial cell (MCEC) culture media consisted of high-glucose 
DMEM media without sodium pyruvate supplemented with 5 % FBS and 1 % Penicillin/Streptomycin. Cells 
were passaged at 70-80 % confluency at a dilution of 1:5 or 1:10, reaching 80 % confluency after 2 or 3 
days, respectively. Mouse vascular aortic smooth muscle cells (SMC) MOVAS-1 were cultured in 
Dulbecco’s Modified Eagle’s Medium – high glucose supplemented with 0.2 mg/ml G418 disulfate salt and 
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10 % FBS. A subcultivation ratio of 1:5 was used to passage the cells when 80-90 % confluent. All cell 
cultures were propagated in an incubator at 37 ◦C and 5 % CO2. 
3.2.3 Preparation of stock solutions for cells treatment 
To investigate the effects of CA and L-AA on cell growth over a range of concentrations, stock solutions 
were prepared in 1X PBS (20 mg/ml) for both CA and L-AA. The stock solutions were then diluted in MCEC 
or SMC media with final concentrations ranging from 1 µg – 1000 µg/ml. Controls consisted of EC or SMC 
growth media with 0.5 % 1X PBS (v/v). PTX stock solution was prepared in DMSO (20 mg/ml), referred as 
PTX in DMSO or in growth media (20 mg/ml), referred as PTX in media where sonication and vortex mixing 
were used to aid PTX powder dissolution and suspension in the aqueous growth media.  PTX in DMSO and 
PTX in media were diluted with media into a final concentration of 100 µg/ml. For the in vitro inflammation 
model, the cells were challenged with a range of LPS concentrations in endothelial cell growth media 
prepared from 1 mg/ ml LPS stock in water, with 100 µg/ml being the highest concentration used to induce 
inflammation. The LPS working concentrations were prepared as 2X to achieve final 1X concentration upon 
exposure to cells.  
3.2.4 Addition of drugs to the cell cultures 
For the CA, L-AA and PTX cell growth investigation, EC and SMC in their respective media were seeded at 
5 x 103 cells/well into a 96- well plate format and incubated at 37 ◦C and 5 % CO2. The cells were allowed 
to adhere and proliferate overnight before the addition of drug solutions. After this time, the media was 
replaced with 200 µl of CA, L-AA, PTX in DMSO and PTX in media at working bioactive additive 
concentrations. In all experiments, the pH of media was not adjusted after the addition of CA. Both cell 
types were exposed to the continuous effects of the bioactive additives for 24 h, 48 h and 72 h. EC or SMC 
growth media was used to control the study. After the given time, an appropriate assay was carried out. 
Cell seeding protocol as outlined above was followed for the CA-PTX tandem studies in MCEC and SMC. 
After an overnight cell growth, both cell types were simultaneously treated with a CA:PTX dose of 100:100 
µg/ml or 50:50 µg/ml. PTX 50 µg/ml and 100 µg/ml, CA 50 µg/ml and 100 µg/ml and untreated cells served 
as controls. PTX was prepared in media. Appropriate assays were carried out at 48 and 72 h. 
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3.2.5 Cell viability and proliferation – qualitative analysis 
Viability and proliferation of MCEC and SMC treated with CA, L-AA and PTX were qualitatively analyzed at 
24 h, 48 h and 72 h. For the PTX-CA tandem assay, these time points were 48 h and 72 h. At the appropriate 
time point, the medium was removed from the plates and all samples were washed with 100 µl 1X PBS. 
50 µl of calcein AM at 2 µM concentration was added to the washed wells and live cells were labelled for 
30 min at 37 °C, 5 % CO2 incubator. Fluorescent images were captured with an ImageXpress Micro 
Spinning Disc Confocal High-Content Imaging System, Molecular Devices. A TRITC filter was used to detect 
live cells. Images were stored in TIFF file format and Image J software was used to process all images 
(https://imagej.nih.gov/ij/). 
3.2.6 Cell viability and proliferation – quantitative analysis 
Quantitative viability and proliferation of MCEC and SMC treated with CA, L-AA and PTX was analyzed at 
24 h, 48 h and 72 h. For the PTX-CA tandem assay, these time points were 48 h and 72 h. At the appropriate 
time point, the medium was removed from the plates and all samples were washed with 100 µl 1X PBS. 
50 µl of calcein AM at 2 µM concentration was added to the washed wells and live cells were labelled for 
30 min at 37 °C in a 5 % CO2 incubator. Following the incubation period, the fluorescence endpoint was 
measured using a fluorescein filter set with excitation at 485 nm, emission at 526 nm, optics: top and gain: 
100 with microplate scanning spectrophotometer. Background fluorescence was determined by setting 
up cell free blanks with calcein staining solution for both EC and SMC media. Cells viability is expressed as 
background corrected mean relative fluorescence units.  
3.2.7 LPS stimulation 
MCEC were grown to approximately 70-80 % confluency before media was switched to low serum 
overnight. The next day MCEC were harvested and re-suspended in complete medium at a density of 
2x106 cells/ ml. For the CA-LPS treatment group, 200 µl of 100 µg/ml CA in growth media was dispensed 
into the wells of a 24-well plate and for the LPS treatment group, 200 µl of media was added to the wells. 
To challenge both groups with LPS, 100 µl of cell suspension was mixed with 100 µl of LPS at 
concentrations ranging from 0.002 – 200 µg/ml to achieve final LPS concentrations of 0.001 – 100 µg/ml. 
To ensure homogeneous distribution of LPS, the cell suspension was mixed by pipetting at least 15 times 
followed by 5 min incubation at room temperature. Cells and LPS were mixed again and transferred into 
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plate wells containing CA in growth media or growth media only for the CA-LPS and LPS sample groups, 
respectively. Controls were prepared by mixing 100 µl of non-treated cell suspension with 100 µl of growth 
media or 100 µl of 200 µg/ml CA in growth media before finally adding to 200 µl of growth media to wells 
in a 24-well plate. Prior to collection of the media, cells were examined for activation and optical images 
were taken with phase contrast microscope. Media was collected at 6 h, 24 h and 48 h and cell debris 
separated by centrifugation for 5 min at 1000 x g at room temperature. The supernatant was transferred 
to fresh tubes and stored at -80 °C. 24 h samples were assayed for IL-6, IL-33, IL-1α, IL-1β and TNF-α pro-
inflammatory cytokine production using a mouse cytokine assay (LXSAMSM, R&D Systems) according to 
the manufacturer instructions. A viability assay was carried out for 6 h, 24 h and 48 h time points on plate 
adherent cells after the media was collected. Briefly, cells were incubated with 10 µl (5 mg/ml) of MTT 
reagent in 100 µl serum free media for 2 h at 37 °C. The MTT formazan crystals were dissolved by addition 
of 100 µl of solubilization buffer (10 % SDS in 0.01 M HCl) followed by further incubation for 4 h at 37 °C. 
Absorbance was read at 570 nm using microplate spectrophotometric reader. Cell viability was 
determined by comparing background corrected absorbance values of treated cells to corrected 
absorbance values of untreated control cells. A ratio of percentage reduction of cell viability relative to 
control cells was used to express the obtained data. 
3.2.8 Statistical Analysis 
All experiments were carried out in independent triplicates or duplicates and are expressed as the mean 
± standard deviation (SD). The number of independent replicates and the  sample size is indicated for each 
respective figure. Statistical analysis was computed in SPSS Statistics for Windows, Version 26.0 (IBM SPSS 
Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp). Comparison of differences between the 
groups was analyzed by One-way ANOVA followed by an appropriate post hoc test; Tukey’s for groups 
with equal variances and Games-Howell’s for groups with unequal variances. A p-value of 0.05 or less 





3.3.1 Viability of MCEC treated with L-AA and CA 
 
Figure 3.2:  Representative fluorescence microscopy images of calcein-stained MCEC treated with a range 
of L-AA and CA concentrations, 0 – 1000 µg). Scale bars = 200 µm. Experiment carried out in independent 




Figure 3.3: Viability and proliferation of MCEC treated with L-AA and CA over 72 hours as expressed by 
mean fluorescence intensity. * designates significant differences with p value ≤ 0.05. ¥ designates groups 
(10 µg, 100 µg, 250 µg, 500 µg and 1000 µg) that are significantly different from all other groups.  







Figure 3.4: Magnified fluorescent images of MCEC treated with CA (1000 µg/ml) and MCEC control 
depicting morphological differences in cell packing at 72 h. Scale bars: 200 µm. 
Fluorescence microscopy images of calcein-stained MCEC treated with various doses of L-AA and CA (1 - 
1000 µg/ml) are shown in Figure 3.2. Reduction in MCEC viability is seen with the use of L-AA 
concentrations as low as 1 µg/ml, where a decrease in cell number is observed at 24 h and 48 h with 
respect to control.  However, at 72 h, both the 1 µg/ml sample and the control exhibit a fully confluent 
state, indicating a slower growth but not a loss of viability. At 1 µg/ml L-AA concentration, cells exhibit 
healthy morphology across all three time points. A 10 fold increase in L-AA concentration (10 µg/ml) 
showed detrimental effects on MCEC viability, seen from images in Figure 3.2 with low cell presence and 
round cell morphology at all time points. The poor cell survival contrasts with CA treated cells where CA 
supports growth of MCEC across all concentrations up to 1 mg/ml and assayed time points 24, 48 and 72 
h. Based on qualitative analysis from Figure 3.2, cells exhibit healthy morphology across all CA 
concentrations and are fully confluent at 72 h time point, except for 1000 µg/ml sample where cells 
appear confluent yet cell gaps exist due to the lack of tight cell packing typical of EC as seen in Figure 3.4. 
These qualitative observations are well supported in Figure  by mean relative fluorescence units (RFU) 
where the MCEC L-AA viability is at zero for all the L-AA concentrations above 1 µg/ml. This L-AA 
concentration slowed MCEC growth significantly (p <0.05) with respect to control, but with increasing 
fluorescence from one time point to another, indicating growth over time. The mean RFU for CA treated 
MCEC showed no significant difference in cell growth across all CA concentrations except for 1000 µg/ml 
where a significant drop of 33 % (p <0.05) in cell viability is noted at 48 h. 
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3.3.2 Viability of SMC treated with L-AA and CA 
 
Figure 3.5: Representative fluorescence microscopy images of calcein stained SMC treated with various 
concentrations of L-AA and CA. Scale bars = 200 µm. Experiment carried out in independent triplicates with 




Figure 3.6: Viability and proliferation of SMC treated with L-AA and CA over 72 hours as expressed by 
fluorescence intensity. No significant differences were identified (p value >0.05) within the groups and 
timepoints except for where specified. ¥. designates groups (250 µg, 500 µg and 1000 µg) that are 
significantly different from all other groups.  Experiment carried out in independent triplicates with sample 
size n=3.  
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Images of calcein-stained SMC treated with a range of L-AA and CA concentrations are shown in Figure 
3.5. No inhibition of growth was found in L-AA treated SMC for concentration up to 100 µg/ml. For L-AA 
concentrations of 250 µg/ml and upwards, a sharper decline in cell growth was observed in Figure 3.5, 
depicted by presence of a decreased cell number and round morphology. CA was found not to impede 
the growth of SMC across a multitude of concentrations where SMC exhibit bright green fluorescence and 
reached a fully confluent state at 72 h. All CA concentrations resulted in healthy elongated cell 
morphology, except for SMC treated with 1000 µg/ml CA dose where cells appear less spread with more 
extracellular space present, especially evident from 48 h sample. Quantitative analysis in Figure 3.6 
confirmed the qualitative observations that CA does not impede SMC growth across all CA concentrations 
while L-AA exhibits growth supporting properties up a 100 µg/ml, inclusive. No significant differences exist 







3.3.3 Comparison of Viability of MCEC and SMC treated with PTX, CA and L-AA 
 
 
Figure 3.7: Representative fluorescence microscopy images of calcein-stained MCEC and SMC treated with 
of PTX in media, PTX in DMSO, CA and L-AA, all at 100 µg/ml over 72 h. Scale bars = 200 µm. Experiment 








Figure 3.8:  Viability and proliferation of MCEC and SMC treated with PTX in media, PTX in DMSO, CA and 
L-AA, all at 100 µg/ml over 72 hours as expressed by fluorescence intensity. DMSO vehicle control was 
found to have no impact on the cells viability (results not shown). * designates significant differences with 
p value ≤ 0.05.  ¥ designates a sample that is significantly different to all groups with p value ≤ 0.05. £ 
designates significant differences from PTX in media and PTX in DMSO. Experiment carried out in 
independent triplicates with sample size n=3.  
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The previous section where cell growth was investigated across a CA and L-AA concentration gradient 
revealed that both SMC and MCEC grew across all tested CA concentrations. L-AA 1 µg/ml was the highest 
concentration that MCEC tolerated while this concentration was 100 µg/ml in the case of SMC. Since the 
L-AA was the limiting reagent in terms of tolerable concentration, a 100 µg/ml dose was selected for the 
subsequent experimental setup. The effects of CA, and the less successful ones of L-AA, on cell growth, 
were further compared against a drug commonly used for stent coating, PTX, at a typical therapeutic dose 
100 µg/ml.  Two PTX preparations were used; PTX dissolved in DMSO and PTX suspended in media to 
represent in vivo conditions. The method of using PTX conditioned media is discussed and validated in 
chapter 2 of this thesis. Briefly, pre-dissolving PTX in organic solvent would result in concentrations that 
are not representative of in vivo due to PTX low solubility in aqueous media. Figure 3.7 shows 
representative images of MCEC and SMC treated with 100 µg/ml of the following bioactive additives: PTX 
in media, PTX in DMSO, CA and L-AA. Here, qualitative analysis confirmed again that 100 µg/ml CA 
supports growth of both SMC and MCEC, while L-AA at this concentration does not inhibit the growth of 
SMC but completely inhibits the MCEC growth at all time points.   
Figure 3.8 quantitative analysis revealed that CA treated MCEC are not significantly different from the 
control at all evaluated time points, indicating no inhibition of growth. Similar trends were observed for 
SMC. CA treated SMCs displayed significantly better growth compared to PTX in DMSO for all time points 
and at 48 and 72 h for PTX in media. L-AA exhibited severe cytotoxic effects on growth of MCEC as soon 
as 24 h post exposure but the cells then began to recover. L-AA treated SMC were significantly more viable 
than both PTX in DMSO and PTX in media at 48 and 72 h, but not significantly different from both the CA 
treated and control SMCs.  
Upon exposure to both PTX in DMSO and PTX in media, SMC cells showed decreasing viability over time. 
This trend is more pronounced in the PTX in DMSO-treated SMC, with merely 4 % viability at 72 h, while 
the PTX in DMSO treated SMC displayed 25 % viability at this time point. MCEC also followed a similar 
trend when treated with the two PTX formulations. However, the initial viability decrease at 24 h with 
respect to control was followed by a cell growth at 48 h before declining again at 72 h, with 41 and 18 % 
viability for PTX in media and PTX in DMSO, respectively. This effect was more prominent in the MCEC 
treated with PTX in media. The results presented here suggest that PTX in media elicits a milder cytotoxic 
effect in comparison to PTX in DMSO, while SMC show a greater susceptibility to both PTX samples than 
EC cells, a selective effect of PTX well described in previous literature[297] .    
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3.3.4 Viability of MCEC challenged with LPS 
 
Figure 3.9: Quantification of MCEC viability (%) at 6 h, 24 h and 48 h treated with a range of LPS 
concentrations (0.001 – 100 µg/ml). Experiment carried out in independent triplicates with sample size 
n=3. The differences between the time points for each of the LPS concentrations are statistically significant 
and are depicted by ¥ symbol, except for 0.001 µg/ml LPS where difference is not significant between 6 
and 24 h time point, depicted by £ sign. 
The first step in the investigation of the potential of CA to lower inflammation in an LPS treated MCEC line 
was to establish an exposure time frame that would result in detectable cytokine production across the 
tested LPS concentrations. An MTT cell viability assay was carried out at 6, 24 and 48 h of LPS exposure to 
detect changes in cells viability as an indication of MCEC activation and production of inflammatory 
markers. Figure 3.9 shows that following 6 h of LPS challenge, cells did not suffer viability loss up to 10 
µg/ml LPS concentration, beyond which a slight decrease in viability is seen down to 90 % at 100 µg/ml. 
24 and 48 h time points both followed a similar trend where a steady decrease in viability was seen with 
every 10-fold increase in LPS concentration with a more pronounced effects at 48 h, with 100 µg/ml LPS 
causing a sharp decrease in viability at 50 % at 24 h and 40 % at 48 h. LPS concentration beyond 0.1 µg/ml 
would be considered not representative as beyond this concentration viability falls below 75 % at 24 h. At 





Figure 3.10: MCEC treated with LPS (0.001 – 100 µg/ml) designated as LPS and MCEC treated 
simultaneously with LPS (0.001 – 100 µg/ml) and CA (100 µg/ml) designated as LPS-CA. Optical images of 
the cells taken at 24 h post treatment. Scale bars = 200 µm. Experiment carried out in independent 
triplicates with sample size n=3.  
MCEC treated with LPS-CA exhibit healthy spreading morphology across all LPS concentrations, as shown 
in phase contrast images provided in Figure 3.10.  MCEC retained characteristic healthy morphology even 
at high LPS doses such as 100 µg/ml. In contrast, MCEC treated with 100 µg/ml LPS only exhibited mainly 
round morphology uncharacteristic of healthy MCEC, with more round cells starting to appear from 0.01 
µg/ml LPS concentration onwards. The optical images in Figure 3.10 indicate that CA may suppress 
inflammation across LPS concentration range starting at 0.001 µg/ml going as high as 100 µg/ml. Based 
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on the MTT viability results for MCEC challenged with LPS, a 24 h time point was selected as an appropriate 
length of cell exposure to elicit desired inflammatory response that would allow quantification of 
inflammatory cytokines, without heavily compromising cell viability 
3.3.5 CA effects on MCEC inflammation  
 
Figure 3.11: CA-LPS treatment group effect on IL-6 expression from an MCEC line against a range of LPS 
concentrations at 24 h. CA-LPS represents MCEC simultaneously treated with various LPS concentrations 
and with 100 µg/ml CA. LPS represents control group were cells were treated with various concentrations 
of LPS only. Results shown are adjusted for cytokine expression in untreated control cells. Experiment 
carried out in independent duplicates with sample size of n=3.  
 
To examine the hypothesis that CA exhibits anti-inflammation properties that may be significant in 
vascular stent coating applications, changes in expression of pro- inflammatory markers were assayed in 
MCEC cell line 24 h post LPS exposure. Expression of IL-6, IL-33, IL-1α, IL-1β and TNF-α was investigated 
as a response to CA treatment in LPS-induced MCEC inflammation model. Only IL-6 expression was 
detected in LPS-induced MCEC. Interleukin 6 (IL-6) expression was found to be LPS dose-dependent up to 
0.1 µg/ml concentration with both groups; control and treatment presenting a similar trend. A decrease 
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in IL-6 expression is seen at 1 µg/ml LPS with a subsequent increase and plateau for both 10 and 100 µg/ml 
LPS concentrations. 100 µg/ml CA is significantly effective in reducing IL-6 expression at 0.1 µg/ml LPS. 
3.3.6 Viability and proliferation of MCEC and SMC under CA-PTX combined treatment 
 
 
Figure 3.12: Representative fluorescence microscopy images of calcein-stained MCEC and SMC captured 
at 48 (A) and 72 h (B). Cells were treated with CA:PTX combined treatment in the ratios of 100:100 (µg/ml) 
and 50:50 (µg/ml) or exposed to single treatment of PTX in media 50 or 100 µg/ml. CA 50 or 100 µg/ml 
and untreated cells were used to control the study (not shown here).  PTX was prepared in media. Scale 





Figure 3.13:  Viability and proliferation of MCEC and SMC treated with CA-PTX over 72 hours. The tested 
doses for the CA:PTX tandem treatment were 100:100 (µg/ml) and 50:50 (µg/ml), depicted in a legend as 
CA PTX 100 and CA PTX 50, respectively. PTX was prepared directly in media. Results are expressed as % 
viability with respect to untreated control. ** designates significant differences with p value ≤ 0.01.  
¥ designates significantly differences between MCEC and SMC within the appropriate time points with p 
value ≤ 0.05. Experiment carried out in independent triplicates with sample size n=3.  
The previous sections have shown that CA supports growth of EC and SMC and significantly improves 
growth of MCEC in comparison to PTX and L-AA treatments and growth of SMC in comparison to PTX 
treated cells. Moreover, CA was found to reduce IL-6 inflammatory marker expression in LPS-induced 
MCEC model. The previous sections have also shown that PTX induces greater cytotoxic effects on SMC 
than on MCEC. These results lead towards a hypothesis that due to the MCEC reduced sensitivity to PTX, 
CA could selectively exhibit a restorative effect on viability of PTX-treated MCEC over PTX-treated SMC. 
To test this hypothesis a tandem CA-PTX treatment on SMC and MCEC was used at two different 
concentration ratios of CA to PTX; 100:100 (µg/ml) and 50:50 (µg/ml) with PTX at 100 or 50 µg/ml used as 
a control for the CA efficacy. The combination total dose (50:50) and a single dose of 100 µg/ml in tandem 
(100:100) were selected to match the typical DES loadings of 100 µg/cm2  [298]. The qualitative analysis 
(Figure 3.12) shows that MCEC have retained typical cobblestone morphology under both tandem 
treatments at 48 and 72 h. The healthy elongated SMC morphology observed under CA-PTX tandem 
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treatment at 48 h is lost at 72 h where mainly round cells are present, indicating loss of viability. 50 µg/ml 
CA-PTX treatment seems to be more beneficial for cell recovery than 100 µg/ml, in both cell types. The 
two PTX concentrations 50 and 100 µg/ml do not appear to exhibit prominently different effects on the 
cell viability but do exhibit time-dependent cytotoxicity with SMC more sensitive to the PTX treatment. 
To confirm these observations a quantitative analysis was carried out as depicted in Figure 3.13.  CA-PTX 
tandem treatment was found to significantly improve MCEC and SMC viability with respect to appropriate 
PTX only treated group for both tested tandem ratios as well as both time points; 48 and 72 h. The effects 
on MCEC recovery are pronounced over time with 2.5 fold increase (15 % to 38 %) for 100:100 CA-PTX 
and 2.4 fold increase (22 % to 53 %) for 50:50 CA-PTX with respect to PTX only treatment at 48 and 72 h, 
respectively. SMC demonstrated a similar trend with 1.7 fold increase (27 % to 48 %) for 100:100 CA-PTX 
and 1.9 fold increase (31 % to 60 %) for 50:50 CA-PTX with respect to PTX only at 48 and 72 h, respectively. 
There are significant cell recovery differences between MCEC and SMC at both tandem concentrations 
and time points with a trade-off between increasing viability of MCEC while still sufficiently suppressing 







Drug-eluting stents coated with anti-proliferative agents such as paclitaxel despite their non-selectivity 
remain a first choice in combating neointimal proliferation since their development in early 2000s [103, 
104]. Although, technical evolutions in stent design and coating strategies have greatly aided the 
reduction of adverse effects of DES, the search for new stent platforms and therapeutic agents continues 
[153]. Future stent generations need to prevent NI growth by selectively inhibiting SMC growth while 
promoting endothelialization and to target other phases of vascular regeneration such as the issue of 
persistent inflammation. As discussed in chapter 1, persistent inflammation is associated with an impaired 
healing mechanism and therefore re-endothelialization, leaving stent struts exposed to blood which can 
result in thrombosis [108, 128].  
Recently, a well-studied and relatively simple compound, L- ascorbic acid (L-AA) garnered interest with 
emerging publications describing new L-AA applications and the potential of being incorporated into 
blood contacting devices to improve biocompatibility. Specifically, L-AA has been shown to exhibit 
selective properties by promoting growth of EC over SMC along with anti-oxidant cardio-protective 
properties [287-289, 299, 300]. The growth promoting properties on EC are attributed to the L-AA role in 
the synthesis of type IV collagen; the main component of basement membrane to which EC are anchored 
to in the vascular wall [301]. The other organic compound finding itself re-purposed is citric acid (CA). 
Although not as heavily investigated in the context of stents and medical devices applications as L-AA, CA 
has been shown to reduce inflammation in EC and promote EC healing [167, 219, 302].    
Here, a comparative study was conducted to investigate the effects of CA on the growth of SMC and EC 
in comparison to L-AA. Both CA and L-AA were investigated across a 1 – 1000 µg/ml concentration range 
to identify a dose that may be significant for EC growth while minimizing SMC growth. CA was shown to 
encourage cell growth for both cell types across all concentrations. L-AA exhibited cytotoxicity to EC even 
at low concentration while this effect was seen with SMC for mid-range concentrations.  These findings 
do not indicate a cell specific CA selectivity and are in disagreement with previously published studies 
where L-AA exhibited growth promoting properties on human EC over SMC in vitro [288, 299]. Although, 
concentrations in the range of 1-1000 µg/ml as used in this study showed positive results, other numerous 
studies investigate L-AA in the context of tumor inhibiting agent by induction of apoptosis and inhibition 
of cell growth with effective concentrations as low as 0.5 mM (88 µg/ml) [303]. Since CA supported EC 
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growth across all tested concentrations, a 100 µg/ml dose was selected for a subsequent comparison 
study for all tested drugs; L-AA, PTX in DMSO and PTX in media. This dose was a convenient concentration 
to use as 100 µg/cm2 PTX loading is commonly used in PTX DES and would thus represent a clinically 
relevant concentration [298]. MCEC exposed to CA at 100 µg/ml showed significantly better cell growth 
over 72 h than MCEC exposed to the same dose of PTX in DMSO, PTX in media and L-AA. Interestingly, L-
AA at 100 µg/ml exhibited more cytotoxicity than PTX. With SMC, CA promoted growth significantly better 
than the PTX samples, but not than L-AA. 1 µg/ml and 100 µg/ml L-AA correspond to 5.7 µM and 567.8 
µM L-AA, respectively, while typical plasma concentration values in humans range from 37 – 121 µM, 
explaining the greater sensitivity of cells to L-AA concentration at 100 µg/ml and above [287]. The findings 
here suggest superior performance of CA over typically used DES coating PTX in both MCEC and SMC and 
over recently studied L-AA in MCEC. Although, CA did not exhibit better growth with respect to controls, 
the results demonstrate the potential positive impact of CA on stent surface endothelialization. To further 
test CA applicability as a bioactive stent coating in combination with existing proliferative drugs such as 
PTX, CA-PTX tandem treatment was used on MCEC and SMC. Treatment with CA-PTX at 100:100 and 50:50 
µg/ml showed a significant recovery of MCEC and SMC viability compared to PTX only-treated cells. 
Interestingly, the improved viability was found to be cell specific with significantly improved recovery of 
CA-PTX treated MCEC over SMC. Although, this preliminary assessment requires further studies to better 
understand the synergic effect and cell type specificity, the findings here demonstrate a novel CA-PTX 
combination treatment with a potential therapeutic effect of the two coatings in tandem form by 
improving endothelialization while supressing smooth muscle cells growth.  Perhaps, the fine-tuning of 
the CA-PTX dose ratio may allow for balance between effective SMC growth inhibition and adequate EC 
recovery. 
Expression of pro-inflammatory cytokines in response to vascular injury to the stent implantation is an 
initial event in inflammatory response and is linked to restenosis and ultimately to re-intervention [304, 
305]. In the second part of this study, expression of IL-6, IL-33, IL-1α, IL-1β and TNF-α pro-inflammatory 
cytokines were investigated as a response to CA treatment in LPS-induced MCEC inflammation model. Out 
of the five cytokines only IL-6 was found to be expressed 24 h post stimulation with a significantly reduced 
expression in CA treated cells induced with 0.1 µg/ml LPS. This is a significant finding since IL-6 modulates 
cytokine expression in response to endothelial injury via a functional polymorphism in its gene promoter 
[306]. The results here suggest the potential of CA as a suitable drug for stent coating that supports 
endothelialization with simultaneous capacity to suppress vascular inflammation cascade by lowering IL-
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6 expression. Although, the CA bioactive properties as reviewed in detail in section 1.4 and the cell 
response to CA as established in the experimental part of this chapter are encouraging, further work is 
required to distinguish between the observed cell effects in the context of endothelialization as a result 
of CA bioactive effects itself or merely due to a pH-related change. 
3.5 Conclusions 
In the comparative study presented here, it was found that CA supports the growth of MCEC and SMC 
across a concentration range of 0.1- 1000 µg/ml. 100 µg/ml CA significantly improved the growth of both 
EC and SMC over typically used stent coating agent PTX at the same dose. On the other hand, L-AA 
promoted growth of SMC up to 100 µg/ml and MCEC up to 1 µg/ml, indicating a greater susceptibility of 
MCEC to L-AA treatment. CA also significantly increased the growth of EC over L-AA in MCEC but not SMC. 
CA-PTX combination treatment showed to significantly improve MCEC and SMC recovery over PTX alone 
treated cells. Moreover, this effect was found to be cell specific with significant differences found between 
the two cell types in favour of MCEC. 100 µg/ml CA inhibited expression of pro-inflammatory cytokine IL-
6 in LPS-induced inflammation model at 0.1 µg/ml LPS. Taken together, these findings demonstrate the 
potential use of CA as an anti-inflammatory coating in combination with PTX in vascular application for 
blood-contacting devices such as stents to mitigate the PTX-induced inflammation. These findings indicate 
the potential of CA to serve as a bioactive and therapeutic coating for re-endothelialization, perhaps in 




CHAPTER 4  
Citric acid functionalized nitinol stent surface 
promotes endothelial cells healing  
_________________________________ 
4.1 Introduction 
Endothelial denudation followed by an impaired or incomplete healing of the intimal layer has been a 
major problem associated with vascular stent implantation for decades [120]. Inadequate endothelial cell 
(EC) healing and subsequent development of restenosis leads to stent failure and re-intervention, thus 
posing a considerable socioeconomic burden on the healthcare system [307]. The use of drug-eluting 
stents (DES) as a next step-up from bare metal stents (BMS), which merely hold the vessel open, could 
actively fight vessel re-narrowing by eluting anti-proliferative drugs. However, the use of DES brings with 
it a new issue of late stent thrombosis associated with a disruption of the cells’ post-injury healing 
mechanism [143, 308]. The process of migration and proliferation of EC has been shown to be impaired 
by the action of the anti-proliferative agent, paclitaxel, which not only suppresses SMC proliferation but 
also endothelial cell proliferation, thus potentially affecting the re-endothelialization process [109, 143, 
170]. Human studies suggest the time required for complete endothelialization after BMS implantation is 
between 3 – 4 months [144], while re-endothelialization after DES implantion has been shown to be 
significantly delayed, in some cases beyond 12 months [143].  
It is now recognized that early endothelialization can prevent neointimal formation and that smart stent 
design is required, where endothelialization can be promoted while neointimal growth is inhibited [108]. 
The manipulation of stent surface properties that can promote endothelial adhesion and reduce 
neointimal growth could be significant in the context of wound healing following stent implantation. This 
need is currently not met with DES where endothelial regeneration is impaired as in the case of stents 
coated with a non-selective anti-proliferative drug such as paclitaxel or with BMS where neointimal tissue 
growth is a challenge [143, 309].  
78 
 
The aim of this study is to assess: i) basic cell properties such as adhesion, migration and proliferation 
required for endothelial regeneration ii) cellular distress through cytokine production and apoptotic 
changes, and iii) to evaluate these as a response to different stent surfaces and coatings.  The current 
understanding of the endothelialization process describes three main mechanisms by which regeneration 
of the endothelial monolayer occurs in the setting of vascular injury in vivo [310]: (i) Migration and 
proliferation of residing EC from the proximal and distal ends of the injured endothelium to the sites of 
vascular stent attachment, known as transanastomotic growth; (ii) Transmural growth, enabled through 
the ability of neighbouring vessels to endothelialize the microporous structure of stent and the 
micropores themselves attracting blood clots resulting in tissue formation; (iii) Recruitment of endothelial 
progenitor cells circulating in the blood by the injured vessel [310]. Binding between cells and the 
extracellular matrix (ECM), in this case a surface of a vascular stent, is an essential part of cell adhesion 
and migration, and this process is facilitated by the interactions between cell surface integrin receptors 
and ECM ligands. Integrins are heterodimeric transmembrane receptors that contain α and β subtypes 
and facilitate cell adhesion [311]. They also function biochemically by sensing whether adhesion has 
occurred. Previously, it has been shown that acidic extracellular environment promotes integrin activation 
resulting in increased cell adhesion and migration [216]. Integrins, made up of a headpiece and 
extracellular leg domains, are typically found in equilibrium among three main conformational states; low, 
medium and high affinity [312]. Acidic extracellular pH can shift the conformational equilibrium towards 
the high affinity state by promoting integrin headpiece opening [216]. Previous research has shown that 
mildly acidic pH can increase the number of activated αvβ3 integrins on cell surfaces making substrate 
binding  more likely to occur and has advantageous effects on cell morphology, spreading, and migration 
speed [216].  
In this work, endothelial healing capability is investigated through cell adhesion, migration, proliferation 
and apoptotic changes in the presence of a citric acid functionalized stent (CAFS) compared to the 
commercially available BMS and DES. The results demonstrate how a nitinol surface can be tailored to 
enhance the endothelialization process. This study suggest that an acidic surface could prove beneficial 
against endothelial denudation and impaired healing of the intimal layer. It also provides a methodology 




4.2 Materials and Methods 
4.2.1 Materials 
MCEC Cardiac Endothelial Cell Lines (CLU510) VH Bio, CALCEIN- AM 1 MG/ML (C3099) BioSciences, 25 
Culture-Inserts 2 Well (80209) Ibidi, Rhodamine Phalloidine (R415) Invitrogen, CellEvent™ Caspase-3/7 
Green Detection Reagent (C10423) Invitrogen, DRAQ7™ (ab109202) Abcam. Following kits and reagents 
were obtained from Sigma Aldrich: Dulbecco’s Modified Eagle’s Medium - without sodium pyruvate 
(D5796), DAPI (D9543), Fetal Bovine Serum (F7524), L-Glutamine (G7513), Penicilin/Streptomycin (P0781), 
1X Trypsin-EDTA (T3924), Phosphate Buffer Saline (P3813), Thiazolyl Blue Tetrazolium Bromide (M5655), 
Annexin V-Cy3™ Apoptosis Detection Kit (APOAC). Vascular stents used throughout the study were kindly 
supplied by Cook Medical, Limerick, Ireland. 
4.2.2 Stent Selection and Preparation 
Three different stent types illustrated in Figure 4.1 were investigated; commercial Zilver Flex® Vascular 
Self-Expanding Stents designated as BMS, Zilver® PTX® Drug-Eluting Peripheral Stents designated as DES 
and non-commercial CA coated stents based on the Zilver Flex platform designated as CAFS. The nitinol 
surface of this stent is ethanol and plasma cleaned prior to coating with CA. CAFS surface is spray coated 
with CA solution prepared as 1 g in 100 ml of water to achieve CA coating of 25 µg/ 10 mm of the stent 
length at a total dose of 100 µg for 40 mm long stent. The coating is approximately 100 nm thick. All stents 
were of 40 mm length and 5 mm diameter. Stents were ethylene oxide sterilized and supplied in sealed 





Figure 4.1: Schematic illustration depicting the three types of stents used in this study; bare metal stent 
(BMS), paclitaxel eluting stent (DES) and citric acid functionalized stent (CAFS). Figure created with 
BioRender (https://biorender.com).  
 
4.2.3 Culture of Mouse Cardiac Endothelial Cells 
All cell culture work was performed in a biological safety cabinet under laminar flow maintaining sterile 
conditions. Immortalized Mouse Cardiac Endothelial (MCE) cells are derived from microvascular neonatal 
mouse cardiac endothelial cells and transfected with lentiviral vectors carrying SV40 T antigen and human 
telomerase. MCEC culture media consisted of high-glucose DMEM media without sodium pyruvate 
supplemented with 5 % FBS and 1 % Penicillin/Streptomycin. Cells were cultured in an incubator at 37 ◦C 
and 5 % CO2. Cells were passaged at 70-80 % confluency in a dilution of 1:5 or 1:10, reaching 80 % 
confluency after 2 or 3 days, respectively. Cell starvation was done with DMEM medium containing 0.5 % 
FBS and other supplements as normal.  
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4.2.4 Conditioned Media Preparation 
To study stent coating in bio-relevant media without the use of solubilisation agents to dissolve 
hydrophobic coatings such as paclitaxel in Zilver PTX stent, the stent conditioned media approach was 
chosen to allow cells to be exposed to drug concentrations that are potentially more relevant of the in 
vivo conditions, which was validated in Chapter 2. To release the bioactive substances from the surface of 
the stents, an approach similar to the “Extractables/Leachables Testing of Medical Devices” was used as 
outlined in ISO 10993 standard [271, 313]. The MCEC growth media exposed to the stents is referred 
hereafter as “BMS, DES or CAFS conditioned media”. Stent conditioned media was prepared by immersion 
of the BMS, DES and CAFS stents in 5 ml of complete cell growth media followed by sonication for 10 min 
to release the coated substance and incubation for at 37 ◦C, 5 % CO2 for 48 h. The required volume of stent 
conditioned media was then used in cell assays. All stent conditioned media was prepared 48 h in advance 
of the scheduled experiments.  
4.2.5 Cell visualization and quantification 
Confocal fluorescent images were captured with an ImageXpress Micro Spinning Disc Confocal High-
Content Imaging System, Molecular Devices. A FITC filter was used to detect live cells, while DAPI and 
TRITC filters were used to detect nuclei and f-actin filaments (Phalloidin Rhodamine) respectively, in PFA 
fixed cells. A FITC filter was used to detect activation of caspase 3/7 in apoptotic cells. In a separate assay, 
the presence of annexin V-Cy3 conjugate in apoptotic cells was visualized using a FITC filter and 6-CFDA 
specific to live cells was detected using a TRITC filter. Emission spectra were used under default settings. 
Images were stored in TIFF file format and Image J software was used to process all images 
(https://imagej.nih.gov/ij/). Cell counting was performed using automated counting functions in Image J. 
Cell morphology was assessed from confocal images using aspect ratio (X:Y dimensions) of at least 10 
randomly selected cells for each sample. 
4.2.6 Zeta Potential (stent-conditioned media) (zeta potential measurements carried out by 
Michele Dully, Bernal Institute, University of Limerick) 
To assess the changes in the EC surface potential when exposed to the different stent conditioned media 
(BMS, DES and CAFS), adherent EC grown in cell culture plates were detached (trypsinized) from the plates 
surface. Cells pelleted by centrifugation were resuspended in the corresponding stent conditioned media 
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(BMS, DES and CAFS) at a density of 0.5x106 cells/ ml. Approximately 1 ml of each cell suspension was 
then transferred into the capillary zeta cell and zeta potential measurements were immediately taken. 
Zeta potential was measured using a Zetasizer Nano ZS (Malvern Instruments) in duplicate with 40 
measurements for each of the sample runs. Samples were kept at 37oC using a heating block. 
Measurements were taken using monomodal mode settings.  
4.2.7 Cell Migration – wound healing assay 
A wound healing assay was performed with the Ibidi Culture-Insert 2 well as indicated in the manufacturer 
instructions. MCEC were trypsinized, trypan blue stained and counted using automated cell counter. Each 
of the cell culture inserts were placed into the center of a well in a 6 well plate. A cell suspension was 
prepared so that 70 µl of cell suspension containing 1.4x104 cells, was applied into each well of the Ibidi 
insert placed in a cell culture plate and incubated at 37 ◦C and 5 % CO2 incubator. At 48 h, a confluent cell 
layer was allowed to stabilize for 24 h with further overnight cell synchronization in low FBS media (0.5 % 
FBS).  After the overnight cell synchronization, inserts were gently removed by using sterile tweezers and 
samples washed with pre-warmed 1X PBS. Plate wells were replenished with 3 ml of BMS, DES and CAFS 
conditioned media. Wound healing was monitored for 24 h with images taken every 2 h for the first 6 h 
followed by 24 h time point using phase contrast inverted microscope at 4x magnification.  Assay was 
carried out in triplicates. All images were processed as described  previously [314]. Percentage wound 
closure was calculated using following formula: 
𝐴0− 𝐴𝑡  
𝐴0
 x100      Eqn. 4.1 
where A0= initial wound area,   
At = area at time t (2, 4, 6 h…) 
4.2.8 Endothelial Cell Adhesion Assay (stent conditioned media) 
To quantify EC adherence in the cell culture plates in the presence of serum free stent conditioned media 
MCEC at 70-80 % confluency were serum starved in 0.5 % FBS overnight before being trypsinized, pelleted, 
washed twice with 1X PBS and re-suspended in serum free media at 5x106 cells/ml. Calcein AM at 2µM 
concentration was added to the cells suspension and cells were labelled for 30 min at 37 °C in a 5 % CO2 
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incubator. Following the incubation, cells were washed twice with serum free growth media and re-
suspended in 1 ml serum free stent conditioned media (BMS, DES, CAFS) at 1x106 cells/ml. 100 µl of 
calcein-labeled cell suspension in stent conditioned media containing 1x105 of cells was then added to 96-
well plate. Cells were allowed to adhere for 30 min before non-adherent calcein labeled cells were 
removed by gentle blotting with pre-warmed media up to four times. Adherent cells were imaged using 
ImageXpress Micro Spinning Disc Confocal High-Content Imaging System using FITC filter. Cell count was 
quantified using Image J and expressed as cells/mm2.  
4.2.9 Endothelial Cell Adhesion Assay (stent surface) 
MCEC at 70-80 % confluency were detached, trypan blue counted and seeded into 15 ml tubes, each 
containing 5 ml of serum free growth media at a seeding density of 1x106 cells/ml. BMS, DES and CAFS 
stents were added into each tube. The tubes were horizontally placed onto a tube rotator with rotations 
around the x-axis for 30 min at 3 RPM. Negative stent controls containing no cells were set up with serum 
free growth media and incubated for 30 min. After the elapsed time, stents were carefully removed with 
tweezers washed in 1X PBS by immersion, fixed with 4 % PFA for 15 min at RT before staining actin 
filaments with Phalloidin-Rhodamine (1:500) and nuclei with DAPI (1:1000). Samples were fixed onto glass 
slides and images of the samples were taken with fluorescent confocal microscope, ImageXpress 
(Molecular Devices) using z-stack function at 4x magnification. Whole stent samples were examined for 
uniformity of cellular coverage and a single strut on the abluminal side of the stents was selected for 
imaging. Cell count was determined from blue channel representing cell nuclei using ImageJ.  
4.2.10 Cell Proliferation Assay (stent conditioned media) 
The effect of stent conditioned media on cell proliferation was analyzed using an MTT viability assay. 
MCEC seeded at a concentration of 0.5x104 cells/well were allowed to adhere and proliferate overnight in 
a complete media. The next morning media was changed for the stent conditioned media. After 24 and 
48 h of cell exposure to stent conditioned media, 10 µl (5mg/ml) of MTT reagent (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) was added to all wells and incubated for 2 h at 37 °C. Positive 
controls were prepared by treating cells with 0.5 % Triton-X 100 for 10 min, negative controls contained 
no cells, untreated control contained cells cultured in a normal growth media. The MTT formazan crystals 
were dissolved by addition of 100 µl of solubilisation buffer (10 % SDS in 0.01 M HCl) followed by further 
incubation for 4 h at 37 °C. Absorbance was read at 570 nm using microplate spectrophotometric reader. 
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Cell viability was determined by comparing background corrected absorbance values of treated cells to 
corrected absorbance values of untreated control cells. A ratio of percentage reduction of cell viability 
relative to control cells was used to express the obtained data.  
4.2.11 Endothelial Cell Proliferation (stent surface) 
For the proliferation assay on the stent surface, 1x106 MCEC were seeded onto stents under rotational 
conditions in a complete media as described in section 4.2.9 and allowed to adhere to the stents for 1 h. 
After the initial adhesion time, the content of the tubes was carefully transferred into a 60 mm petri dishes, 
one corresponding to each sample BMS, DES and CAFS and stored at 37 ◦C, 5 % CO2 incubator. Petri dishes 
were tilted to allow full immersion of the stent into the media. Stent samples were washed with 1X PBS 
and fixed with 4 % PFA for 15 min at RT and then DAPI and f-actin stained, imaged using confocal 
microscope (ImageXpress, Molecular Devices) and cell count was performed in Image J.  
4.2.12 Cytokine production (cell conditioned media) 
To prepare cell conditioned media for cytokine assessment, media used in the proliferation assay (stent 
surface) was collected from the respective petri dishes at 48 h and centrifuged to pellet non-adherent 
cells at 1000 x g for 10 min. To remove any contaminants and insoluble particles from the stent coating, 
the supernatants were filtered using a 0.22 µm polyvinylidene fluoride (PVDF) filter. BMS, DES, CAFS and 
control cell conditioned media was stored at -80 ◦C in 1 ml aliquots until needed. MCEC were seeded at 
5000 cells/well into a 96 well plate and allowed to adhere and proliferate overnight for 12 h. The next day 
media from wells was discarded and cells washed with 1X PBS before treated with the respective cell 
conditioned media. After 48 h of exposure, the effect of cytokine production was evaluated using the MTT 
viability assay.  
4.2.13 Apoptotic assay – imaging  
Expression of two apoptotic assay markers, caspase 3/7 and annexin V, was assayed for in MCEC at 48 h 
post- exposure to stent conditioned media. To prepare cell samples, 200 µl of 1x104 /ml MCEC were 
seeded in a 96-well plate and allowed to adhere overnight. The next morning cells were treated with the 
respective stent conditioned media. Media exchange was carried out to prepare a negative live control 
and 10 % DMSO (v/v) in media was used to induce apoptosis as positive controls. All reagents were 
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prepared and the assay carried out according to the manufacturer’s recommendation with some protocol 
modifications as stated here. Briefly, for the annexin V-cy3 and 6-CFDA staining method, media was 
removed at 48 h, cell samples washed twice with 1X PBS followed by three washes with 50 µl 1X binding 
buffer. Samples were then incubated in 50 µl of the double staining solution for 10 minutes at room 
temperature. After the incubation time, samples were further washed with 50 µl of 1X binding buffer and 
images were taken as described in section 4.2.5. For the Caspase 3/7 staining, at 48 h the plates were 
spun down at 1000 for 5 minutes.  100 µl of the 200 µl supernatant was gently removed and 100 µl of 7.5 
µM caspase 3/7 reagent was added to each sample followed by incubation at 37 °C for 30 minutes. 
Samples were imaged as per section 4.2.5. Fluorescence intensity was measured in ImageJ and expressed 
as corrected total cell fluorescence (CTCF) using the following formula: 
 
          Eqn 4.2 
 𝐶𝑇𝐶𝐹 =  𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 – (𝐴𝑟𝑒𝑎 𝑜𝑓 𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 ×  𝑀𝑒𝑎𝑛 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑟𝑒𝑎𝑑𝑖𝑛𝑔𝑠)    
             
4.2.14 Apoptotic assay - Flow cytometric quantification 
The presence of apoptotic cells in MCEC samples exposed to stent conditioned media for 48 h were 
assessed on an Accuri C6 flow cytometer equipped with a blue and red laser emitting light at 488 and 640 
nm, respectively. Cells were collected, pelleted at 1000 RPM for 5 minutes followed by a washing step 
with 1X binding buffer. Samples and controls were re-suspended as 1x106/ml and stained with Annexin V-
cy3 (1:100) and DRAQ7 (1:100) for 10 minutes at room temperature. Negative controls were live cells 
without any treatment while dead controls were prepared by treating cells with 0.1 % triton x-100. FMO 
controls (fluorescence minus one) were also accordingly prepared; each containing only one fluorophore. 
Apoptotic cells due to annexin v-cy3 fluorescence were detected by the FL-2 filter (585/40 nm) and dead 
cells labelled with DRAQ7 were detected with FL-4 filter (675/25 nm). 80,000 events were collected with 
single cell population gated in the FlowJo software version 10.7 (http://www.flowjo.com/). Total MCEC 
numbers of each; apoptotic, dead and double positive subsets were expressed as percentage of total 
single cell population. 
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4.2.15 Statistical Analysis 
All experiments were carried out in independent triplicates or duplicates and are expressed as the mean 
± standard deviation (SD). The number of independent replicates and the sample size is indicated for each 
respective figure. For multiple-sample comparison, the data were analyzed using Microsoft Excel’s 
statistical function for one-way ANOVA to determine a presence of significant differences between the 
different sample treatment groups.  For a subsequent post hoc analysis, an appropriate t-test was used 
with p-value adjusted with Bonferroni correction to avoid type I error. A p-value of 0.05 or less indicates 





4.3.1 Zeta potential (stent-conditioned media) 
 
Figure 4.2: Zeta potential measurements as determined by exposure of MCEC to stent conditioned media. 
Trypsinized cells were re-suspended in stent conditioned media at a density of 0.5x106 cells/ ml with 
measurements taken immediately at 37 ◦C using Zetasizer Nano ZS (Malvern Instruments). Error bars 
represent standard deviation. Experiment carried out in independent triplicates with sample size n=3. 
¥  indicates a significant differences from all other groups. 
To evaluate the interactions of stent conditioned media and cell surface, zeta potential measurements 
were carried out. An increase in electronegativity of the cells from -8.52 mV to -10.20 mV is observed for 
the CAFS sample compare to the control cells (EC), indicating adsorption of citric acid dissociated carboxyl 
groups onto the EC surface. In the case of DES stent condition media there is no change in the 
electronegativity with respect to the control. Similarly, no change in the electronegativity for the BMS 
sample as this is a bare surface therefore nothing is released into the media that could interact in the cell 
surface interface.  
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4.3.2 Endothelial Cell Adhesion (stent-conditioned media) 
 
Figure 4.3: Representative confocal images of calcein-labelled mouse cardiac endothelial cells that 
remained adherent after 30 min of cells exposure to the stent conditioned media during the adhesion 
assay. Scale bars = 200 µm. Experiment performed in triplicates with n=3. Images were analyzed for cell 
count using Image J software and adhesion was expressed as number of adherent cells per mm2 in form of 
a bar graph. ** denotes p < 0.01. Experiment carried out in independent triplicates with sample size n=3. 
To investigate the effects of stent surface coatings on cell adhesion, MCEC were labelled with calcein and 
seeded in the presence of serum free stent conditioned media. Fluorescent confocal images of the 
adherent cells were taken after 30 min. Serum free media was used to avoid the contribution of the 
extracellular matrix proteins to cell adhesion, Figure 4.3. The image analysis shows that the paclitaxel 
eluting from the DES does promote the adhesion of cells to the plate, as statistical analysis revealed a 
significantly higher adhesion compared to BMS, CAFS and control samples (p<0.01).  BMS and CAFS 
adhesion levels represented by the cell count were comparable to the control sample, with the BMS 
sample displaying slightly lower mean adhesion. 
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4.3.3 Endothelial Cell Adhesion (stent surface) 
 
Figure 4.4: Adhesion of mouse cardiac endothelial cells to the surface of BMS, DES and CAFS struts under 
rotation (3 rpm) at 30 min in a serum free media. To detect cells, samples are f-actin stained (Phalloidin-
Rhodamine) and cell nuclei are counterstained with DAPI. Images of the stent samples are taken with 
ImageXpress spinning disc confocal microscope. Scale bars = 200 µm. Experiment performed in 
independent duplicates with n=1.  
Adhesion of MCEC to the stent surfaces was investigated in a serum free media at 30 min. In Figure 4.4, 
the BMS, which has an uncoated nitinol surface, exhibits a minimal cell presence. On the other hand, the 
DES containing paclitaxel coating seems to be well populated with dense cells clusters. CAFS stent surface, 
although not as densely as the DES, exhibits cells evenly populated across the stent struts. For controls in 
this experiment (not shown), stents were incubated in media with no cells and stained with DAPI and 
phalloidin-rhodamine at the 30 min time point same as samples. None of the control stents showed 
positive staining for cells. 
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4.3.4 Endothelial Cell Migration (stent-conditioned media) 
 
Figure 4.5: (A) Percentage wound closure area for the MCEC in the presence of BMS, DES, CAFS and control 
stent conditioned media at 0 h, 2 h, 4 h, 6 h and 24 h time points. Statistical analysis of the migration assay 
results:  p<0.05 Control-BMS and Control-DES at 2 h, p<0.05 Control-DES at 4 h, 6 h and 24 h time points. 
(B) Representative images of the wound healing assays for the MCEC in the presence of BMS, DES, CAFS 
and control stent conditioned media at indicated time points. The cell free (unhealed area) was measured 
using Image J software [314]. Scale bars = 500 µm. Experiment carried out in independent triplicates with 
sample size n=3. 
 
The wound healing potential of the EC in the presence of stent conditioned media was assessed using a 
classical wound healing assay as depicted in Figure 4.5. To minimize cell proliferation, the cell monolayers 
were synchronized in serum free media overnight before being exposed to the stent conditioned media. 
For the cells treated with the CAFS conditioned media, a significantly improved migration (12.85 % wound 
closure) compared to the BMS (7.04 % wound closure) and DES samples (4.81 % wound closure) can be 
seen at the 2 h time point. This observation was confirmed to be statistically significant as the migration 
of the control (16.32 % wound closure) was significantly different only from DES and BMS samples but not 
from CAFS sample as shown in Figure 4.5. This analysis implies that the CAFS sample compares best to the 
control sample, which has the highest rate of migration. A similar trend, where CAFS sample has an 
increased effect on cell migration and tightly follows the migration of control cells can be seen for the 
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subsequent time points. Although higher than the BMS, the wound healing of the CAFS sample is not 
significantly different for the 4 h (20.14, 27.64 % wound closure) and 6 h (38.46, 45.50 % wound closure) 
time points. The DES sample falls just behind the BMS sample at 2 h (4.81 %), nonetheless it shows a 
significant inhibition of migration for 4 h (10.11 %) and 6 h (23.94 %) time points. In fact, at the 24 h time 
point the wound remains open for the DES sample with a percentage closure of 66.88 % compared to all 
other tested samples that had fully closed wounds at 24 h. Images of the DES sample taken at 48 h (not 
shown here) showed that the wound remained open even at this time point.   
4.3.5 Endothelial proliferation (stent-conditioned media)  
 
Figure 4.6:  Viability of mouse cardiac endothelial cells exposed to stent conditioned media for 24 h and 
48 h as measured by an MTT assay expressed as a mean percentage viability of control. Absorbance 
measured at 570 nm. Statistical analysis p<0.01 at 24 h, p<0.05 at 48 h. Experiment performed in 
independent triplicates with a sample size of n= 3. 
The MTT proliferation assay is a quantitative and sensitive detection assay for metabolically active cells, 
capable of reducing tetrazolium (MTT reagent) into insoluble formazan crystals, based on a linear 
relationship between cell activity and absorbance at 570 nm. Figure 4.6 shows time-dependent effects of 
stent conditioned media on endothelial cell viability over a 48 h time period. All results are normalized 
and discussed with respect to the untreated control taken as having 100 % viability. The results show no 
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significant decrease in viability in the case of the CAFS sample over a 24 and 48 h time period with respect 
to the control. As expected, cells in the DES conditioned media sample exhibited practically no change in 
the proliferation levels from 24 h (53 %) to 48 h (51 %). EC in the BMS conditioned media exhibited 
proliferation levels (48 %) similar to that of DES sample (53 %) at 24 h, with greatly improved proliferation 
at 48 h (100 %), surpassing the viability of cells exposed to the CAFS conditioned media (82 %). Statistical 
analysis revealed that the CAFS sample is significantly different from DES sample at 48 h and from both 
BMS and DES at 24 h.  
4.3.6 Endothelial Cells Morphology (stent-conditioned media) 
 
Figure 4.7: Morphological assessment of mouse cardiac endothelial cells grown in the presence of the stent 
conditioned media for 48 h. (A) The calculated X:Y ratio for the cell shape index was plotted against the 
individual samples using a boxplot. (B) Images taken using IMX spinning disc confocal microscope. Blue 
channel is DAPI (nuclear counterstain) and red channel is Phalloidin-Rhodamine (cytoplasmic stain binding 
to f-actin). Scale bars = 50 µm. Experiment carried out in independent triplicates, a minimum of 10 cells 
analyzed for each sample. ** denotes significant difference p < 0.01.  
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Confocal images were analyzed to describe differences in endothelial morphology for cells grown in the 
BMS, DES, and CAFS stent conditioned media at 48 h using Image J analysis. Cell shape index (Y dimension 
divided by X dimension) shown in the box plot in Figure 4.7 was plotted on the y-axis against the tested 
samples. Higher cell shape index based on the higher ratio between x and y cell axis indicates elongated 
cell morphology. On the other hand, circular cells will display lower cell shape index. CAFS sample cells 
exhibit elongated morphology represented by the highest mean cell shape index (2.66) amongst all 
samples. The difference in morphology for the CAFS sample was confirmed by the statistical analysis with 
p<0.001. BMS and DES samples retained the cobble-stone morphology of the control sample cells with 
mean cell shape index values 1.57, 1.61 and 1.79 for BMS, DES and control, respectively. 
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4.3.7 Endothelial proliferation (stent surface) 
 
Figure 4.8: (A) Representative confocal images of mouse cardiac endothelial cell adherence to the stent 
struts at 48 h - DAPI (blue) and Phalloidin-Rhodamine (red). First row (iA) and second row (iB) represent 
samples assessed in independent duplicates with sample size n=1. Images taken with ImageXpress Micro 
Spinning Disc Confocal High-Content Imaging System, Molecular Devices. ii) Representative phase contrast 
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optical images show altered morphology of MCEC that adhered and proliferated on the petri dishes 
surfaces at 48 h. Scale bars = 200 µm. Samples assessed in independent duplicates with n=1 (B) Cell count 
as quantified from nuclei in iA and iB representing endothelial adhesion to the stent struts at 48 h. (C) 
Viability of MCEC exposed to cell conditioned media for 48 h as measured by MTT assay and expressed as 
a mean percentage viability of control. Absorbance measured at 570 nm. * denotes significant difference 
p < 0.05 and ** denotes significant difference p < 0.01. Experiments performed in independent duplicates 
with a minimum sample size of n= 3.  
Confocal microscopy with the use of fluorescent labels was used to identify and quantify MCEC  
proliferation on the stent surface at 48 h. To ensure consistency in cell adhesion across the stent surface, 
cells were seeded under rotational conditions for the first hour followed by a static incubation. Figure  (A) 
shows representative images of cells on the surface of the stent struts at 48 h. Image J was used to obtain 
the cell number by counting cell nuclei. The lowest strut coverage with a minimal cell number was 
detected on the DES sample. While BMS exhibited a significant number of cells evenly covering the strut 
surface, the CAFS sample showed a significant increase in strut coverage by the MCEC in Figure 4.8 (B). 
Due to the low cell presence in the DES sample, the brightness of the red (TRITC) channel was auto 
adjusted in ImageJ to show the outlines of the stent strut. Figure 4.8 (A) also shows phase contrast images 
of cells present on the surface of petri dishes at 48 h, as not all seeded cells would adhere to the stent 
surface. The images signify the stent coating effects on the residing cell population, as seen in the case of 
the DES.  
To investigate stress levels that cells experience during the stent proliferation assay, cell conditioned 
media was used. The cell conditioned media collected after the stent proliferation assay at 48 h was used 
to grow MCEC and an MTT assay was carried out at 48 h as shown in Figure 4.8 (C). The viability of BMS 
and CAFS samples are similar to the control indicating no or minimal presence of cytokines, while 5 % 
viability of DES sample demonstrates the presence of inhibitory cytokine levels on cell viability. Note that 
in the presence of stent conditioned media, the viability of DES samples were just above 50 % (Figure 4.6) 
indicating that the impact of the DES coating alone cannot be responsible for the reduction to 5 % cell 




4.3.8 Apoptotic assay imaging  
 
Figure 4.9: Representative confocal images of mouse cardiac endothelial cells exposed to BMS, DES and 
CAFS conditioned media and evaluated for presence of apoptosis by annexin V-Cy3 or caspase 3/7 staining 
at 48 h post-treatment. Untreated cells represent negative control and cells treated with 10 % DMSO 
served as positive control. In annexin V-Cy3/6CFDA staining, untreated cells are identified by green 
fluorescence while apoptotic cell fluoresce in the red spectra. In the caspase 3/7 assay a single stain is used 
to identify presence of apoptotic bodies by green fluorescence. Untreated cells exhibit no fluorescence. 
Respective CTCF numbers included on each image. Scale bars = 200 µl. Experiment carried out in 
independent duplicates with a sample size n= 3. * indicates significant difference p< 0.05. 
Apoptotic changes in MCEC as a response to stent conditioned media were evaluated through fluorescent 
imaging via annexin V binding to phosphatidylserine (PS) at the plasma membrane of affected cells. 
Representative fluorescence images are seen in the top row in Figure 4.9 where annexin V positive 
apoptotic cells can be identified by the presence of both red and green staining, dead or necrotic cells by 
presence of red fluorescence while live untreated cells display bright green fluorescence due to 6-CFDA, 
a metabolic stain interacting with esterases of live cells. Dead or necrotic cells emitting red fluorescence 
are seen in positive control where cells were treated with 10 % DMSO. The negative control without any 
treatment fluoresces green due to live untreated cells. Qualitatively the images show that treatment with 
stent conditioned media did not induce apoptosis in any of the samples, i.e.  a lack of red staining which 
if present would indicate changes in the plasma membrane and thus apoptosis. Although, all samples 
exhibited green staining, demonstrating intact cell viability, there is an evident decrease in cell number 
and morphological changes in the DES sample. The annexin V assay involves multiple cell washing steps 
with annexin V binding buffer during which the apoptotic or necrotic floaters are lost resulting in a critical 
population subset excluded from the analysis. 
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To evaluate both adherent and floating cells, activation of caspase 3/7 was assessed in a separate 
experiment as seen in the bottom row of Figure 4.9. Caspases 3/7 in apoptotic cells cleave a four amino 
peptide (DEVD) in CellEvent™ Caspase-3/7 Green reagent allowing DNA binding resulting in bright green 
fluorescence. The highest number of apoptotic cells was detected in the DES stent conditioned media 
sample with fluorescence significantly higher (p< 0.05) than from all other samples as demonstrated by 
corrected total cell fluorescence (CTCF) values. A low level fluorescence was detected in BMS and CAFS 
stent conditioned media samples but was not found to be significantly different from the negative control 
(no treatment). In conclusion, qualitative evaluation of apoptotic markers: annexin V and caspase 3/7 lead 
to conflicting results, requiring an alternative method that would allow quantitative analysis of the whole 
cell population.   
 





Figure 4.10: Flow cytometric measurements of MCEC treated with stent conditioned media for 48 h by 
annexin V-Cy3 binding and DRAQ7 uptake. Flow cytometric data shows a distribution of cell population 
subsets. Dead cell signified by uptake of DRAQ7 are found in quadrant 1 while apoptotic cells exhibiting 
annexin V-Cy 3 binding are in quadrant 3. Double positive cells or late apoptotic cells are located in 
quadrant 2 and live cells in quadrant 4. Live cells without any treatment and dead cells treated with 0.1 % 
Triton-X served as controls to identify live versus dead subsets. Appropriate florescence minus one (FMO) 
controls were also set up. Bar graph shows statistics for each of the quadrants expressed as a percentage 
of total singe cell population. ¥ denotes a significant difference to all other groups within the quadrant. 
Experiment carried out in independent duplicates with a sample size n= 3. 
To accurately quantify apoptotic changes in the whole cell population annexin V/DRAQ7 flow cytometric 
analysis was carried out on MCEC at 48 h post-treatment. Flow cytometry with the use of double staining 
such as annexin V and propidium iodide (PI) allows separation and quantitation of early apoptotic, late 
apoptotic and necrotic cell subsets. Apoptotic induction causes phosphatidylcholine (PS), normally 
residing in the inner plasma membrane leaflet, to be exposed on the outer membrane allowing binding 
of annexin V.  Annexin V can bind plasma membrane but cannot enter cells and is therefore used for 
detection of early apoptotic cells (annexin V+, DRAQ7-). On the other hand, DRAQ7, which is equivalent of 
classical PI staining, binds directly to DNA and is only permeable to cells with compromised membranes, 
thus used to identify late apoptotic (annexin V+, DRAQ7+) or necrotic cells (annexin V-, DRAQ7+).  
In Figure 4.10, a marginal proportion of apoptotic cells was detected in BMS (0.27 ± 0.28 %) and CAFS 
conditioned media-treated MCEC (0.55 ± 0.16 %), while this value was slightly elevated in DES conditioned 
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media treated cells (1.70 ± 0.24 %). The apoptotic cells are annexin V+ and DRAQ7- located in quadrant 3. 
The dead cells subset that would have taken up DRAQ7 due to compromised cell membranes is located in 
quadrant 1. All samples exhibited a low level of dead cells  < 5 %, a value normally seen in a healthy cell 
population, except for DES where this value was just above 5 % at 5.42 ±1.73 % and was found to be 
significantly different from live control sample. The double positive subset, indicating late apoptotic 
changes were noted in the DES conditioned media cell samples where 51.30 ± 5.28 % cells were found in 
quadrant 2.  For BMS, CAFS and live control this value was below 3 %. In summary, BMS and CAFS samples 
exhibit low levels of both double positive and DRAQ7 positive cells, indicating low presence of late 
apoptotic and necrotic cells. However, these changes are not significantly different from the live control. 
On the other hand, the DES conditioned media treated cells demonstrated significantly different levels of 
double positive cells and dead cells with respect to the control.  
4.4 Discussion 
The development of “smart” vascular stents that would inhibit SMC proliferation while promoting 
endothelialization would be of enormous medical benefit in cardiovascular interventions. While drug- 
eluting stents containing anti-proliferative agents inhibit proliferation of SMC, they also delay the 
regrowth of the EC. The present study addresses the feasibility of a CAFS nitinol stent for improving 
vascular biocompatibility specifically enhancing endothelialization. The interaction of mouse endothelial 
cells with BMS, DES and CAFS in terms of cell adhesion, migration and proliferation was investigated using 
two methods; a stent conditioned media approach and cell exposure to the stent surface itself. The BMS 
(Zilver Flex®, Cook Medical) used in this study is a bare metal nitinol stent without any pre-treatment or 
coating. The DES (Zilver® PTX®, Cook Medical) is a nitinol stent with a polymer-free amorphous paclitaxel 
coating on its abluminal side applied at a dose density of 3 µg/mm2. The CAFS is a non-commercial nitinol 
stent coated with CA at a total dose of 100 µg on the abluminal side (US patent 10874772B2). Prior to the 
coating process, the DES is ethanol cleaned while the CAFS is ethanol and atomically cleaned. The stent 
conditioned media method, described in detail in chapter 2, was developed to investigate the effects of 
stent coatings in a form that would be most representative of in vivo conditions. Poorly soluble drugs, 
such as paclitaxel are often reconstituted in organic solvents, not representing the drug solubility in the 
body [315-318].  
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The cell adhesion levels were highest for the DES in both investigative methods used. Paclitaxel (PTX), 
coated on the DES, has been reported to be minimally soluble in water-based solutions (1µg/ml in water 
at 37 °C with shaking) such as the media used in the production of stent conditioned media [265]. 
Therefore, a minute amount of paclitaxel would be soluble (< 0.59 µg/ml, section 2.3.3) and able to 
traverse the plasma membrane with the majority of paclitaxel being present in the form of insoluble 
particles, either on the stent or suspended in the stent conditioned media. Previous tissue 
pharmacokinetics studies have revealed that vessel surface deposition analysis of crystalline stent-eluted 
paclitaxel has shown higher concentrations at the vessel surface than in the arterial tissue at 24 h and 7 
days. On the other hand, the tissue and vessel surface levels were similar for the amorphous form of the 
drug for the same time points assessed, suggesting that the amorphous paclitaxel is more lipophilic and 
is retained in tissue more easily than the crystalline form [256]. The paclitaxel used in this study is reported 
to be mainly amorphous and therefore should have a higher affinity for cells [319]. Image based adhesion 
analysis shown in Figure 4.3 revealed a significant increase in DES conditioned media cell anchorage levels 
likely caused by the attraction between cells and the paclitaxel. The findings of the DES conditioned media 
were supported by the highest cell anchorage found on the surface of DES, which was well populated with 
dense cells clusters, perhaps coinciding with the location of the paclitaxel coating. Cell adhesion in the 
BMS conditioned media shown in Figure 4.3 did not correlate with cell anchorage on the BMS strut surface, 
where a minimal cell number was present. This is clarified by the lack of coating on the BMS surface; 
therefore no agent is present to enhance or suppress adhesion in the stent conditioned media. CAFS 
samples promoted cell anchorage in both stent conditioned media and on the stent surface itself. It has 
been demonstrated that an acidic extracellular environment causes conformational changes in αVβ3 
integrin, the main cell adhesion protein, resulting in increased cell affinity for the substrate, thus adhesion 
[216].  
Evaluation of EC migration such as during a wound healing assay is one of the key indicators of endothelial 
recovery. The injured endothelium requires a rapid restoration of the denuded areas, achieved through a 
migration of adjacent EC to the injured sites to form a functional endothelial barrier. It is now recognized 
that accelerated endothelialization can prevent neointimal proliferation, which results in the thickening 
of vascular wall and restenosis. For practical reasons endothelial migration was only evaluated in the 
presence of the stent conditioned media. Here, MCEC migration (Figure 4.5) demonstrates that an 
extracellular acidic environment, as in the case of the CAFS conditioned media, significantly enhances cell 
migration at 2 h in vitro. For the 4 h, 6 h and 24 h time points there is no significant difference between 
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BMS and CAFS conditions with respect to the control. Tissue wound healing is a complex and intrinsic 
multi-factorial orchestrated process with cell migration being only one of the many contributors. Although 
this result cannot be directly translated into the in vivo situation, the enhanced CAFS sample cell migration 
across all the time points, especially the 2 h time point suggests a potential beneficial effect on 
accelerating endothelialization during the early stages of wound healing.   
Proliferation is another essential indicator of the stent-cell interaction and successful endothelialization. 
Paclitaxel is known to be a lipophilic drug that exerts its mechanism of action by binding to the microtubuli 
of the cells cytoskeleton and prevents its disassembly during cell division, ultimately preventing cell 
proliferation [180]. The DES conditioned media results demonstrate that paclitaxel is effective at inhibiting 
proliferation over a 48 h time period. EC viability is significantly better when CAFS conditioned media is 
used over BMS and DES at 24 h. The 24 h enhanced proliferation of CA diminishes at 48 h where BMS 
viability is comparable with CAFS.  Similar, to the migration assays, these results suggest that the CAFS 
sample performs significantly better during the early stages of healing and thus may be significant for 
endothelialization in vivo. In addition, cell imaging revealed that the CAFS conditioned media induced a 
more elongated morphology in MCEC at 48 h. EC under physiological conditions exhibit elongated spindle 
shaped morphology aligned with the direction of blood flow [320]. Paradise et al. have shown that an 
extracellular acidic environment causes elongated morphology characteristic of migratory state of cells. 
Increased integrin activation results in increased cell substratum adhesiveness which results in increased 
cell spreading. Acidic extracellular environments can lead to such effects as longer filopodia, better 
adhesion efficiency, and a more spread and elongated morphology [216].  
The minimal cell number recorded in the DES proliferation assay combined with the cell viability results 
in Figure 4.6 suggest that the cytostatic paclitaxel in combination with the stent surface becomes cytotoxic 
over time as the cells cannot withstand the continuous exposure and eventually die. One could argue that 
under the stent proliferation experimental set up, cells are exposed to accumulated paclitaxel 
concentration that otherwise they would not be in an in vivo situation. However, as previously described 
paclitaxel is highly lipophilic and accumulates in tissues rather than being washed off by the blood flow 
into the circulation. Thus, this set up essentially represents such drug accumulation. The altered cell 
morphology, typical of paclitaxel-induced cell cycle arrest [299, 321], is seen in the optical images in Figure 
4.8. The result is significant from a perspective that it is the combination of the insoluble fraction of the 
paclitaxel drug and the stent surface causing cell death. The soluble fraction of paclitaxel acts on the cells 
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at the petri dish surface independently of the stent surface causing morphological changes, but not cell 
death. Similarly, in the case of DES conditioned samples in 4.6, soluble as well as physical paclitaxel 
particles are present and a suppressed proliferation but not cell death is seen at 48 h.  
Cell viability, as influenced by the stress levels during cells exposure to the stent samples, was evaluated 
using cell conditioned media. Cell viability was dramatically decreased in the case of DES, from ~50 % in 
DES conditioned media to ~5 % in DES cell conditioned media while increased viability was noted in the 
CAFS sample (from 82 % in CAFS conditioned media to ~93 % in CAFS cell conditioned media). The 
inhibitory effects of DES cell conditioned media on cell viability indicates a significant presence of 
cytokines. Similarly, the highly encouraging endothelial coverage of CAFS during the proliferation assay 
signifies no or minimal cytokine release. In contrast, largely unaffected viability of cells grown in the 
presence of both BMS cell and stent conditioned media is significantly reduced during the stent 
proliferation assay, highlighting the impact of the stent surface itself on the endothelialization. Thus, these 
findings emphasize the importance of stent functionalization and demonstrate that the stent surface can 
be tailored towards endothelial regeneration by coating with CA. 
Apoptosis, programmed cell death, is a critical process of homeostasis in tissues such as during 
revascularization. However, apoptosis detection can also be an important storyteller of early cell changes 
due to extrinsic or intrinsic factors that can reveal endothelial dysfunction and therefore a cell’s ability to 
regenerate vascular wall. The microtubule stabilizing effects of PTX result in micronucleated cells (mitotic 
slippage), a phenomenon described previously in numerous studies [184, 272] and also demonstrated in 
chapter 2 of this manuscript leads to subsequent cell death via apoptotic or non-apoptotic pathways [16, 
322, 323]. Here, the induction of apoptosis by stent-conditioned media was evaluated via fluorescence 
microscopy and flow cytometry. While no annexin V apoptotic MCEC were detected by fluorescence 
microscopy, it was shown in Figure 4.9 that treatment with DES conditioned media significantly increased 
the number of apoptotic cells as determined by caspase 3/7 fluorescent imaging. The conflicting result 
lies in the sample preparation, as annexin V microscopy detection does not take into account detached 
floating cells that may be undergoing late apoptotic or necrotic process. However, this population subset 
is included in the caspase3/7 imaging. Flow cytometry analysis of a whole cell population revealed a 
significant cell subset of DES stent conditioned media treated cells undergo late apoptosis, shown in Figure 
4.10 and indicated by the double positive detection of annexin V and the nuclear stain DRAQ7. A negligible 
cell number was identified to be apoptotic with half of the population undergoing late apoptosis at this 
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time point, indicating that apoptotic process is initiated before the selected evaluation time point of 48 h. 
BMS and CAFS conditioned media treated samples exhibit insignificant levels of dead and apoptotic cell 
subsets that were not different from controls.  
It is well known that an acidic extracellular environment is present under a number of physiological and 
pathological contexts such as in wound healing and cancer microenvironments [324, 325]. It has been 
shown that extracellular acidification affects cellular adhesion and migration. EC preferentially migrate 
towards an acidified environment and exhibit stronger adhesion under the acidic conditions. On the 
molecular level, this is explained by a headpiece opening of integrin αvβ3; a transmembrane receptor 
binding to extracellular matrix ligands. This high affinity conformation allows integrin αvβ3 binding to 
extracellular ligands, such as fibronectin at specific acidic sequences [216]. CA due to its antithrombogenic 
properties has been used as a coating or in combination with other materials on a number of blood 
contacting devices [169]. Antithrombogenic properties of CA are assigned due to its negatively charged 
and hydrophilic carboxyl groups, where hydrophilic surfaces are known to inhibit protein adsorption and 
are therefore used in blood contacting devices [169, 326]. This is due to the water molecules strong 
binding to the hydrophilic surface that are then hard to displace by circulating plasma proteins such as 
thrombosis-associated fibrinogen [327]. The increase in negativity on the cells surface due to the 
adsorption of CA carboxyl group was demonstrated by the dynamic light scattering method as shown in 
Figure 4.2. It is hypothesized that when CA interacts with surfaces it makes them more hydrophilic and 
therefore antithrombogenic.  While citric acid can suppress platelet adhesion, it may also mimic the ARG-
GLY-ASP (RGD) sequence, especially the acidic ASP residue which is particularly important for integrin 
binding, thus increasing cell adhesion and migration and therefore proliferation.  
The goal of this investigation was to evaluate the effects of CAFS versus BMS and DES commercial stents 
on endothelial regeneration. Although, the CAFS appears to promote endothelial adhesion, migration, 
and proliferation on the stent surfaces as well as in the case of the stent conditioned media, vascular 
healing is a multi-factorial process and thus the translation of these results into the in vivo situation 
requires careful consideration. The influence of blood flow on the endothelial regeneration was not taken 
into consideration, for example. A 3D model of vascular regeneration or animal studies would be required 
to further support our claims that the CA has the potential to promote endothelialization and further 





Citric acid functionalized nitinol vascular stents were compared to commercial bare metal (Zilver Flex) and 
paclitaxel eluting stents (Zilver PTX) in terms of reendothelialization. To study the effect of stent coatings, 
a stent conditioned media methodology was developed in an attempt to represent in vivo conditions. It 
has been demonstrated that a stent surface functionalized by CA targets endothelial regeneration by 
promoting adhesion, migration, and proliferation. Overall, distinct advantages for a citric acid 
functionalized nitinol stent over commercial Zilver PTX DES and Zilver Flex BMS stent are reported. These 
findings indicate the potential of CAFS to serve as a bioactive and therapeutic surface for 







5 CHAPTER 5  
Fabrication of 2-layered 3D vascular 
cellularized model for studying stent-cell 
interactions in situ 
___________________________________ 
5.1 Introduction 
In-stent restenosis is the reoccurrence of vascular vessel narrowing as a response to medical stent 
placement into a blood vessel during the process of angioplasty. It is described as a chronic response to 
the wound created during angioplasty and is defined as >75 % cross-sectional area luminal narrowing of 
the stented artery and is discussed in detail in chapter 1. It is evident from a review of the literature that 
there is a need to move from 2D cell cultures towards in-vivo like 3D models to better mimic the cell 
environment and for a shift from using animal models, which can have different physiological responses 
to those in human tissue, as discussed in section 1.5 of this thesis. In stent-cell research, this is also 
imperative, mainly due to the issue of many existing models neglecting dynamic blood flow, outer radial 
force of the expanded stent and using model vessels that do not match the mechanical properties of 
native tissues as well as the difficulty in modelling stent-implantation conditions in a cell culture dish. To 
this end, various experimental approaches have been previously explored; direct cell seeding onto the 
stent surface using rotors, pre-coating of the stent surface to induce cell adhesion [328], silicone tubing 
serving as a vessel in cardiovascular research [329] and thick collagen gels imprinted with metal disks or 
thin metal films to simulate stent implantation conditions [330, 331]. Studies are often complemented 
with porcine or murine animal models, or ex vivo tissue studies. However, no in vitro standard model or 
routine testing method exists to examine the impact of stent deployment and implantation. The medical 
devices industry relies on costly animal testing before proceeding to clinical trials. While it is known that 
the stages of healing in animals are similar to humans, the time response differs significantly. Virmani et 
al. conducted an extensive review on these differences, concluding that the lesion sites in animals are 
completely healed at 90 and 180 days, whereas in humans these timepoints may correspond to two-three 
years post-implantation [332]. The issue above is two-tiered. Firstly, the lack of a standard model for early 
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testing preceeding the animal models leads to difficulties in translating the in vitro data to in vivo. Secondly, 
the temporal healing difference in animals require a human in-vivo like model for standard testing of 
stent-cell interactions. To this end, the goal of this work was to establish a three-dimensional model 
consisting of medial and intimal layers in which a stent could be deployed that would allow a better 
prediction of tissue-stent response.  
Type I collagen has been extensively used in three-dimensional cell culture as well as in tissue engineering 
strategies. As an extracellular matrix component, collagen type I is an abundant protein with load bearing 
properties. Although, various synthetic materials and biodegradable polymers have been used to create 
vascular tissue (discussed in section 1.5), collagen is often the material of choice in vascular tissue 
engineering due to its excellent biocompatibility, high cell loading capacity and it has been shown to 
achieve appropriate load-bearing properties in engineered tissues [333-335]. Two studies, describing the 
fabrication of collagen-based tubular tissue for vascular applications in a bioreactor system, were 
identified from literature and were used as a starting point for the purpose of the investigation presented 
herein [239, 336]. Both studies achieve formation of medial and intimal layers, however they differ in the 
protocol used for the medial layer formation. While Meghezi et al. achieved a mature medial layer after 
2 weeks, Loy et al. were able to significantly shorten this period by densification of collagen via excess 
water expulsion [238, 239]. Although the short maturation step appears attractive from the perspective 
of significantly shorter lead-time to mature construct, it needs to be investigated whether appropriate 
viscoelastic properties equivalent to the 2 weeks maturation method can be achieved. Mechanical 
strength of collagen-based tissues is attributed to a substantial SMC contribution to the remodeling 
process of the collagen network over time [337, 338]. The excellent biological characteristics and behavior 
in engineered tissue make collagen-based tubular tissue a promising candidate to be considered as an 
industry standard for testing stent-tissue interactions, aligning with the replace, reduce and refine 3Rs 
principle of animal testing [339-341].  
Based on the conducted literature review search and the associated issue of delivering in vivo-like tubular 
models with suitable biological and mechanical properties for vascular applications that would allow 
prediction of stent-cell interactions and could potentially replace animal models, the aim of this work was; 
i) to design an industry standard bioreactor that could be repeatedly steam sterilized and would allow for 
scale up studies, ii) to elucidate optimal conditions for tissue maturation leading to appropriate 
viscoelastic properties iii) to execute a preliminary study on the biological and  biomechanical properties 
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of the constructed tissue. Pending the outcome of these studies, stent deployment into the constructed 
tissue with the application of dynamic blood flow to mimic the in vivo conditions and allowing the study 
of stent-tissue interactions would be the subsequent stages of development but were beyond the scope 
of this study.  
5.2 Materials and Methods 
5.2.1 Materials 
10 mg/ml collagen type I from rat tail (354236, Corning) was used in this study. The following reagents 
were obtained from Sigma Aldrich: Dulbecco’s Modified Eagle’s Medium - without sodium pyruvate 
(D5796), Fetal Bovine Serum (F7524), L-Glutamine (G7513), Penicilin/Streptomycin (P0781), 1X Trypsin-
EDTA (T3924), Phosphate Buffer Saline, PBS (P3813), G 418 disulfate salt solution (G8168), sodium 
hydroxide (221465), 4 % Paraformaldehyde (PFA) in PBS (HT5011). Mouse cardiac endothelial cell lines 
(MCEC CLU510, VH Bio), mouse vascular smooth muscle cells (MOVAS ATCC® CRL-2797), LIVE/DEAD 
viability kit (L3224, BioSciences).  
5.2.2 Bioreactor assembly 
As a proof of concept, the bioreactor assembly for medial layer fabrication was replicated as described by 
Meghezi et al. and can be seen in Figure 5.2. To minimize batch to batch inconsistencies of the formed 
tissue and variability of the bioreactor assembly due to the materials not purpose-intended, we decided 
to re-design the bioreactor including improved features for scalability of this study. The workflow of tissue 
fabrication and the individual parts are summarized in Figure 5.1 and in Appendix A: Supplementary 
Information, Figure A2-A5, respectively. All parts required for the bioreactor assembly including the rotor 
for luminal seeding were custom designed by Cook Medical (Limerick, Ireland). The choice of materials 
was dictated by tissue biocompatibility and ability to withstand repeated high temperatures experienced 
during autoclave sterilization cycles. The parts were made from clear polycarbonate polymeric material 
or from medical grade silicone, in the case of gauze grippers.  
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5.2.3 Cell culture 
All cell culture work was performed in a biological safety cabinet under a laminar flow maintaining sterile 
conditions. Cell lines were expanded as follows; Immortalized Mouse Cardiac Endothelial cell (MCEC) 
culture media consisted of high-glucose DMEM media without sodium pyruvate supplemented with 5 % 
FBS and 1 % Penicillin/Streptomycin. Cells were passaged at 70-80 % confluency in a dilution of 1:5 or 1:10, 
reaching 80 % confluency after 2 or 3 days, respectively. Mouse vascular aortic smooth muscle cells 
MOVAS-1 were cultured in Dulbecco’s Modified Eagle’s Medium – high glucose supplemented with 0.2 
mg/ml G418 disulfate salt and 10 % FBS. A subcultivation ratio of 1:5 was used to passage the cells when 
80-90 % confluent. All cell cultures were propageted in an incubator at 37 ◦C and 5 % CO2. In order to 
ensure viability of both EC and SMC in the mature construct for subsequent future studies, a media 
composition assessment was carried out. Briefly, each cells type was separately seeded in the presence 
of various EC and SMC growth media ratios (1:3, 1:1, 3:1) as indicated in Figure 5.9 and allowed to 
proliferate for 48 h. The media was then removed, and cells were stained with LIVE/DEAD assay to 
evaluate viability using fluorescence microscopy.    
5.2.4 Fluorescent imaging 
Here, the mature tubular construct was cut open in the longitudinal direction and squares of 
approximately 1 x 1 cm area were obtained and covered with PBS in 24-well plates. Confocal fluorescent 
images were captured with ImageXpress Micro Spinning Disc Confocal High-Content Imaging System, 
Molecular Devices.  FITC and TRITC filter were used to detect live cells and dead cells respectively, while 
DAPI and TRITC filter to detect nuclei and f-actin filaments (Phalloidin Rhodamine) respectively, in PFA 
fixed tissue. Emission spectra was used under default settings. Images were stored in TIFF file format and 
Image J software was used to process all images (https://imagej.nih.gov/ij/). Cell counting was performed 
using automated counting functions in Image J. The percentage mean fluorescence intensity (MFI) was 
calculated from signal intensity of the red channel using the following formula: 
Eqn: 5.1  
 𝑀𝐹𝐼 =  
𝑟𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝑚𝑎𝑥𝑖𝑚𝑢𝑛 𝑟𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
 𝑥 100 
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5.2.5 Medial layer fabrication 
The methods for medial layer fabrication described by Loy et al. (Method 1) and Meghezi et al. (Method 
2) were adopted and assesed for time to yield mature construct versus viscoelastic properties matching 
native tissue. As a first step, cellularized collagen gel representing the medial layer was prepared from 
collagen type I, buffered solution and SMC in growth media. Briefly, buffered solution consisting of 10X 
PBS, deionized water and 1M sodium hydroxide (NaOH) was prepared based on a final volume of collagen-
cell mixture and according to gelation instruction of the collagen type I (Corning). At 80-90 % confluence, 
SMC were harvested, counted and re-suspended in growth media so that the final cell concentration in 
collagen-cell mixture was 1x106 /ml. 10 mg/ml collagen stock was diluted to 8 mg/ml stock using 0.02N 
acetic acid. Finally, 8 mg/ml collagen, prepared buffered solution and cells in cell culture media were 
mixed in a 50 % : 25 % : 25 % ratio respectively, to yield a 4 mg/ml final collagen concentration. pH of the 
mixture was measured using pH strips and if required further neutralized with 1 M NaOH to achieve ~ pH 
7.0 – 7.4. This procedure was carried out on ice to prevent gelation of the collagen. The prepared collagen-
cell mixture was carefully aspirated using pre-cooled tips and dispensed into the tubular mandrel-mould 
complex, Figure 5.4. The mixture was allowed to gel at room temperature for 1 h under sterile conditions. 
For example, 8 ml of the resulting collagen-cell mixture was poured into a tubular custom mandrel-mould 
which allowed for the production of a tubular construct with a 15 mm outside diameter, 5.0 mm inner 
diameter and 5 cm length. Once gelated, the tubular mould was gently removed. At this point, if 
densification of the collagen network was to be carried out (Method 1), the construct was rotated for 1 h 
at 3 rpm in the reservoir under dry conditions as described by Loy et al. to expel the excess water and 
accelerate the maturation step. Following the densification step (Method 1) or directly after 1 h gelation 
(Method 2), the obtained construct was transferred into reservoir containing pre-warmed cell culture 
media with caps placed at either side for static maturation at 37 ◦C and 5 % CO2 for 3 days (Method 1) or 
2 weeks (Method 2). The media was changed every 2 days.  
5.2.6 Intimal layer fabrication 
To harvest the medial layer, the bioreactor was transferred into a cell culture hood and the construct 
gently removed from its mandrel with the aid of sterile tweezers and moved into a petri dish containing 
pre-warmed growth media. EC were harvested, counted and re-suspended in growth media to achieve 
seeding density of 80,000 cells/ cm2. The total required number of cells for luminal coating was 
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determined based on the surface area of luminal space using the following formula: 𝐴 = 𝜋 𝑟 ℎ, where 
radius is known 𝑟 = 5 𝑚𝑚, and h is variable depending on the construct height. At this point, it was first 
placed onto a ring fixture through cotton grippers, one side of the tubular construct was capped with a 
plastic wedge and EC at 80,000 cells/ cm2 were seeded from the other side of the lumen. The EC 
resuspended in the EC growth media were maintained within the lumen of the vascular construct with 
the use of plastic wedges capped at either side. The reservoir was then filled with SMC growth media and 
fixed onto a rotating unit at 3 rpm and 37 ◦C, 5 % CO2 for 24 h. After 24 h of luminal seeding a construct 
now consisting of medial and intimal layer can be harvested for further mechanical and biological 
characterization. Following mechanical and biological characterization, the plan would be to use the 
construct for studying stent-cell interactions following stent deployment into the construct lumen. The 












Figure 5.1: Fabrication of medial and intimal layer over for 3 days via Method 1 or over 2 weeks via 





5.2.7 Mechanical and biological characterization (mechanical characterization carried out by 
Rachel Cahalane, Bernal Institute, University of Limerick) 
To characterize viscoelastic mechanical properties of the mature construct, the samples were cross-
sectionally cut in 1:5 ratio of width to length. Fatigue tests were carried out on ring shaped specimens as 
per published guidelines [342]. Here, the mature construct cut into rings was attached to the pins of a 
mechanical CellScale Biotester (CellScale, Canada) and immersed in PBS at 37 ◦C. Initial displacement was 
achieved using load cells, this value was determined to be 0 % stretch. The fatigue test consisted of 
applying 10-30 % cyclic stretch at 5 % strain per second. The elastic modulus was calculated by using the 
linear portion of the stress-strain curve. For biological characterization, samples were assesed using 
histological or fluorescent staining. Fluorescent staining was carried out on unfixed tissue to evaluate cells’ 
viability within the medial layer scaffold or on mature PFA fixed construct to evaluate architecture of 
medial as well as intimal layer as described in section 5.2.4.   
5.2.8 Statistical Analysis 
The experimental results are presented where appropriate as mean ± SD. All experiments were carried 




5.3 Results and Discussion 
5.3.1 Bioreactor initial assembly- proof of concept 
 
 
Figure 5.2: Components of the bioreactor for tubular tissue fabrication as described by Meghezi et al. A) 
Mandrel running through a vented cap with the gauze-grippers designed to support the gelation of the 
collagen-cell mixture. Inner mould to support the collagen-cell mixture during the gelation period. Media 
reservoir fitted with a 0.22 µm filter for media withdrawal and extra aeration. B) Mandrel-mould complex 
and media reservoir. C) Fully assembled bioreactor.  
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The bioreactor assembly for tubular tissue fabrication as described by Meghezi et al. was replicated to 
evaluate suitability of the design for routine studies (Figure 5.2). Where possible, the materials were 
sourced as listed in the study. Although, the main materials such as syringe tube for mandrel-mould 
complex or 50 ml centrifuge tube for media reservoir are commonly found in the tissue culture laboratory, 
others were more difficult to match and alternative materials needed to be used. Briefly, to create a 
mandrel-mould complex, a hole was drilled through the vented cap of a 50 ml centrifuge tube, taking care 
not to disturb the filter membrane. A mandrel fitted with gauze grippers consisting of master flex tubing 
and gauze was then pushed through this hole (Figure 5.2 (B)). Silicone stoppers were used to hold the 
mandrel in place and seal the orifice. A tubular mould was made from a 15 ml syringe for polymerization 
of the collagen-cell mixture. A 50 ml centrifuge tube was used as a media reservoir. All the connections 
were sealed with medical grade glue. The fully assembled mini-bioreactor can be seen in Figure 5.2 (C). 
While the dry bioreactor assembly worked well, small leakages were detected from the side port filter 
attachement when the bioreactor was filled with the media. The curvature of the media reservoir provides 
only a small surface area for the flat luer port attachment that is hard to compensate for with a glue. 
Likewise, when the mandrel-mould complex was tested with collagen-cell mixture for the capacity to 
support gelation over 1 h, it was difficult to achieve a snug fit of gauze grippers with the mould, causing 
dripping leakage, affecting the gelation of collagen-cell mixture. However, the most challenging proved to 
be the consistency of bioreactor assembly from batch to batch. Gauze grippers were difficult to neatly 
assemble and reproduce.  The mandrel –cap complex is held in place with the use of silicone stoppers. 
These stoppers were obscure to cut into a shape with a flat base.  If the base of the stoppers was not 
evenly flat, the mandrel was off-centre. Medical grade glue was used to seal all the connections. However, 
gentle handling of bioreactor was required not to disturb any of the seals. Although, the part materials 
are autoclavable, the option of re-using the bioreactor for multiple runs was not feasible; it is not 
recommended to subject the bioreactor parts to repeated autoclave cycles. For this reason a new 
bioreactor would be needed for every run. In summary, the assembly of the bioreactor as outlined by 
Meghezi et al. serves as a proof of concept study for fabrication of tubular tissue for vascular applications. 
As it stands, this concept would require durable yet tissue biocompatible materials, feature specific 
improved designed for scalability, precision tools to achieve acceptable batch to batch consistency and 




5.3.2 Bioreactor re-design 
 
 
Figure 5.3: Overview of the improved bioreactor design as drawn in Computer-aided design (CAD) software 
in collaboration with Cook Medical. Left to right: mandrel-cap complex, assembled bioreactor unit and a 
bioreactor platform for scale up studies. 
Following the proof of concept analysis of the former bioreactor, the bioreactor was redesigned with 
improved features to tackle the time input and inconsistency associated with manual fabrication with 
consideration for its purpose as an industry standard in mind. The new concept was proposed and drawn 
in Computer-aided design (CAD) software in collaboration with Cook Medical (Figure 5.3). Firstly, to meet 
the material requirement of tissue biocompatibilty, durability and suitability for steam sterilization, 
polycarbonate was selected as the material of choice for the main body components. Polycarbonate is a 
readily available, relatively cheap thermoplastic polymer that is durable and commonly used for medical 
applications due to its decades long safety track record [343]. Extruded polycarbonate tubes and rods of 
various diameter that can simply be cut into desired lengths are especially suitable for the new design of 
the media reservoir and mandrel. The polycarbonate bioreactor caps were custom moulded and fitted 
with two o-rings per each cap ensuring a tight seal. The main feature upgraded in the mandrel-mould 
complex were the gauze grippers. The gauze grippers, dictating the construct length and allowing gelation, 
were custom moulded and made from a single piece of medical grade silicone. This is a major change from 
the former design where gauze grippers were made from three separate pieces of masterflex tubing cuts 
and gauze glued together. Eliminating the need of glue and cutting down from three parts to one reduced 
part variability and increased functionality due to the improved design. The new bottom gripper provided 
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a snug fit between the mandrel and the walls of tubular mould. The top gripper consisted of two flanges; 
the lower flange with a snug fit to the tubular mould’s wall determining the top length of the collagen 
construct and the upper flange sitting on top of the tubular mould edge via overhangs. Both of the flanges 
designed with heterogenous perimeter allow for easy collagen-cell mixture dispensing, stabilizing and 
preventing the slippage of the madrel. A flat holder with a fitting for mandrel and the tubular mould was 
added for the ease of handling during the initial 1 h gelation. The mandrel was made into a length to fit 
within the openings of the top and bottom caps of the media resevoir. The mandrel at its distal end, would 
fit into tapered opening at the centre of the bottom cap. This set up ensured that the mandrel could be 
securely fitted in the bottom cap during the fitting of the top media reservoir cap. The proximal end of 
the mandrel would fit the blind hole of the top media reservoir cap. The small improvement of bottom 
cap opening, as opposed to the earlier blind hole design, ensured that the geled construct was fitted 
securely in the middle of the media reservoir, elimintaing tissue damage due to the leaning against the 
walls of the media reservoir during the top cap fittings. The bottom media reservoir cap was designed 
with a groove on its outer wall fitting the fixture holder on the custom made rotator for endothelial 
luminal seeding. Likewise, the top media reservoir cap with a square feature would fit with the the square 
driver socket on the rotator. The rotator itself with a measurements of 25o x 60 mm would easily fit into 
the cell culture incubator. For the luminal seeding two fringe fixtures were used with an opening in the 
middle to fit the capping wedges and opening along the circumference for media flow. The capping 
wedges were used to cap the construct at either end during the EC seeding. The early feature of the loose 
ring fixtures was later replaced due to the sliding alongside horizontal axis within the bioreactor as well 
as sliding in the direction of rotation causing twists in the construct. The new replacement fixture based 
on the existing rings with extra openings at the back side allowed for insertion of stabilizing rods running 
along the length of the bioreactor. The extra openings on the inner side allowed for placement of distance 
rods, fully securing the rings in fixed position. As an additional feature a platform capable of holding five 
bioreactor units has been added for scale up studies, Figure 5.3. A collection of the individual bioreactor 
parts can be found in Appendix A: Supplementary Information, Figure A2-A5. In summary, a bioreactor 
capable of fabricating two-layered tissue that went through several revisions with the final revision 





5.3.3 Construct fabrication 
 
Figure 5.4: Medial layer fabrication workflow. A) Collagen-smooth muscle cells mixture poured into the 
mandrel-mould complex was allowed to gel for 1 h at RT. B) After 1 h gelation the external mould was 
removed. C) For the Method 1, the construct was densified for 1 h under rotation. D) Static maturation for 
3 days (Method 1) or 2 weeks (Method 2) at 37◦C, 5 % CO2. 
 
Figure 5.5: Intimal layer fabrication workflow. A) Following static maturation, the bioreactor was 
dismantled and mandrel removed. B) The medial layer construct was secured with flanges in the bioreactor 
media reservoir. Caps were placed at either end to trap the EC for luminal seeding. C) EC were seeded into 
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the construct lumen under rotating conditions for 24 h and 37◦C, 5 % CO2 at 3 RPM. D) Mature construct 
was harvested for further biological and mechanical characterization.  
The re-designed bioreactor consistently produced an ‘immature’ medial layer after 1 h of polymerization, 
as shown in Figure 5.4 (B) that was easy to handle during the subsequent steps of construct fabrication. 
Unlike in the ‘proof of concept’ bioreactor, no leakages of collagen-cell mixture were observed from the 
mandrel-mould complex during the preparation and the polymerization step. This is a significant design 
improvement as even small leakages can interrupt uniformity of the cell-collagen mixture, disturbing the 
relatively rapid polymerization process. In the next step, the feasibility of a shorter tissue maturation step 
(Method 1) without compromising the mechanical and biological properties of the construct was 
investigated against the longer tissue maturation step (Method 2). Both methods are outlined in section 
5.2.5. Although, Method 1 follows the protocol published by Loy et al where 1 h densification with 
subsequent immersion in PBS for 24 h leads to appropriate mechanical properties, this outcome was not 
achieved when the same conditions were replicated with culture media instead of PBS. For this reason, 
Method 1 was altered to include a 3 day static maturation followed by a densification step. Densification 
by excess water expulsion led to a rapid shrinkage of the outer medial layer diameter (not shown) and the 
excess water was analyzed for cell presence using trypan blue exclusion assay, with no cells detected (data 
not shown), indicating no cell loss during densification. Both, Method 1 with densification and 3 day static 
maturation and Method 2 without densification and a 14 day maturation step only, produced a mature 
medial layer. A representative photograph is shown in Figure 5.4 (D). In the next step, the mandrel was 
removed to allow luminal seeding of EC as shown in Figure 5.5 (A). This was easily achieved with the use 
of tweezers and mandrel being greased with silicone oil (polydimethylsiloxane fluid, Dow Corning) prior 
to the initial assembly. The constructed medial layer tissue was conveniently handled with a tweezer via 
cotton grippers without physically damaging the usable length of the tubular tissue. The improved 
features of construct attachment during the rotational luminal seeding proved to work well, greatly 






5.3.4 Biological and mechanical characterization 
 
Figure 5.6: A) Fluorescent images of the medial layer fabricated using Method 1 where live cells are stained 
with calcein (green fluorescence), dead cells with ethidium homodimer (red fluorescence) Scale = 200 µm. 
Experiment carried out in independent duplicates. B) Collagen construct sample at a stretch C) Collagen 
sample at relaxation D) Fatigue test were carried out in circumferential direction. Samples immersed in 
PBS at 37◦C followed by applying 10-30 % cyclic stretches with a 5 N load cell at 5 % strain per second. 




Figure 5.7: A) Fluorescent images of the medial layer of mature tissue fabricated using Method 2 where 
live cells are stained with calcein (green fluorescence), dead cells with ethidium homodimer (red 
fluorescence) Scale = 200 µm. B) Collagen sample at a stretch C) Collagen sample at relaxation D) Collagen 
sample during the pull test to failure E) Fatigue test carried out in circumferential direction. Sample 
immersed in PBS at 37 ◦C followed by applying for 10 %-50 % cyclic stretches with a 5 N load cell at 5 % 
strain per second. F) Pull test to failure carried out in circumferential direction. Sample immersed in PBS at 
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37 ◦C. Sample pre-conditioned for 5 cycles and 5 N pre-load applied. Successful mechanical characterization 
carried out as a monoplicate. 
Following the formation of mature medial layer through Method 1 and 2, biological and mechanical 
characterization was carried out to identify a suitable fabrication method before proceeding with luminal 
seeding. The medial layer, owing to the SMC remodeling activity on the collagen’s network, is responsible 
for the increased strength of the construct and appropriate viscoelastic properties. Fluorescent imaging 
of Method 1 medial tissue revealed viable SMC by positive green fluorescent staining (calcein) and 
elongated morphology while the presence of dead cells was recognized by red fluorescence (Figure 5.6 
(A). Figure 5.6 (B –C) shows mature collagen construct at a 10 % stretch and relaxation, respectively. It is 
evident from Figure 5.6 (C) that the construct does not exhibit elastic behavior as it lacks the ability to 
recover from the applied stretch demonstrated by the construct folding. From the damage that was 
visually assessed during the testing, we hypothesize that permanent damage had already occurred in the 
sample at a stretch of less than 10 % as seen from force-displacement graph Figure 5.6 (D). This may be 
due to the short maturation period not providing enough time for the SMC to remodel collagen matrix 
increasing the stability of collagen fibrils network.  
The mature medial layer produced using method 2, with the longer maturation time and without 
densification, was fluorescently labelled and imaged as seen in Figure 5.7 (A). Green staining (calcein) 
represents viable SMC and red staining (ethidium homodimer) dead cells. SMC exhibited elongated 
morphology typical of healthy cells. Method 2 mature medial layer tested for elasticity with fatigue and 
pull test to failure exhibited elastic properties up to 30 % stretches, evident visually from images captured 
during testing Figure 5.7 (B-D). When the sample was stretched to 30 % Figure 5.7 (B) it was able to recover 
from this stretch with no stretch damage present in its structure Figure 5.7 (C). This behavior is 
documented in the graphs Figure 5.7 (E) and (F). During the fatigue test increase in load, over 10 % - 30 % 
stretch cycles can be seen. After 30 % the load plateaus again, indicating damage occurring in the 
construct. The elastic modulus from the linear portion of this curve around 10 % stretch was estimated to 
be 2 MPa. In native vessels this value was reported to be 1.55±0.26 MPa [344]. 2 MPa is possibly an 
overestimation because too much preload may have been applied to the samples. The advantageous 
mechanical properties of the Method 2 medial layer, compared to Method 1, lie in the longer time for 
matrix metalloproteases (MMPs) to remodel extracellular space, in this case collagen network. Collagen, 
as the main component of the connective tissue is subject to MMP degradation.  The process takes place 
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through degradation and remodeling, resulting in collagen network with biologically relevant mechanical 
strength (Seliktar et al. 2001). 
The identification of viable cells via fluorescence imaging and a mechanical characterization that allowed 
estimation of elasticity demonstrate that Method 2 with a 14 day maturation period is a more suitable 
method for medial layer fabrication. Therefore, the subsequent luminal seeding of EC was carried using 
Method 2 medial layer fabrication. 
 
5.3.5 Intimal layer biological characterization 
 
Figure 5.8: Fluorescent images of abluminal (medial layer) and luminal (intimal layer) of mature construct 
fabricated using Method 2 taken at proximal, medial and distal areas. PFA fixed tissue was stained with 
blue DAPI (nuclei) and red Phalloidin-Rhodamine (f-actin filaments). Scale= 200 µm. Images taken with 
ImageXpress Micro Spinning Disc Confocal High-Content Imaging System, Molecular Devices. Experiment 
carried out in duplicates with n=1. Representative data set of the duplicates shown. 
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The harvested mature medial layer was produced using Method 2 as established in the comparison of the 
Method 1 and 2 in section 5.3.4. The lumen of the medial layer was seeded with EC to create the intimal 
layer, resulting in a mature construct composed of two layers; medial and intimal. Upon successful 
fabrication, the medial layer consists of SMC embedded in the collagen network and a monolayer of EC 
anchored to the collagen in the luminal side. To evaluate the formation of these two distinct layers, the 
mature harvested construct was fluorescently labelled and imaged. Fluorescent images were first taken 
for abluminal side (medial layer). The samples immersed in PBS were then flipped and the luminal side 
(intimal layer) was imaged. All three abluminal imaging locations revealed a developed network of SMC 
with elongated morphology demonstrated by presence of both nuclei and cytoplasmic staining. Luminal 
samples show presence of EC by positive nuclear staining; however, lacking cytoplasmic staining, 
indicating a poorly developed monolayer. This result may be time dependent, with 24 h seeding being not 
sufficient for cells to accommodate to the new conditions. The lack of luminal pre-coating may also have 
influenced the weak cell anchorage as indicated by poor cytoplasmic staining. Although, collagen itself is 
highly cell adhesive, fibronectin is typically used to increase success of cell adhesiveness acting as a 
biological glue [345]. The mean % fluorescence intensity was found to be 39.91 % and 12.30 % for 
abluminal and luminal cytoplasmic staining, respectively as quantified from the red channel. Although, a 
use of cell-specific stain such as junctional VE-cadherin immunofluorescent staining distinguishing EC from 
SMC would allow to confidently determine presence or lack of intimal layer, this analysis provides 
preliminary indication of cell anchorage to the lumen.   
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5.3.6 Preparation for co-culture 
 
Figure 5.9: Representative fluorescent images of EC and smooth muscle cells incubated in varied ratios of 
EC to SMC media. Images taken at 48 h, live cells are stained with green and dead cells red. Graphs 
represent percentage area of live cells and percentage dead cells with respect to control. Ratios represent: 
EC media: SMC media. Controls consisted of 100 % EC or SMC growth media. Experiment carried out in 
independent duplicates with n=1. Representative data set of the duplicates shown. Scale bars= 200 µm. 
The two selected publications for this study consider the fabrication of tubular construct as an endpoint 
outcome where maintenance in growth media supporting both of the tissue layers is not required. 
Specifically, the medial layer is fabricated first through collagen-cell-SMC media mixture followed by the 
intimal layer fabrication where ECs are seeded in their respective media. Therefore, ECs do not have 
access to the SMC media and vice versa. To predict the mature construct survival post-deployment, cell 
viability was assessed under various growth media compositions for the EC and SMC grown as 
monocultures. Both of the cell types were minimally affected by the changing media ratios in terms of live 
cell area occupancy. The dead cells count has increased from 5 % in the case of the 100 % SMC media 
control to 15 % when 3:1 of EC to SMC media was used. The dead cell count remained at approx. 10 % for 
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the EC samples across all media ratios, indicating that the SMC are more sensitive to media changes. To 
conclude, the most suitable media ratio was found to be 1:3, based on the low % dead count for this ratio 
in SMC and the occupancy of both live cells types that remained unaffected across all three media ratios 
5.4 Conclusions and Future Work 
The design and manufacture of a bioreactor suitable for tubular tissue fabrication with re-useable parts 
that are easy to assemble and handle was achieved during this work. Tubular cellularized tissue consisting 
of a medial layer was fabricated using two different protocols. Both approaches yielded vascular model 
suitable for further characterization and the presence of live cells within the collagen tissue was confirmed 
for both methods. However, only the method involving a longer static maturation period and therefore 
improved tissue remodeling yielded tissue with suitable viscoelastic properties relevant to those of native 
vessels and was used for subsequent fabrication of a complete vascular model consisting of a medial and 
intimal layer. The main conclusion points relating to the tissue fabrication are that the initial preparation 
steps are crucial for the success of the tissue fabrication. Since collagen is a highly viscous liquid at 4°C, 
appropriate temperature of the collagen and plastics used to handle it are necessary for achieving the 
correct concentrations of the cell-collagen mixture while appropriate pH of the cell-mixture is crucial for 
its successful polymerization. In terms of potential future work to complete this study, a cell type specific 
biological or histological characterization is required to better assess the formation of medial and intimal 
layer. Evaluation of viscoelastic properties in a longitudinal direction in combination with circumferential 
direction would also provide more accurate prediction of strength of the constructed tissue.  To complete 
the 3D of stent-cell interactions, the future work would include perfusion system connected to the 
constructed tissue to simulate physiological conditions of blood vessels. There is an opportunity to create 
diseased tissue by inducing calcification of smooth muscle cells, as per previously described protocol, to 





6.0 Conclusions and Future Directions  
___________________________________  
 
The aims of this project were: i) to develop a method that would allow for studying existing and novel 
stent coatings to represent hydrophobic drug concentrations in a cell environment ii) to evaluate a novel 
bioactive stent coating candidate in terms of its ability to promote vascular healing iii) and to establish a 
3D cellularized tubular vascular model to allow studying stent-cell interactions.  
In vitro cell studies of hydrophobic drugs face difficulties associated with their low aqueous solubility. To 
study poorly soluble drugs in bio-relevant media, solubilizing agents are frequently used to make highly 
concentrated stocks before final reconstitution in media. This results in drug concentrations that are not 
representative of in vivo conditions and may pose adverse effects on cells’ biological functions. This is 
especially true of typically hydrophobic stent coatings intended for vascular applications, where poor in 
vitro to in vivo correlation exists. To this end, we proposed a method for preparation of hydrophobic drug 
suspensions in bio-relevant media via stent conditioned media using PTX as a model drug. Since the drug 
is present as a suspension, this media was validated for its content uniformity and potency. Further, we 
have quantified PTX uptake by EC and showed that PTX stent conditioned media suppress cellular growth 
equivalent to the 1 - 0.1 µM DMSO dissolved PTX. The method of stent-conditioned media can be 
extended to other hydrophobic stent coatings providing a simplified method of studying stent coatings 
and stent leachables in a 2D environment.  
A thorough literature review on current drug-eluting stent state-of-the-art revealed that anti-proliferative 
drugs such as taxanes and rapamycins released from stents not only inhibit growth of SMC but also delay 
endothelial healing, potentially leading to late stent thrombosis. Therefore, highlighting the need for novel 
bioactive stent coating candidates with the ability to target key events in the pathogenesis of in-stent 
restenosis. CA with anti-coagulant and anti-oxidant properties is one such drug that has been shown to 
display encouraging properties on growth in EC cultures. CA was investigated against L-AA; an antioxidant 
molecule reported to preferentially promote EC growth, and PTX; typically used anti-proliferative stent 
coating from the taxane drug family. In this thesis, CA was found to exhibit growth supporting properties 
on EC across a range of concentrations that were significantly better than the model stent coating drug 
127 
 
PTX and better than the L-AA which inhibited EC proliferation at concentrations ≥100 µg/ml.   It was 
demonstrated that CA-PTX combination treatment significantly improves cell viability in comparison to 
PTX only treated cells, with MCEC exhibiting greater cell recovery over SMC. Furthermore, cell treatment 
with CA was found to reduce inflammation in LPS-induced inflammation model by significantly reducing 
IL-6 expression. Thus, this part of the thesis demonstrates that CA is a promising candidate for use as a 
coating in stents and other endovascular devices. To test this hypothesis, CA functionalized nitinol vascular 
stents were compared to bare metal and paclitaxel eluting stents. Overall, distinct advantages of the CA 
functionalized nitinol stent in terms of EC adhesion, migration, and proliferation were reported. It is 
thought that acidic extracellular environments promote cell anchorage and migration by inducing 
conformational change in integrins, the main cell adhesion proteins. These novel findings indicate the 
potential of a CA functionalized stent to serve as a bioactive and therapeutic surface for re-
endothelialization, perhaps in combination with a SMC proliferation inhibitor coating, to prevent 
restenosis. These results are of large potential impact for vascular stent applications where promoting 
endothelialization while suppressing smooth muscle cells growth can prevent stent failure due to NIH.  
The field of tissue engineering has been rapidly expanding over the last few years. The technological 
advances in this research area represent an opportunity to bridge the gap between traditional 2D cell 
culture and vivo testing. A bioreactor system was designed and manufactured for a fabrication of a 3D 
cellularized 2-layered tubular model consisting of medial and intimal tissue. At its final stage, the mature 
fabricated tissue would allow application of a perfusion system to simulate blood flow and stent 
deployment to study stent-cell interactions in their macro-scale, reducing the time, financial and ethical 
burden associated with animal studies. To this end, a protocol for fabrication of such tissue was optimized 
and preliminary biomechanical characterization indicated viscoelastic properties similar to those of native 
vessels. The viscoelastic properties of the construct are achieved through the remodeling of the medial 
layer and therefore a careful tuning with a trade-off between cellular biocompatibility and mechanical 
properties of the scaffolding material determine its in vivo relevancy. In this work, collagen type I with an 
excellent cell compatibility yet lacking in mechanical strength was used requiring a lengthy maturation. 
Perhaps, a collagen incorporated with fibronectin could reduce the maturation time by promoting elastin 
deposition, thereby strengthening the ECM network. A more in depth analysis of the cell populations is 
required, especially of the luminal ECs to establish a barrier formation through a VE-cadherin, the main 
EC regulator of vascular permeability. Even with a mature tissue characterized in terms of its cell 
population, for a truly physiologically relevant vascular model tissue, functionality as whole requires 
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characterization. Vasodilation as a key function of vascular homeostasis could verify the significance of a 
3D model and its value over use of animal models. Release of NO in blood is a standard indirect method 
for determination eNOS activity thus vascular functionality in high-risk category patients. Since stent 
restenosis is a process orchestrated by a number of cell types other than ECs and SMCs, especially immune 
cells, it is necessary to incorporate these into the future work for CA preclinical development, and for a 
3D co-culture model of restenosis.  
In summary, macro-scale vascular models will find their value over organs-on-chips as the need for 
standardization and validation grows due to the recent increase in merge between pharmaceutical and 
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6 Appendices  
A: Supplementary Information 
7  
8  
9 Figure A1:  Calibration curve of Nickel absorption. Readings of the PTX stent conditioned media (DES 
MCEC) and media control (DMEM MCEC). Stent conditioned media prepared by stent incubation in 
the endothelial growth media was analyzed for nickel presence by Varian Plus atomic absorption 
spectrophotometer using an air–acetylene flame. A standard curve was obtained from nickel 
standards prepared in the range of 0.1 to 10 ppm. Working conditions were set as follows: lamp 











Figure A2: Design of mandrel-mould complex and a physical form of the same with gauze grippers  
 




Figure A4: Design of the rotational unit fitted with a bioreactor for the luminal seeding 
 
Figure A5: Rotational unit fitted with a bioreactor for the luminal seeding 
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